• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Crosslinked polymer compositions comprise a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH2) or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer which contains, or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further comprise other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents. Also disclosed are methods for using the crosslinked polymer compositions to effect adhesion between a first surface and a second surface; to effect tissue augmentation; to prevent the formation of surgical adhesions; and to coat a surface of a synthetic implant.
    公开号:US20010003126A1
    申请号:US09/733,739
    申请日:2000-12-08
    公开日:2001-06-07
    发明作者:Woonza Rhee；Frank DeLustro；Richard Berg
    申请人:Rhee Woonza M.；Delustro Frank A.；Berg Richard A.；
    IPC主号:A61L31-16
    专利说明:
    [0001] This application is a continuation-in-part of U.S. application Ser. No. 08/573,799, filed Dec. 18, 1995, which application is incorporated herein by reference in full, and to which we claim priority under 35 U.S.C. § 120. [0001] FIELD OF THE INVENTION
    [0002] This invention relates generally to crosslinked polymer compositions comprising a first synthetic polymer containing multiple nucleophilic groups crosslinked using a second synthetic polymer containing multiple electrophilic groups, and to methods of using such compositions as bioadhesives, for tissue augmentation, in the prevention of surgical adhesions, and for coating surfaces of synthetic implants, as drug delivery matrices and for ophthalmic applications. [0002] BACKGROUND OF THE INVENTION
    [0003] U.S. Pat. No. 5,162,430, issued Nov. 10, 1992, to Rhee et al., and commonly owned by the assignee of the present invention, discloses collagen-synthetic polymer conjugates prepared by covalently binding collagen to synthetic hydrophilic polymers such as various derivatives of polyethylene glycol. [0003]
    [0004] Commonly owned U.S. Pat. No. 5,324,775, issued Jun. 28, 1994, to Rhee et al., discloses various insert, naturally occurring, biocompatible polymers (such as polysaccharides) covalently bound to synthetic, non-immunogenic, hydrophilic polyethylene glycol polymers. [0004]
    [0005] Commonly owned U.S. Pat. No. 5,328,955, issued Jul. 12, 1994, to Rhee et al., discloses various activated forms of polyethylene glycol and various linkages which can be used to produce collagen-synthetic polymer conjugates having a range of physical and chemical properties. [0005]
    [0006] Commonly owned, copending U.S. application Ser. No. 08/403,358, filed Mar. 14, 1995, discloses a crosslinked biomaterial composition that is prepared using a hydrophobic crosslinking agent, or a mixture of hydrophilic and hydrophobic crosslinking agents. Preferred hydrophobic crosslinking agents include any hydrophobic polymer that contains, or can be chemically derivatized to contain, two or more succinimidyl groups. [0006]
    [0007] Commonly owned, copending U.S. application Ser. No. 08/403,360, filed Mar. 14, 1995, discloses a composition useful in the prevention of surgical adhesions comprising a substrate material and an anti-adhesion binding agent, where the substrate material preferably comprises collagen and the binding agent preferably comprises at least one tissue-reactive functional group and at least one substrate-reactive functional group. [0007]
    [0008] Commonly owned, U.S. application Ser. No. 08/476,825, filed Jun. 7, 1995, by Rhee et al., discloses bioadhesive compositions comprising collagen crosslinked using a multifunctionally activated synthetic hydrophilic polymer, as well as methods of using such compositions to effect adhesion between a first surface and a second surface, wherein at least one of the first and second surfaces is preferably a native tissue surface. [0008]
    [0009] Japanese patent publication No. 07090241 discloses a composition used for temporary adhesion of a lens material to a support, to mount the material on a machining device, comprising a mixture of polyethylene glycol, having an average molecular weight in the range of 1000 - 5000, and poly-N-vinylpyrrolidone, having an average molecular weight in the range of 30,000 -200,000. [0009]
    [0010] West and Hubbell, Biomaterials (1995) 16:1153-1156, disclose the prevention of post-operative adhesions using a photopolymerized polyethylene glycol-co-lactic acid diacrylate hydrogel and a physically crosslinked polyethylene glycol-co-polypropylene glycol hydrogel, Poloxamer 407®. [0010]
    [0011] Each publication cited above and herein is incorporated herein by reference in its entirety to describe and disclose the subject matter for which it is cited. [0011]
    [0012] We now disclose a detailed description of preferred embodiments of the present invention, including crosslinked polymer compositions comprising synthetic polymers which contain multiple nucleophilic groups crosslinked using synthetic polymers containing multiple electrophilic groups, and methods for using these compositions to effect adhesion between a first surface and a second surface (wherein at least one of the first and second surfaces is preferably a native tissue surface) or to effect the augmentation of tissue, or to prevent surgical adhesion, or to coat surfaces of synthetic implants, or for delivering drugs or other active agents, or for ophthalmic applications. [0012] SUMMARY OF THE INVENTION
    [0013] The present invention discloses a crosslinked polymer composition comprising a first synthetic polymer containing two or more nucleophilic groups, and a second synthetic polymer containing two or more electrophilic groups which are capable of covalently bonding to one another to form a three dimensional matrix. [0013]
    [0014] A preferred composition of the invention comprises polyethylene glycol containing two or more primary amino groups as the first synthetic polymer, and polyethylene glycol containing two or more succinimidyl groups (a five-membered ring structure represented herein as —N(COCH[0014] 2)2) as the second synthetic polymer.
    [0015] In a general method for preparing a composition for the delivery of a negatively charged compound (such as a protein or drug), a first synthetic polymer containing two or more nucleophilic groups is reacted with a second synthetic polymer containing two or more electrophilic groups, wherein the first synthetic polymer is present in molar excess in comparison to the second synthetic polymer, to form a positively charged matrix, which is then reacted with a negatively charged compound. In a general method for preparing a matrix for the delivery of a positively charged compound, a first synthetic polymer containing two or more nucleophilic groups is reacted with a second synthetic polymer containing two or more electrophilic groups, wherein the second synthetic polymer is present in molar excess in comparison to the first synthetic polymer, to form a negatively charged matrix, which is then reacted with a positively charged compound. [0015]
    [0016] In a general method for effecting the nonsurgical attachment of a first surface to a second surface, a first synthetic polymer containing two or more nucleophilic groups is mixed with a second synthetic polymer containing two or more electrophilic groups to provide a reaction mixture; the reaction mixture is applied to a first surface before substantial crosslinking has occurred; and the first surface is contacted with a second surface to effect adhesion between the two surfaces. [0016]
    [0017] In a general method for augmenting soft or hard tissue within the body of a mammalian subject, a first synthetic polymer containing two or more nucleophilic groups and a second synthetic polymer containing two or more electrophilic groups are administered simultaneously to a tissue site in need of augmentation and the reaction mixture is allowed to crosslink in situ to effect augmentation of the tissue. Alternatively, the first synthetic polymer and the second synthetic polymer may be mixed immediately prior to being administered to a tissue site, such that the majority of the crosslinking reaction proceeds in vivo. [0017]
    [0018] In a general method for preventing the formation of adhesions following surgery, a first synthetic polymer containing two or more nucleophilic groups is mixed with a second synthetic polymer containing two or more electrophilic groups to provide a reaction mixture; the reaction mixture is applied to tissue comprising, surrounding, or adjacent to a surgical site before substantial crosslinking has occurred between the nucleophilic groups and the electrophilic groups; the reaction mixture is allowed to continue crosslinking in situ until equilibrium crosslinking has been achieved; and the surgical site is closed by conventional methodologies. [0018]
    [0019] In a general method for coating a surface of a synthetic implant, a first synthetic polymer containing two or more nucleophilic groups is mixed with a second synthetic polymer containing two or more electrophilic groups to provide a reaction mixture; the reaction mixture is applied to a surface of a synthetic implant; and the components of the reaction mixture are allowed to crosslink with each other on the surface of the implant. [0019]
    [0020] A feature of the invention is that the crosslinked polymer compositions are optically clear, making the compositions and methods of the invention particularly suited for use in ophthalmic applications in which optical clarity is a requirement. Furthermore, the compositions of the invention are comprised of biocompatible, non-immunogenic components which leave no toxic, potentially inflammatory or immunogenic reaction products at the tissue site of administration. [0020]
    [0021] Another feature of the invention is that the crosslinked polymer compositions have a high compression strength and high swellability, i.e., a composition that has been dried will swell to three times (or more) its dried size upon rehydration, and is more “elastic.” Since these polymers are generally very hydrophilic, they are more easily injected, i.e., the crosslinked composition stays as a “cohesive mass” when injected through a fine gague (27-30 gague) needle. [0021]
    [0022] Yet another feature of the invention is that nucleophilic groups on the first synthetic polymer may covalently bind to primary amino groups on lysine residues of collagen molecules at the tissue site of administration, in effect, “biologically anchoring” the composition to the host tissue. [0022]
    [0023] One feature of the invention is that the components of the compositions are non-immunogenic and do not require a “skin test” prior to beginning treatment, as do currently available xenogeneic collagen compositions, such as those manufactured from bovine hides. [0023]
    [0024] Another feature of the invention is that, unlike collagen, the compositions of the invention are not subject to enzymatic cleavage by matrix metalloproteinases, such as collagenase, and are therefore not readily degradable in vivo and, as such, are expected to have greater long-term persistence in vivo than prior art collagen compositions. [0024]
    [0025] Still another feature is that, when the groups on each of the polymers utilized react to form an amide bond, the manufacturing of the compositions of the present invention can be highly controlled rendering more consistent quality of products. [0025] BRIEF DESCRIPTION OF THE DRAWINGS
    [0026] FIG. 1 shows compression force versus displacement for disks (approximate dimensions: 5 mm thick×5 mm diameter) of crosslinked polymer compositions comprising tetra-amino PEG (10,000 MW) crosslinked using tetrafunctionally activated SE-PEG [0026]
    [0027] (10,000 MW), measured using the Instron Universal Tester, Model 4202, at a compression rate of 2 mm per minute. [0027]
    [0028] FIG. 2 shows compression force versus displacement for disks (approximate dimensions: 5 mm thick×5 mm diameter) of crosslinked polymer compositions comprising tetra-amino PEG (10,000 MW) crosslinked using trifunctionally activated SC-PEG (5,000 MW), measured using the Instron Universal Tester, Model 4202, at a compression rate of 2 mm per minute. [0028]
    [0029] FIG. 3 shows the chemical structure of two commercially available polyethylene glycols containing multiple primary amino groups. [0029]
    [0030] FIGS. [0030] 4 to 13 show the formation of various crosslinked synthetic polymer compositions from hydrophilic polymers.
    [0031] FIGS. [0031] 14 to 18 show the formation of various crosslinked synthetic polymer compositions from hydrophobic polymers. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS OF THE INVENTION
    [0032] In accordance with the present invention, crosslinked polymer compositions are prepared by reacting a first synthetic polymer containing two or more nucleophilic groups with a second synthetic polymer containing two or more electrophilic groups capable of covalently binding with the nucleophilic groups on the first synthetic polymer. [0032]
    [0033] The components of the present invention are non-immunogenic and, as such, do not require a “skin test” prior to starting treatment, as does xenogenic collagen. Also, unlike collagen, the compositions of the invention are not subject to enzymatic cleavage by matrix metalloproteinases (e.g., collagenase) and are therefore expected to have greater long-term persistence in vivo than currently available collagen compositions. [0033]
    [0034] The concept behind the present invention is that a synthetic polymer containing multiple nucleophilic groups (represented below as “X”) will react with a synthetic polymer containing multiple electrophilic groups (represented below as “Y”), resulting in a covalently bound polymer network, as follows: [0034]
    [0035] wherein ≧2, n≧2,and m+n≧5; [0035]
    [0036] X=—NH[0036] 2, —SH, —OH, —PH2, —CO—NH—NH2, etc., and can be the same or different;
    [0037] Y=—CO[0037] 2N(COCH2)2, —CO2H, —CHO, —CHOCH2, —N═C═O, SO2CH═CH2, —N(COCH)2), —S—S—(C5H4N), etc., and can be the same or different; and
    [0038] Z=functional group resulting from the union of a nucleophilic group (X) and an electrophilic group (Y). [0038]
    [0039] As noted above, it is also contemplated by the present invention that X and Y may be the same or different, i.e., the polymer may have two different electrophilic groups, or two different nucleophilic groups, such as with glutathione. [0039]
    [0040] The backbone of each polymer is preferably an alkylene oxide, particularly, ethylene oxide, propylene oxide, and mixtures thereof. Examples of difunctional alkylene oxides can be represented by: [0040] X-polymer-X Y-polymer-Y
    [0041] wherein X and Y are as defined above, and the term “polymer” represents - (CH[0041] 2CH2O)n- or -(CH(CH3)CH2O)n- or -(CH2CH2O)n-(CH(CH3)CH2O)n
    [0042] The required functional group X or Y is commonly coupled to the polymer backbone by a linking group (represented below as “Q”), many of which are known or possible. There are many ways to prepare the various functionalized polymers, some of which are listed below: [0042] wherein Q = whole structure = —O—(CH2)n— polymer —O—(CH2)n—X (or Y) —S—(CH2)n— polymer —S—(CH2)n—X (or Y) —NH—(CH2)n— polymer —NH—(CH2)n—X (or Y) —O2C—NH—(CH2)n— polymer —O2C—NH—(CH2)n—X (or Y) —O2C—(CH2)n— polymer —O2C—(CH2)n—X (or Y) —O2C—CR1H— polymer —O2C—CRH—X (or Y) —O—R2—CO—NH— polymer —O—R—CO—NH—X (or Y)
    [0043] wherein n=1-10 in each case; [0043]
    [0044] R[0044] 1=H, CH3, C2H5, etc.;
    [0045] R[0045] 2=CH2, CO—NH—CH2 CH2.
    [0046] Q[0046] 1 and Q2 may be the same or different.
    [0047] For example, when Q[0047] 2 =OCH2CH2 (there is no Q1 in this case); Y=—CO2N(COCH2)2; and X=—NH2, —SH, or —OH, the resulting reactions and Z groups would be as follows:
    [0048] An additional group, represented below as “D”, can be inserted between the polymer and the linking group to increase-degradation of the crosslinked polymer composition in vivo, for example, for use in drug delivery applications. [0048]
    [0049] Some useful biodegradable groups “D” include lactide, glycolide, ε-caprolactone, poly(α-hydroxy acid), poly(amino acids), poly(anhydride), and various di- or tripeptides. [0049]
    [0050] Synthetic Polymers [0050]
    [0051] In order to prepare the compositions of the present invention, it is first necessary to provide a first synthetic polymer containing two or more nucleophilic groups, such as primary amino groups or thiol groups, and a second synthetic polymer containing two or more electrophilic groups capable of covalently binding with the nucleophilic groups on the second synthetic polymer, As used herein, the term “polymer” refers inter alia to polyalkyls, polyamino acids and polysaccharides. Additionally, for external or oral use, the polymer may be polyacrylic acid or carbopol. [0051]
    [0052] As used herein, the term “synthetic polymer” refers to polymers that are not naturally occurring and that are produced via chemical synthesis. As such, naturally occurring proteins such as collagen and naturally occurring polysaccharides such as hyaluronic acid are specifically excluded. Synthetic collagen, and synthetic hyaluronic acid, and their derivatives, are included. Synthetic polymers containing either nucleophilic or electrophilic groups are also referred to herein as “multifunctionally activated synthetic polymers”. The term “multifunctionally activated” (or, simply, “activated”) refers to synthetic polymers which have, or have been chemically modified to have, two or more nucleophilic or electrophilic groups which are capable of reacting with one another (i.e., the nucleophilic groups react with the electrophilic groups) to form covalent bonds. Types of multifunctionally activated synthetic polymers include difunctionally activated, tetrafunctionally activated, and star-branched polymers. [0052]
    [0053] Multifunctionally activated synthetic polymers for use in the present invention must contain at least two, more preferably, at least three, functional groups in order to form a three-dimensional crosslinked network with synthetic polymers containing multiple nucleophilic groups (i.e., “multi-nucleophilic polymers”). In other words, they must be at least difunctionally activated, and are more preferably trifunctionally or tetrafunctionally activated. If the first synthetic polymer is a difunctionally activated synthetic polymer, the second synthetic polymer must contain three or more functional groups in order to obtain a three- dimensional crosslinked network. Most preferably, both the first and the second synthetic polymer contain at least three functional groups. [0053]
    [0054] Synthetic Polymers Containing Multiple Nucleophilic Groups [0054]
    [0055] Synthetic polymers containing multiple nucleophilic groups are also referred to generically herein as “multi-nucleophilic polymers”. For use in the present invention, multi-nucleophilic polymers must contain at least two, more preferably, at least three, nucleophilic groups. If a synthetic polymer containing only two nucleophilic groups is used, a synthetic polymer containing three or more electrophilic groups must be used in order to obtain a three-dimensional crosslinked network. [0055]
    [0056] Preferred multi-nucleophilic polymers for use in the compositions and methods of the present invention include synthetic polymers that contain, or have been modified to contain, multiple nucleophilic groups such as primary amino groups and thiol groups. Preferred multi-nucleophilic polymers include: (i) synthetic polypeptides that have been synthesized to contain two or more primary amino groups or thiol groups; and (ii) polyethylene glycols that have been modified to contain two or more primary amino groups or thiol groups. In general, reaction of a thiol group with an electrophilic group tends to proceed more slowly than reaction of a primary amino group with an electrophilic group. [0056]
    [0057] Preferred multi-nucleophilic polypeptides are synthetic polypeptides that have been synthesized to incorporate amino acids containing primary amino groups (such as lysine) and/or amino acids containing thiol groups (such as cysteine). Poly(lysine), a synthetically produced polymer of the amino acid lysine (145 MW), is particularly preferred. Poly(lysine)s have been prepared having anywhere from 6 to about 4,000 primary amino groups, corresponding to molecular weights of about 870 to about 580,000. [0057]
    [0058] Poly(lysine)s for use in the present invention preferably have a molecular weight within the range of about 1,000 to about 300,000; more preferably, within the range of about 5,000 to about 100,000; most preferably, within the range of about 8,000 to about 15,000. Poly(lysine)s of varying molecular weights are commercially available from Peninsula Laboratories, Inc. (Belmont, Calif.). [0058]
    [0059] Polyethylene glycol can be chemically modified to contain multiple primary amino or thiol groups according to methods set forth, for example, in Chapter 22 of [0059] Poly(ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications, J. Milton Harris, ed., Plenum Press, NY (1992). Polyethylene glycols which have been modified to contain two or more primary amino groups are referred to herein as “multi-amino PEGs”. Polyethylene glycols which have been modified to contain two or more thiol groups are referred to herein as “multi- thiol PEGs”. As used herein, the term “polyethylene glycol(s)” includes modified and or derivatized polyethylene glycol(s).
    [0060] Various forms of multi-amino PEG are commercially available from Shearwater Polymers (Huntsville, Ala.) and from Texaco Chemical Company (Houston, Tex.) under the name “Jeffamine”. Multi-amino PEGs useful in the present invention include Texaco's Jeffamine diamines (“D” series) and triamines (“T” series), which contain two and three primary amino groups per molecule, respectively. General structures for the Jeffimine diamines and triamines are shown in FIG. 3. [0060]
    [0061] Polyamines such as ethylenediamine (H[0061] 2N—CH2 CH2—NH2), tetramethylenediamine (H2N-(CH2)4—NH2), pentamethylenediamine (cadaverine) (H2N-(CH2)5—NH2), hexamethylenediamine (H2N-(CH2)6—NH2), bis(2-hydroxyethyl)amine (HN-(CH2CH2OH2)2), bis(2)aminoethyl)amine (HN-(CH2CH2NH2)2), and tris(2-aminoethyl)amine (N-(CH2CH2NH2)3) may also be used as the synthetic polymer containing multiple nucleophilic groups.
    [0062] Synthetic Polymers Containing Multiple Electrophilic Groups [0062]
    [0063] Synthetic polymers containing multiple electrophilic groups are also referred to herein as “multi-electrophilic polymers.” For use in the present invention, the multifunctionally activated synthetic polymers must contain at least two, more preferably, at least three, electrophilic groups in order to form a three-dimensional crosslinked network with multi-nucleophilic polymers [0063]
    [0064] Preferred multi-electrophilic polymers for use in the compositions of the invention are polymers which contain two or more succinimidyl groups capable of forming covalent bonds with electrophilic groups on other molecules. Succinimidyl groups are highly reactive with materials containing primary amino (—NH[0064] 2) groups, such as multi-amino PEG, poly(lysine), or collagen. Succinimidyl groups are slightly less reactive with materials containing thiol (—SH) groups, such as multi-thiol PEG or synthetic polypeptides containing multiple cysteine residues.
    [0065] As used herein, the term “containing two or more succinimidyl groups” is meant to encompass polymers which are commercially available containing two or more succinimidyl groups, as well as those that must be chemically derivatized to contain two or more succinimidyl groups. As used herein, the term “succinimidyl group” is intended to encompass sulfosuccinimidyl groups and other such variations of the “generic” succinimidyl group. The presence of the sodium sulfite moiety on the sulfosuccinimidyl group serves to increase the solubility of the polymer. [0065]
    [0066] Hydrophilic Polymers [0066]
    [0067] Hydrophilic polymers and, in particular, various polyethylene glycols, are preferred for use in the compositions of the present invention. As used herein, the term “PEG” refers to polymers having the repeating structure (OCH[0067] 2 CH2)n.
    [0068] Structures for some specific, tetrafunctionally activated forms of PEG are shown in FIGS. [0068] 4 to 13, as are generalized reaction products obtained by reacting tetrafunctionally activated PEGs with multi-amino PEGs. As depicted in the Figures, the succinimidyl group is a five-member ring structure represented as —N(COCH2)2. In FIGS. 4 to 13, the symbol ΛΛΛ denotes an open linkage.
    [0069] FIG. 4 shows the reaction of tetrafunctionally activated PEG succinimidyl glutarate, referred to herein as SG-PEG, with multi-amino PEG, and the reaction product obtained thereby. [0069]
    [0070] Another activated form of PEG is referred to as PEG succinimidyl propionate [0070]
    [0071] (SE-PEG). The structural formula for tetrafunctionally activated SE-PEG and the reaction product obtained by reacting it with multi-amino PEG are shown in FIG. 5. In a general structural formula for the compound, the subscript 3 is replaced with an “m”. In the embodiment shown in FIG. 4, m=3, in that there are three repeating CH[0071] 2 groups on either side of the PEG.
    [0072] The structure in FIG. 5 results in a conjugate which includes an “ether” linkage which is less subject to hydrolysis. This is distinct from the conjugate shown in FIG. 4, wherein an ester linkage is provided. The ester linkage is subject to hydrolysis under physiological conditions. [0072]
    [0073] Yet another functionally activated form of polyethylene glycol, wherein m=2, is shown in FIG. 6, as is the conjugate formed by reacting the tetrafunctionally activated PEG with a multi-amino PEG. [0073]
    [0074] Another functionally activated PEG similar to the compounds of FIGS. 5 and 6 is provided when m=1. The structural formula of the tetrafunctionally activated PEG and resulting conjugate formed by reacting the activated PEG with multi-amino PEG are shown in FIG. 7. It is noted that this conjugate includes both an ether and a peptide linkage. These linkages are stable under physiological conditions. [0074]
    [0075] Another functionally activated form of PEG is referred to as PEG succinimidyl succinamide (SSA-PEG). The structural formula for the tetrafunctionally activated form of this compound and the reaction product obtained by reacting it with multi-amino PEG are shown in FIG. 8. In the structure shown in FIG. 8, m=2; however, related compounds, wherein m =1 or m =3 - 10, may also be used in the compositions of the invention. [0075]
    [0076] The structure in FIG. 8 results in a conjugate which includes an “amide” linkage which, like the ether linkage previously described, is less subject to hydrolysis and is therefore more stable than an ester linkage. [0076]
    [0077] Yet another activated form of PEG is provided when m=0. This compound is referred to as PEG succinimidyl carbonate (SC-PEG). The structural formula of tetrafunctionally activated SC-PEG and the conjugate formed by reacting it with multi-amino PEG are shown in FIG. 9. [0077]
    [0078] As discussed above, preferred activated polyethylene glycol derivatives for use in the invention contain succinimidyl groups as the reactive group. However, different activating groups can be attached at sites along the length of the PEG molecule. For example, PEG can be derivatized to form functionally activated PEG propion aldehyde (A-PEG), the tetrafunctionally activated form of which is shown in FIG. 10, as is the conjugate formed by the reaction of A-PEG with multi-amino PEG. The linkage shown in FIG. 10 is referred to as a -(CH[0078] 2)m—NH—linkage, where m=1- 10.
    [0079] Yet another form of activated polyethylene glycol is functionally activated PEG glycidyl ether (E-PEG), of which the tetrafunctionally activated compound is shown in FIG. 11, as is the conjugate formed by reacting such with multi-amino PEG. [0079]
    [0080] Another activated derivative of polyethylene glycol is functionally activated PEG-isocyanate (I-PEG), which is shown in FIG. 2, along with the conjugate formed by reacting such with multi-amino PEG. [0080]
    [0081] Another activated derivative of polyethylene glycol is functionally activated PEG-vinylsulfone (V-PEG), which is shown in FIG. 13, below, along with the conjugate formed by reacting such with multi-amino PEG. [0081]
    [0082] Preferred multifunctionally activated polyethylene glycols for use in the compositions of the present invention are polyethylene glycols containing succinimidyl groups, such as SG-PEG and SE-PEG (shown in FIGS. [0082] 4 -7), preferably in trifunctionally or tetrafunctionally activated form.
    [0083] Many of the activated forms of polyethylene glycol described above are now available commercially from Shearwater Polymers, Huntsville, Ala., and Union Carbide, South Charleston, W.Va. [0083]
    [0084] Hydrophobic Polymers [0084]
    [0085] Hydrophobic polymers can also be used to prepare the compositions of the present invention. Hydrophobic polymers for use in the present invention preferably contain, or can be derivatized to contain, two or more electrophilic groups, such as succinimidyl groups, most preferably, two, three, or four electrophilic groups. As used herein, the term “hydrophobic polymer” refers to polymers which contain a relatively small proportion of oxygen or nitrogen atoms. [0085]
    [0086] Hydrophobic polymers which already contain two or more succinimidyl groups include, without limitation, disuccinimidyl suberate (DSS), bis(sulfosuccinimidyl) suberate (BS[0086] 3), dithiobis(succinimidylpropionate) (DSP), bis(2-succinimidooxycarbonyloxy) ethyl sulfone (BSOCOES), and 3,3′-dithiobis(sulfosuccinimidylpropionate (DTSPP), and their analogs and derivatives. The above-referenced polymers are commercially available from Pierce (Rockford, Ill.), under catalog Nos. 21555,21579, 22585,21554, and 21577, respectively. Structural formulas for the above-referenced polymers, as well as generalized reaction products obtained by reacting each of these polymers with amino PEG, are shown below in FIGS. 14 -18, respectively.
    [0087] Preferred hydrophobic polymers for use in the invention generally have a carbon chain that is no longer than about 14 carbons. Polymers having carbon chains substantially longer than 14 carbons generally have very-poor solubility in aqueous solutions and, as such, have very long reaction times when mixed with aqueous solutions of synthetic polymers containing multiple nucleophilic groups. [0087]
    [0088] Derivatization of Polymers to Contain Functional Groups [0088]
    [0089] Certain polymers, such as polyacids, can be derivatized to contain two or more functional groups, such as succinimidyl groups. Polyacids for use in the present invention include, without limitation, trimethylolpropane-based tricarboxylic acid, di(trimethylol propane)-based tetracarboxylic acid, heptanedioic acid, octanedioic acid (suberic acid), and hexadecanedioic acid (thapsic acid). Many of these polyacids are commercially available from DuPont Chemical Company. [0089]
    [0090] According to a general method, polyacids can be chemically derivatized to contain two or more succinimidyl groups by reaction with an appropriate molar amount of [0090]
    [0091] N-hydroxysuccinimide (NHS) in the presence of N,N′-dicyclohexylcarbodiimide (DCC). [0091]
    [0092] Polyalcohols such as trimethylolpropane and di(trimethylol propane) can be converted to carboxylic acid form using various methods, then further derivatized by reaction with NHS in the presence of DCC to produce trifunctionally and tetrafunctionally activated polymers, respectively, as described in commonly owned, copending U.S. application Ser. No. 08/403,358. Polyacids such as heptanedioic acid (HOOC-(CH[0092] 2)5—COOH), octanedioic acid (HOOC-(CH2)6—COOH), and hexadecanedioic acid (HOOC-(CH2)14—COOH) are derivatized by the addition of succinimidyl groups to produce difunctionally activated polymers.
    [0093] Polyamines such as ethylenediamine (H[0093] 2N-CH2 CH2—NH2), tetramethylenediamine (H2N-(CH2)4—NH2), pentamethylenediamine (cadaverine) (H2N-(CH2)5—NH2), hexamethylenediamine (H2N-(CH2)6—NH2), bis(2-hydroxyethyl)amine (HN-(CH2CH2OH)2), bis(2)aminoethyl)amine (HN-(CH2CH2NH2)2), and tris(2-aminoethyl)amine (N-(CH2CH2NH2)3) can be chemically derivatized to polyacids, which can then be derivatized to contain two or more succinimidyl groups by reacting with the appropriate molar amounts of N-hydroxysuccinimide in the presence of DCC, as described in U.S. application Ser. No. 08/403,358. Many of these polyamines are commercially available from DuPont Chemical Company.
    [0094] Preparation of Crosslinked Polymer Compositions [0094]
    [0095] In a general method for preparing the crosslinked polymer compositions of the invention, a first synthetic polymer containing multiple nucleophilic groups is mixed with a second synthetic polymer containing multiple electrophilic groups. Formation of a three-dimensional crosslinked network occurs as a result of the reaction between the nucleophilic groups on the first synthetic polymer and the electrophilic groups on the second synthetic polymer. [0095]
    [0096] Hereinafter, the term “first synthetic polymer” will be used to refer to a synthetic polymer containing two or more nucleophilic groups, and the term “second synthetic polymer” will be used to refer to a synthetic polymer containing two or more electrophilic groups. The concentrations of the first synthetic polymer and the second synthetic polymer used to prepare the compositions of the present invention will vary depending upon a number of factors, including the types and molecular weights of the particular synthetic polymers used and the desired end use application. [0096]
    [0097] In general, we have found that when using multi-amino PEG as the first synthetic polymer, it is preferably used at a concentration in the range of about 0.5 to about 20 percent by weight of the final composition, while the second synthetic polymer is used at a concentration in the range of about 0.5 to about 20 percent by weight of the final composition. For example, a final composition having a total weight of 1 gram (1000 milligrams) would contain between about 5 to about 200 milligrams of multi-amino PEG, and between about 5 to about 200 milligrams of the second synthetic polymer. [0097]
    [0098] Use of higher concentrations of both first and second synthetic polymers will result in the formation of a more tightly crosslinked network, producing a stiffer, more robust gel. As such, compositions intended for use in tissue augmentation will generally employ concentrations of first and second synthetic polymer that fall toward the higher end of the preferred concentration range. Compositions intended for use as bioadhesives or in adhesion prevention do not need to be as firm and may therefore contain lower polymer concentrations. [0098]
    [0099] Because polymers containing multiple electrophilic groups will also react with water, the second synthetic polymer is generally stored and used in sterile, dry form to prevent the loss of crosslinking ability due to hydrolysis which typically occurs upon exposure of such electrophilic groups to aqueous media. Processes for preparing synthetic hydrophilic polymers containing multiple electrophylic groups in sterile, dry form are set forth in commonly assigned, copending U.S. application Ser. No. 08/497,573, filed Jun. 30, 1995. For example, the dry synthetic polymer may be compression molded into a thin sheet or membrane, which can then be sterilized using gamma or, preferably, e-beam irradiation. The resulting dry membrane or sheet can be cut to the desired size or chopped into smaller size particulates. [0099]
    [0100] Polymers containing multiple nucleophilic groups are generally not water- reactive and can therefore be stored in aqueous solution. [0100]
    [0101] The crosslinked polymer compositions can also be prepared to contain various imaging agents such as iodine or barium sulfate, or fluorine, in order to aid visualization of the compositions after administration via X-ray, or [0101] 19F-MRI, respectively.
    [0102] Incorporation of Other Components into the Crosslinked Synthetic Polymer [0102]
    [0103] Naturally occurring proteins, such as collagen, and derivatives of various naturally occurring polysaccharides, such as glycosaminoglycans, can additionally be incorporated into the compositions of the invention. When these other components also contain functional groups which will react with the functional groups on the synthetic polymers, their presence during mixing and/or crosslinking of the first and second synthetic polymer will result in formation of a crosslinked synthetic polymer-naturally occurring polymer matrix. In particular, when the naturally occurring polymer (protein or polysaccharide) also contains nucleophilic groups such as primary amino groups, the electrophilic groups on the second synthetic polymer will react with the primary amino groups on these components, as well as the nucleophilic groups on the first synthetic polymer, to cause these other components to become part of the polymer matrix. [0103]
    [0104] In general, glycosaminoglycans must be chemically derivatized by deacetylation, desulfation, or both in order to contain primary amino groups available for reaction with electrophilic groups on synthetic polymer molecules. Glycosaminoglycans that can be derivatized according to either or both of the aforementioned methods include the following: hyaluronic acid, chondroitin sulfate A, chondroitin sulfate B (dermatan sulfate), chondroitin sulfate C, chitin (can be derivatized to chitosan), keratan sulfate, keratosulfate, and heparin. Derivatization of glycosaminoglycans by deacetylation and/or desulfation and covalent binding of the resulting glycosaminoglycan derivatives with synthetic hydrophilic polymers is described in further detail in commonly assigned, allowed U.S. patent application Ser. No. 08/146,843, filed Nov. 3, 1993. [0104]
    [0105] Similarly, electrophilic groups on the second synthetic polymer will react with primary amino groups on lysine residues or thiol groups on cysteine residues of certain naturally occurring proteins. Lysine-rich proteins such as collagen and its derivatives are especially reactive with electrophilic groups on synthetic polymers. As used herein, the term “collagen” is intended to encompass collagen of any type, from any source, including, but not limited to, collagen extracted from tissue or produced recombinantly, collagen analogues, collagen derivatives, modified collagens, and denatured collagens such as gelatin. Covalent binding of collagen to synthetic hydrophilic polymers is described in detail in commonly assigned U.S. Pat. No. 5,162,430, issued Nov. 10, 1992, to Rhee et al.. [0105]
    [0106] In general, collagen from any source may be used in the compositions of the invention; for example, collagen may be extracted and purified from human or other mammalian source, such as bovine or porcine corium and human placenta, or may be recombinantly or otherwise produced. The preparation of purified, substantially non-antigenic collagen in solution from bovine skin is well known in the art. Commonly owned, U.S. Pat. No. 5,428,022, issued Jun. 27, 1995, to Palefsky et al., discloses methods of extracting and purifyng collagen from the human placenta. Commonly owned, copending U.S. application Ser. No. 08/183,648, filed Jan. 18, 1994, discloses methods of producing recombinant human collagen in the milk of transgenic animals, including transgenic cows. The term “collagen” or “collagen material” as used herein refers to all forms of collagen, including those which have been processed or otherwise modified. [0106]
    [0107] Collagen of any type, including, but not limited to, types I, II, III, IV, or any combination thereof, may be used in the compositions of the invention, although type I is generally preferred. Either atelopeptide or telopeptide-containing collagen may be used; however, when collagen from a xenogeneic source, such as bovine collagen, is used, atelopeptide collagen is generally preferred, because of its reduced immunogenicity compared to telopeptide-containing collagen. [0107]
    [0108] Collagen that has not been previously crosslinked by methods such as heat, irradiation, or chemical crosslinking agents is preferred for use in the compositions of the invention, although previously crosslinked collagen may be used. Non-crosslinked atelopeptide fibrillar collagen is commercially available from Collagen Corporation (Palo Alto, Calif.) at collagen concentrations of 35 mg/ml and 65 mg/ml under the trademarks Zyderm® I Collagen and Zyderm II Collagen, respectively. Glutaraldehyde crosslinked atelopeptide fibrillar collagen is commercially available from Collagen Corporation at a collagen concentration of 35 mg/ml under the trademark Zyplast® Collagen. [0108]
    [0109] Collagens for use in the present invention are generally in aqueous suspension at a concentration between about 20 mg/ml to about 120 mg/ml; preferably, between about 30 mg/ml to about 90 mg/ml. [0109]
    [0110] Although intact collagen is preferred, denatured collagen, commonly known as gelatin, can also be used in the compositions of the invention. Gelatin may have the added benefit of being degradable faster than collagen. [0110]
    [0111] Because of its tacky consistency, nonfibrillar collagen is generally preferred for use in compositions of the invention that are intended for use as bioadhesives. The term “nonfibrillar collagen” refers to any modified or unmodified collagen material that is in substantially nonfibrillar form at pH 7, as indicated by optical clarity of an aqueous suspension of the collagen. [0111]
    [0112] Collagen that is already in nonfibrillar form may be used in the compositions of the invention. As used herein, the term “nonfibrillar collagen” is intended to encompass collagen types that are nonfibrillar in native form, as well as collagens that have been chemically modified such that they are in nonfibrillar form at or around neutral pH. Collagen types that are nonfibrillar (or microfibrillar) in native form include types IV, VI, and VII. [0112]
    [0113] Chemically modified collagens that are in nonfibrillar form at neutral pH include succinylated collagen and methylated collagen, both of which can be prepared according to the methods described in U.S. Pat. No. 4,164,559, issued Aug. 14, 1979, to Miyata et al., which is hereby incorporated by reference in its entirety. Due to its inherent tackiness, methylated collagen is particularly preferred for use in bioadhesive compositions, as disclosed in commonly owned, U.S. application Ser. No. 08/476,825. [0113]
    [0114] Collagens for use in the crosslinked polymer compositions of the present invention may start out in fibrillar form, then be rendered nonfibrillar by the addition of one or more fiber disassembly agent. The fiber disassembly agent must be present in an amount sufficient to render the collagen substantially nonfibrillar at pH 7, as described above. Fiber disassembly agents for use in the present invention include, without limitation, various biocompatible alcohols, amino acids, inorganic salts, and carbohydrates, with biocompatible alcohols being-particularly preferred. Preferred biocompatible alcohols include glycerol and propylene glycol. Non-biocompatible alcohols, such as ethanol, methanol, and isopropanol, are not preferred for use in the present invention, due to their potentially deleterious effects on the body of the patient receiving them. Preferred amino acids include arginine. Preferred inorganic salts include sodium chloride and potassium chloride. Although carbohydrates, such as various sugars including sucrose, may be used in the practice of the present invention, they are not as preferred as other types of fiber disassembly agents because they can have cytotoxic effects in vivo. [0114]
    [0115] Because it is opaque and less tacky than nonfibillar collagen, fibrillar collagen is less preferred for use in bioadhesive compositions. However, as disclosed in commonly owned, U.S. application Ser. No. 08/476,825, fibrillar collagen, or mixtures of nonfibrillar and fibrillar collagen, may be preferred for use in adhesive compositions intended for long-term persistence in vivo, if optical clarity is not a requirement. [0115]
    [0116] For compositions intended for use in tissue augmentation, fibrillar collagen is preferred because it tends to form stronger crosslinked gels having greater long-term persistency in vivo than those prepared using nonfibrillar collagen. [0116]
    [0117] In general, the collagen is added to the first synthetic polymer, then the collagen and first synthetic polymer are mixed thoroughly to achieve a homogeneous composition. The second synthetic polymer is then added and mixed into the collagen / first synthetic polymer mixture, where it will covalently bind to primary amino groups or thiol groups on the first synthetic polymer and primary amino groups on the collagen, resulting in the formation of a homogeneous crosslinked network. Various deacetylated and/or desulfated glycosaminoglycan derivatives can be incorporated into the composition in a similar manner as that described above for collagen. [0117]
    [0118] For use in tissue adhesion as discussed below, it may also be desirable to incorporate proteins such as albumin, fibrin or fibrinogen into the crosslinked polymer composition to promote cellular adhesion. [0118]
    [0119] In addition, the introduction of hydrocolloids such as carboxymethylcellulose may promote tissue adhesion and/or swellability. [0119]
    [0120] Administration of the Crosslinked Synthetic Polymer Compositions [0120]
    [0121] The compositions of the present invention may be administered before, during or after crosslinking of the first and second synthetic polymer. Certain uses, which are discussed in greater detail below, such as tissue augmentation, may require the compositions to be crosslinked before administration, whereas other applications, such as tissue adhesion, require the compositions to be administered before crosslinking has reached “equilibrium.” The point at which crosslinking has reached equilibrium is defined herein as the point at which the composition no longer feels tacky or sticky to the touch. [0121]
    [0122] In order to administer the composition prior to crosslinking, the first synthetic polymer and second synthetic polymer may be contained within separate barrels of a dual-compartment syringe. In this case, the two synthetic polymers do not actually mix until the point at which the two polymers are extruded from the tip of the syringe needle into the patient's tissue. This allows the vast majority of the crosslinking reaction to occur in situ, avoiding the problem of needle blockage which commonly occurs if the two synthetic polymers are mixed too early and crosslinking between the two components is already too advanced prior to delivery from the syringe needle. The use of a dual-compartment syringe, as described above, allows for the use of smaller diameter needles, which is advantageous when performing soft tissue augmentation in delicate facial tissue, such as that surrounding the eyes. [0122]
    [0123] Alternatively, the first synthetic polymer and second synthetic polymer may be mixed according to the methods described above prior to delivery to the tissue site, then injected to the desired tissue site immediately (preferably, within about 60 seconds) following mixing. [0123]
    [0124] In another embodiment of the invention, the first synthetic polymer and second synthetic polymer are mixed, then extruded and allowed to crosslink into a sheet or other solid form. The crosslinked solid is then dehydrated to remove substantially all unbound water. The resulting dried solid may be ground or comminuted into particulates, then suspended in a nonaqueous fluid carrier, including, without limitation, hyaluronic acid, dextran sulfate, dextran, succinylated noncrosslinked collagen, methylated noncrosslinked collagen, glycogen, glycerol, dextrose, maltose, triglycerides of fatty acids (such as corn oil, soybean oil, and sesame oil), and egg yolk phospholipid. The suspension of particulates can be injected through a small-gauge needle to a tissue site. Once inside the tissue, the crosslinked polymer particulates will rehydrate and swell in size at least five-fold. [0124]
    [0125] Use of Crosslinked Synthetic Polymers to Deliver Charged Compounds [0125]
    [0126] By varying the relative molar amounts of the first synthetic polymer and the second synthetic polymer, it is possible to alter the net charge of the resulting crosslinked polymer composition, in order to prepare a matrix for the delivery of a charged compound (such as a protein or drug). As such, the delivery of charged proteins or drugs, which would normally diffuse rapidly out of a neutral carrier matrix, can be controlled. [0126]
    [0127] For example, if a molar excess of a first synthetic polymer containing multiple nucleophilic groups is used, the resulting matrix has a net positive charge and can be used to ionically bind and deliver negatively charged compounds. Examples of negatively charged compounds that can be delivered from these matrices include various drugs, cells, proteins, and polysaccharides. Negatively charged collagens, such as succinylated collagen, and glycosaminoglycan derivatives, such as sodium hyaluronate, keratan sulfate, keratosulfate, sodium chondroitin sulfate A, sodium dermatan sulfate B, sodium chondroitin sulfate C, heparin, esterified chondroitin sulfate C, and esterified heparin, can be effectively incorporated into the crosslinked polymer matrix as described above. [0127]
    [0128] If a molar excess of a second synthetic polymer containing multiple electrophilic groups is used, the resulting matrix has a net negative charge and can be used to ionically bind and deliver positively charged compounds. Examples of positively charged compounds that can be delivered from these matrices include various drugs, cells, proteins, and polysaccharides. Positively charged collagens, such as methylated collagen, and glycosaminoglycan derivatives, such as esterified deacetylated hyaluronic acid, esterified deacetylated desulfated chondroitin sulfate A, esterified deacetylated desulfated chondroitin sulfate C, deacetylated desulfated keratan sulfate, deacetylated desulfated keratosulfate, esterified desulfated heparin, and chitosan, can be effectively incorporated into the crosslinked polymer matrix as described above. [0128]
    [0129] Use of Crosslinked Synthetic Polymers to Deliver Biologically Active Agents [0129]
    [0130] The crosslinked polymer compositions of the present invention may also be used for localized delivery of various drugs and other biologically active agents. Biologically active agents such as growth factors may be delivered from the composition to a local tissue site in order to facilitate tissue healing and regeneration. [0130]
    [0131] The term “biologically active agent” or “active agent” as used herein refers to organic molecules which exert biological effects in vivo. Examples of active agents include, without limitation, enzymes, receptor antagonists or agonists, hormones, growth factors, autogenous bone marrow, antibiotics, antimicrobial agents and antibodies. The term “active agent” is also intended to encompass various cell types and genes which can be incorporated into the compositions of the invention. The term “active agent” is also intended to encompass combinations or mixtures of two or more active agents, as defined above. [0131]
    [0132] Preferred active agents for use in the compositions of the present invention include growth factors, such as transforming growth factors (TGFs), fibroblast growth factors (FGFs), platelet derived growth factors (PDGFs), epidermal growth factors (EGFs), connective tissue activated peptides (CTAPs), osteogenic factors, and biologically active analogs, fragments, and derivatives of such growth factors. Members of the transforming growth factor (TGF) supergene family, which are multifunctional regulatory proteins, are particularly preferred. Members of the TGF supergene family include the beta transforming growth factors (for example, TGF-β1, TGF-β2, TGF-β3); bone morphogenetic proteins (for example, BMP-1, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9); heparin-binding growth factors (for example, fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF)); Inhibins (for example, Inhibin A, Inhibin B); growth differentiating factors (for example, GDF-1); and Activins (for example, Activin A, Activin B, Activin AB). [0132]
    [0133] Growth factors can be isolated from native or natural sources, such as from mammalian cells, or can be prepared synthetically, such as by recombinant DNA techniques or by various chemical processes. In addition, analogs, fragments, or derivatives of these factors can be used, provided that they exhibit at least some of the biological activity of the native molecule. For example, analogs can be prepared by expression of genes altered by site-specific mutagenesis or other genetic engineering techniques. [0133]
    [0134] Biologically active agents may be incorporated into the crosslinked synthetic polymer composition by admixture. Alternatively, the agents may be incorporated into the crosslinked polymer matrix, as described above, by binding these agents with the functional groups on the synthetic polymers. Processes for covalently binding biologically active agents such as growth factors using functionally activated polyethylene glycols are described in commonly assigned U.S. Pat. No. 5,162,430, issued Nov. 10, 1992, to Rhee et al.. Such compositions preferably include linkages that can be easily biodegraded, for example as a result of enzymatic degradation, resulting in the release of the active agent into the target tissue, where it will exert its desired therapeutic effect. [0134]
    [0135] A simple method for incorporating biologically active agents containing nucleophilic groups into the crosslinked polymer composition involves mixing the active agent with the first synthetic polymer (or first synthetic polymer / collagen mixture) prior to adding the second synthetic polymer. This procedure will result in covalent binding of the active agent to the crosslinked polymer composition, producing a highly effective sustained release composition. [0135]
    [0136] The type and amount of active agent used will depend, among other factors, on the particular site and condition to be treated and the biological activity and pharmacokinetics of the active agent selected. [0136]
    [0137] Use of Crosslinked Synthetic Polymers to Deliver Cells or Genes [0137]
    [0138] The crosslinked polymer compositions of the present invention can also be used to deliver various types of living cells or genes to a desired site of administration in order to form new tissue. The term “genes” as used herein is intended to encompass genetic material from natural sources, synthetic nucleic acids, DNA, antisense-DNA and RNA. [0138]
    [0139] When used to deliver cells, for example, mesenchymal stem cells can be delivered to produce cells of the same type as the tissue into which they are delivered. Mesenchymal stem cells are not differentiated and therefore can differentiate to form various types of new cells due to the presence of an active agent or the effects (chemical, physical, etc.) of the local tissue environment. Examples of mesenchymal stem cells include osteoblasts, chondrocytes, and fibroblasts. Osteoblasts can be delivered to the site of a bone defect to produce new bone; chondrocytes can be delivered to the site of a cartilage defect to produce new cartilage; fibroblasts can be delivered to produce collagen wherever new connective tissue is needed; neurectodermal cells can be delivered to form new nerve tissue; epithelial cells can be delivered to form new epithelial tissues, such as liver, pancreas, etc.. [0139]
    [0140] The cells or genes may be either allogeneic or xenogeneic in origin. For example, the compositions can be used to deliver cells or genes from other species which have been genetically modified. Because the compositions of the invention are not easily degraded in vivo, cells and genes entrapped within the crosslinked polymer compositions will be isolated from the patient's own cells and, as such, will not provoke an immune response in the patient. In order to entrap the cells or genes within a crosslinked polymer matrix, the first polymer and the cells or genes may be pre-mixed, then the second polymer is mixed into the first polymer/cell or gene mixture to form a crosslinked matrix, thereby entrapping the cells or genes within the matrix. [0140]
    [0141] As discussed above for biologically active agents, when used to deliver cells or genes, the synthetic polymers preferably also contain biodegradable groups to aid in controlled release of the cells or genes at the intended site of delivery. [0141]
    [0142] Use of the Crosslinked Synthetic Polymers as Bioadhesives [0142]
    [0143] We have found that the preferred compositions of the invention tend to have unusually high tackiness, making them particularly suitable for use as bioadhesives, for example, for use in surgery. As used herein, the terms “bioadhesive”, “biological adhesive”, and “surgical adhesive” are used interchangeably to refer to biocompatible compositions capable of effecting temporary or permanent attachment between the surfaces of two native tissues, or between a native tissue surface and a non-native tissue surface or a surface of a synthetic implant. [0143]
    [0144] In a general method for effecting the attachment of a first surface to a second surface, the first synthetic polymer and the second synthetic polymer are applied to a first surface, then the first surface is contacted with a second surface to effect adhesion between the first surface and the second surface. Preferably, the first synthetic polymer and second synthetic polymer are first mixed to initiate crosslinking, then delivered to a first surface before substantial crosslinking has occurred between the nucleophilic groups on the first synthetic polymer and the electrophilic groups on the second synthetic polymer. The first surface is then contacted with the second surface, preferably immediately, to effect adhesion between the two surfaces. At least one of the first and second surfaces is preferably a native tissue surface. [0144]
    [0145] For example, the first synthetic polymer and second synthetic polymer are generally provided in separate syringes, the contents of which-are then mixed together using syringe-to-syringe mixing techniques just prior to delivery to a first surface. The first synthetic polymer and second synthetic polymer are preferably mixed for a minimum of 20 (preferably, 20 to 100; more preferably, 30 to 60) passes to ensure adequate mixing. As crosslinking between the corresponding reactive groups on the two synthetic polymers is generally initiated during the mixing process, it is important to deliver the reaction mixture to the first surface as soon as possible after mixing. [0145]
    [0146] The reaction mixture can be extruded onto the first surface from the opening of a syringe or other appropriate extrusion device. Following application, the extruded reaction mixture can be spread over the first surface using a spatula, if necessary. Alternatively, the first synthetic polymer and the second synthetic polymer can be mixed together in an appropriate mixing dish or vessel, then applied to the first surface using a spatula. [0146]
    [0147] In another method for preparing the reaction mixture, the first synthetic polymer and second synthetic polymer are contained in separate chambers of a spray can or bottle with a nozzle, or other appropriate spraying device. In this scenario, the first and second polymers do not actually mix until they are expelled together from the nozzle of the spraying device. Following application of the reaction mixture to a surface containing collagen, the first surface is contacted with a second surface. If the two surfaces are contacted before substantial crosslinking has occurred between the synthetic polymer and the crosslinking agent, the reactive groups on the crosslinking agent will also covalently bond with primary amino groups on lysine residues of collagen molecules present on either or both of the surfaces, providing improved adhesion. [0147]
    [0148] The two surfaces may be held together manually, or using other appropriate means, while the crosslinking reaction is proceeding to completion. Crosslinking is typically complete within 5 to 60 minutes after mixing of the first and second synthetic polymers. However, the time required for complete crosslinking to occur is dependent on a number of factors, including the types and molecular weights of the two synthetic polymers and, most particularly, the concentrations of the two synthetic polymers (i.e., higher concentrations result in faster crosslinking times). [0148]
    [0149] At least one of the first and second surfaces is preferably a native tissue surface. As used herein, the term “native tissue” refers to biological tissues that are native to the body of the specific patient being treated. As used herein, the term “native tissue” is intended to include biological tissues that have been elevated or removed from one part of the body of a patient for implantation to another part of the body of the same patient (such as bone autografts, skin flap autografts, etc.). For example, the compositions of the invention can be used to adhere a piece of skin from one part of a patient's body to another part of the body, as in the case of a burn victim. [0149]
    [0150] The other surface may be a native tissue surface, a non-native tissue surface, or a surface of a synthetic implant. As used herein, the term “non-native tissue” refers to biological tissues that have been removed from the body of a donor patient (who may be of the same species or of a different species than the recipient patient) for implantation into the body of a recipient patient (e.g., tissue and organ transplants). For example, the crosslinked polymer compositions of the present invention can be used to adhere a donor cornea to the eye of a recipient patient. [0150]
    [0151] As used herein, the term “synthetic implant” refers to any biocompatible material intended for implantation into the body of a patient not encompassed by the above definitions for native tissue and non-native tissue. Synthetic implants include, for example, artificial blood vessels, heart valves, artificial organs, bone prostheses, implantable lenticules, vascular grafts, stents, and stent/graft combinations, etc.. [0151]
    [0152] Use of Crosslinked Synthetic Polymers in Ophthalmic Applications [0152]
    [0153] Because of their optical clarity, the crosslinked polymer compositions of the invention which do not contain collagen are particularly well suited for use in ophthalmic applications. For example, a synthetic lenticule for correction of vision can be attached to the Bowman's layer of the cornea of a patient's eye using the methods of the present invention. As disclosed in commonly assigned, allowed U.S. application Ser. No. 08/147,227, filed Nov. 3,1993, by Rhee et al., a chemically modified collagen (such as succinylated or methylated collagen) which is in substantially nonfibrillar form at pH 7 can be crosslinked using a synthetic hydrophilic polymer, then molded into a desired lenticular shape and allowed to complete crosslinking. The resulting crosslinked collagen lenticule can then be attached to the Bowman's layer of a de-epithelialized cornea of a patient's eye using the methods of the present invention. By applying the reaction mixture comprising the first and second synthetic polymers to the anterior surface of the cornea, then contacting the anterior surface of the cornea with the posterior surface of the lenticule before substantial crosslinking has occurred, electrophilic groups on the second synthetic polymer will also covalently bind with collagen molecules in both the corneal tissue and the lenticule to firmly anchor the lenticule in place. (Alternatively, the reaction mixture can be applied first to the posterior surface of the lenticule, which is then contacted with the anterior surface of the cornea.) [0153]
    [0154] The compositions of the present invention are also suitable for use in vitreous replacement. [0154]
    [0155] Use of Crosslinked Synthetic Polymer Compositions in Tissue Augmentation [0155]
    [0156] The crosslinked polymer compositions of the invention can also be used for augmentation of soft or hard tissue within the body of a mammalian subject. [0156]
    [0157] As such, they may be better than currently marketed collagen-based materials product for soft tissue augmentation, because they are less immunogenic and more persistent. Examples of soft tissue augmentation applications include sphincter (e.g., urinary, anal, esophageal) sphincter augmentation and the treatment of rhytids and scars. Examples of hard tissue augmentation applications include the repair and/or replacement of bone and/or cartilaginous tissue. [0157]
    [0158] The compositions of the invention are particularly suited for use as a replacement material for synovial fluid in osteoarthritic joints, where the crosslinked polymer compositions serve to reduce joint pain and improve joint function by restoring a soft hydrogel network in the joint. The crosslinked polymer compositions can also be used as a replacement material for the nucleus pulposus of a damaged intervertebral disk. As such, the nucleus pulposus of the damaged disk is first removed, then the crosslinked polymer composition is injected or otherwise introduced into the center of the disk. The composition may either be crosslinked prior to introduction into the disk, or allowed to crosslink in situ. [0158]
    [0159] In a general method for effecting augmentation of tissue within the body of a mammalian subject, the first and second synthetic polymers are injected simultaneously to a tissue site in need of augmentation through a small-gauge (e.g., 25 - 32 gauge) needle. Once inside the patient's body, the nucleophilic groups on the first synthetic polymer and the electrophilic groups on the second synthetic polymer will react with each other to form a crosslinked polymer network in situ. Electrophilic groups on the second synthetic polymer may also react with primary amino groups on lysine residues of collagen molecules within the patient's own tissue, providing for “biological anchoring” of the compositions with the host tissue. [0159]
    [0160] Use of the Crosslinked Synthetic Polymer Compositions to Prevent Adhesions [0160]
    [0161] Another use of the crosslinked polymer compositions of the invention is to coat tissues in order to prevent the formation of adhesions following surgery or injury to internal tissues or organs. In a general method for coating tissues to prevent the formation of adhesions following surgery, the first and second synthetic polymers are mixed, then a thin layer of the reaction mixture is applied to the tissues comprising, surrounding, and/or adjacent to the surgical site before substantial crosslinking has occurred between the nucleophilic groups on the first synthetic polymer and the electrophilic groups on the second synthetic polymer. Application of the reaction mixture to the tissue site may be by extrusion, brushing, spraying (as described above), or by any other convenient means. [0161]
    [0162] Following application of the reaction mixture to the surgical site, crosslinking is allowed to continue in situ prior to closure of the surgical incision. Once crosslinking has reached equilibrium, tissues which are brought into contact with the coated tissues will not stick to the coated tissues. At this point in time, the surgical site can be closed using conventional means (sutures, etc.). [0162]
    [0163] In general, compositions that achieve complete crosslinking within a relatively short period of time (i.e., 5 - 15 minutes following mixture of the first synthetic polymer and the second synthetic polymer) are preferred for use in the prevention of surgical adhesions, so that the surgical site may be closed relatively soon after completion of the surgical procedure. [0163]
    [0164] Use of the Crosslinked Synthetic Polymers to Coat Implants [0164]
    [0165] Another use of the crosslinked polymer compositions of the invention is as a coating material for synthetic implants. In a general method for coating a surface of a synthetic implant, the first and second synthetic polymers are mixed, then a thin layer of the reaction mixture is applied to a surface of the implant before substantial crosslinking has occurred between the nucleophilic groups on the first synthetic polymer and the electrophilic groups on the second synthetic polymer. In order to minimize cellular and fibrous reaction to the coated implant, the reaction mixture is preferably prepared to have a net neutral charge. Application of the reaction mixture to the implant surface may be by extrusion, brushing, spraying (as described above), or by any other convenient means. Following application of the reaction mixture to the implant surface, crosslinking is allowed to continue until complete crosslinking has been achieved. [0165]
    [0166] Although this method can be used to coat the surface of any type of synthetic implant, it is particularly useful for implants where reduced thrombogenicity is an important consideration, such as artificial blood vessels and heart valves, vascular grafts, vascular stents, and stent/graft combinations. The method may also be used to coat implantable surgical membranes (e.g., monofilament polypropylene) or meshes (e.g., for use in hernia repair). Breast implants may also be coated using the above method in order to minimize capsular contracture. [0166]
    [0167] The compositions of the present invention may also be used to coat lenticules, which are made from either naturally occurring or synthetic polymers. [0167]
    [0168] Use of the Crosslinked Synthetic Polymers to Treat Aneurism [0168]
    [0169] The crosslinked polymer compositions of the invention can be extruded or molded in the shape of a string or coil, then dehydrated. The resulting dehydrated string or coil can be delivered via catheter to the site of a vascular malformation, such as an aneurysm, for the purpose of vascular occlusion and, ultimately, repair of the malformation. The dehydrated string or coil can be delivered in a compact size and will rehydrate inside the blood vessel, swelling several times in size compared to its dehydrated state, while maintaining its original shape. [0169]
    [0170] Other Uses for the Crosslinked Synthetic Polymers [0170]
    [0171] As discussed in commonly assigned, copending application Ser. No. 08/574,050, filed Dec. 18, 1995, which is incorporated herein by reference, the crosslinked polymer compositions of the invention can be used to block or fill various lumens and voids in the body of a mammalian subject. The compositions can also be used as biosealants to seal fissures or crevices within a tissue or structure (such as a vessel), or junctures between adjacent tissues or structures, to prevent leakage of blood or other biological fluids. [0171]
    [0172] The crosslinked polymer compositions can also be used as a large space-filling device for organ displacement in a body cavity during surgical or radiation procedures, for example, to protect the intestines during a planned course of radiation to the pelvis. [0172]
    [0173] The crosslinked polymer compositions of the invention can also be coated onto the interior surface of a physiological lumen, such as a blood vessel or Fallopian tube, thereby serving as a sealant to prevent restenosis of the lumen following medical treatment, such as, for example, balloon catheterization to remove arterial plaque deposits from the interior surface of a blood vessel, or removal of scar tissue or endometrial tissue from the interior of a Fallopian tube. A thin layer of the reaction mixture is preferably applied to the interior surface of the vessel (for example, via catheter) immediately following mixing of the first and second synthetic polymers. Because the compositions of the invention are not readily degradable in vivo, the potential for restenosis due to degradation of the coating is minimized. The use of crosslinked polymer compositions having a net neutral charge further minimizes the potential for restenosis. [0173] EXAMPLES
    [0174] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make the preferred embodiments of the conjugates, compositions, and devices and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, molecular weight, etc.) but some experimental errors and deviation should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric. [0174] EXAMPLE 1 (Preparation of Crosslinked Multi-amino PEG Compositions)
    [0175] 0.15 grams of di-amino PEG (3400 MW, obtained from Shearwater Polymers, Huntsville, Ala) in 250 ul of water was mixed with 0.1 g of trifunctionally activated SC-PEG (5000 MW, also obtained from Shearwater Polymers) using syringe-to-syringe mixing. The reaction mixture was extruded onto a petri dish and formed a soft gel at room temperature. [0175]
    [0176] 0.15 gram of di-amino PEG in 250 μl of water was mixed with 0.1 g of tetrafunctionally activated SE-PEG (also from Shearwater Polymers) using syringe-to-syringe mixing. The reaction mixture was extruded onto a petri dish and formed a soft gel at room temperature. [0176] EXAMPLE 2 (Preparation of Crosslinked Multi-amino PEG Compositions)
    [0177] The following stock solutions of various di-amino PEGs were prepared: [0177]
    [0178] Ten (10) grams of Jeffamine ED-2001 (obtained from Texaco Chemical Company, Houston, Tex.) was dissolved in 9 ml of water. [0178]
    [0179] Ten (10) grams of Jeffamine ED-4000 (also obtained from Texaco Chemical Company) was dissolved in 9 ml of water. 0.1 grams of di-amino PEG (3400 MW, obtained from Shearwater Polymers, Huntsville, Ala.) was dissolved in 300 μl of water. [0179]
    [0180] Each of the three di-amino PEG solutions prepared above was mixed with aqueous solutions of trifunctionally activated SC-PEG (TSC-PEQ, 5000 MW, also obtained from Shearwater Polymers) as set forth in Table 1, below. [0180] TABLE 1 Preparation of Crosslinked Polymer CompositionsDi-amino PEG TSC-PEG + Aqueous Solvent 50 ul   0 mg + 50 μl water 50 ul 10 mg + 50 μl PBS  50 ul 10 mg + 100 μl PBS 250 ul  50 mg + 500 μl PBS
    [0181] The solutions of di-amino PEG and TSC-PEG were mixed using syringe-to-syringe mixing. Each of the materials was extruded from the syringe and allowed to set for 1 hour at 37° C. Each of the materials formed a gel. In general, the gels became softer with increasing water content; the gels containing the least amount of aqueous solvent (water or PBS) were firmest. [0181] EXAMPLE 3 (Characterization of Crosslinked Multi-amino PEG Compositions)
    [0182] Fifty (50) milligrams of tetra-amino PEG (10,000 MW, obtained from Shearwater Polymers, Huntsville, Ala.) in 0.5 ml PBS was mixed, using syringe-to-syringe mixing, with 50 mg of tetrafunctionally activated SE-PEG (“tetra SE-PEG”, 10,000 MW, also obtained from Shearwater Polymers) in 0.5 ml PBS or trifunctionally activated SC-PEG (“tri SC-PEG”, 5000 MW, also obtained from Shearwater Polymers) in 0.5 ml PBS. [0182]
    [0183] Syringes containing each of the two mixtures were incubated at 37° C. for approximately 16 hours. Both compositions formed elastic gels. The gels were pushed out of the syringes and sliced into 5 - 6 mm thick disks having a diameter of 5 mm, for use in compression and swellability testing, as described below. [0183]
    [0184] Compression force versus displacement for the two gels was measured in the Instron Universal Tester, Model 4202, at a compression rate of 2 mm per minute, using disks of the two gels prepared as described above. Compression force (in Newtons) versus gel displacement (in millimeters) is shown in FIGS. [0184] 1 and 2 for gels prepared using the tetra SE-PEG and tri SC-PEG, respectively.
    [0185] Under compression forces as high as 30 - 35 Newtons, the gels did not break, but remained elastic. [0185]
    [0186] Disks of each of the two gels, prepared as described above, were weighed and the dimensions (diameter and length) measured. The disks were then immersed in PBS and incubated at 37° C. After 3 days incubation, the disks were removed from the PBS, weighed, and measured. Results of swellability testing are shown in Table 2, below. [0186] TABLE 2 Swellability Testing of Crosslinked Multi-amino PEG Compositions Dimensions (in mm) Gel Weight (in grams) (diameter/thickness) Crosslinking Before After Before After Agent Swelling Swelling Swelling Swelling Tetra SE-PEG 0.116 0.310 5.0/5.0 7.1/8.1 Tri SC-PEG 0.131 0.287 5.0/6.0 6.4/8.5
    [0187] As shown above, the gels swelled two to three times in weight, as well as swelling an average of about 50% in both diameter and thickness. [0187] EXAMPLE 4 (Preparation of Crosslinked Poly(lysine) Compositions)
    [0188] Ten (10) milligrams of poly-L-lysine hydrobromide (8,000 MW, obtained from Peninsula Laboratories, Belmont, Calif.) in 0.1 ml phosphate buffer (0.2 M, pH=6.6) was mixed with 10 mg of tetraflnctionally activated SE-PEG (10,000 MW, obtained from Shearwater Polymers, Huntsville, Ala.) in 0.1 ml PBS. The composition formed a soft gel almost immediately. [0188] EXAMPLE 5 (Preparation and Mechanical Testing of Crosslinked Multi-amnino PEG Compositions)
    [0189] Gels comprising tetra-amino PEG (10,000 MW, obtained from Shearwater Polymers, Huntsville, Ala.) and 14% (by weight) of tetrafunctionally activated SE-PEG (“tetra SE-PEG”, 10,000 MW, also obtained from Shearwater Polymers) were prepared by mixing the tetra-amino PEG (at a concentration of 25 mg/ml in water) with the tetra SE-PEG (in PBS) in a petri dish. The resulting tetra-amino PEG / SE-PEG mixtures were incubated for 16 hours at 37° C. [0189]
    [0190] The mixture containing 1% SE-PEG did not form a gel due to the low SE-PEG concentration. The mixture containing 2% SE-PEG formed a gel at some point during the 16-hour incubation period. The mixtures containing 3 and 4% SE-PEG formed gels within approximately 46 minutes of mixing. The gel containing 2% SE-PEG was readily extrudable through a 30-gauge needle; the gel containing 3% SE-PEG could be extruded through a 27-gauge needle. [0190]
    [0191] The effect of elevated temperature on gel formation was evaluated. Gels comprising tetra-amino PEG and 2.5% (by weight) tetra SE-PEG were prepared and incubated at temperatures of 37° C and 40-50° C. Elevated temperature was found to have a marked effect on gelation time: the tetra-amino PEG / SE-PEG mixture incubated at 37° C. formed a gel within approximately 20-25 minutes, whereas mixtures incubated at 40-50° C formed gels within approximately 5 minutes. Both gels were extrudable through a 27-gauge needle. The effect of pH on gel formation was evaluated. Gels comprising tetra-amino PEG and 2.5% (by weight) tetra SE-PEG were prepared as set forth in Table 3, below. [0191] TABLE 3 Effect of pH on Gel Formation of Tetra-amino PEG/Tetra SE-PEG Formulations pH of pH of pH of Tetra-amino Tetra Resulting Gelation PEG SE-PEG Mixture Gelation Time Temp. 10 4.1 6.9 10-15 minutes 45° C. 10 7.0 7.2 <5 minutes 45° C.
    [0192] Extrudability through a 27-gauge needle was evaluated for gels comprising tetra-amino PEG and 1 - 3% (by weight) tetra SE-PEG. The gels were contained within 1-cc syringes. The force required to depress the syringe plunger at a rate of 5 centimeters per minute was measured using the Instron Universal Tester, Model 4202. Results of extrusion testing are presented in Table 4, below. [0192] TABLE 4 Extrusion of Tetra-amino PEG/Tetra SE-PEG Gels Through a 27-Gauge NeedleConcentration of SE-PEG (by weight) Extrusion Force (N) 1.5-2% 10-11   2-2.5% 52 2.5-3% 88
    [0193] Extrusion forces of 100 N or less are considered acceptable for manual injection without the aid of a syringe assist device. [0193]
    [0194] Tensile strength (i.e., elasticity) of 3 mm thick gels comprising tetra-amino PEG and 2.5, 5, and 10% (by weight) tetra SE-PEG was measured using the Instron Universal Tester, Model 4202. Gels of varying initial lengths were stretched at a rate of 10 millimeters per minute. Length of each gel, strain at failure (change in length as a percentage of the initial length), and force at failure are set forth in Table 5, below. [0194] TABLE 5 Tensile Strength of Tetra-amino PEG/Tetra SE-PEG GelsSE-PEG Conc. Initial Strain at Force at (wt %) Length (cm) Failure Failure (N) 10 1.4 139% 0.4 10 1.9  99% 0.5 10 2.5  78% 0.5 5 1.3 111% 0.2 5 1.3  99% 0.2 5 1.6  94% 0.2 2.5 1.0 237% <0.1 2.5 1.5 187% <0.1 2.5 1.7 129% <0.1
    [0195] Gels containing 5 and 10% tetra SE-PEG approximately doubled in length prior to breaking. Gels containing 2.5% SE-PEG approximately tripled in length prior to breaking, but were considerably weaker (i.e., lower force at failure) than the more highly crosslinked gels. [0195] EXAMPLE 6 (Effect of pH on Gel Formation of Tetra-amino PEG/Tetra SE-PEG Formulations)
    [0196] Gels comprising various concentrations of tetra-amino PEG and tetra SE-PEG at pH 6, 7, and 8 were prepared in petri dishes. Following mixing of the tetra-amino PEG and tetra SE-PEG, the dishes were tilted repeatedly; the gelation time was considered to be the point at which the formulation ceased to flow. The effect of pH on gelation time of the various tetra-amino PEG / tetra SE-PEG formulations at room temperature is shown in Table 6, below. [0196] TABLE 6 Effect of pH on Gel Formation of Tetra-amino PEG/Tetra SE-PEG FormulationsTetra-amino PEG Tetra SE-PEG Conc. (mg/ml) Conc. (mg/ml) pH Gelation Time 20 20 6 >90.0 min 20 20 7 20.0 min 20 20 8 1.4 min 50 50 6 24.0 min 50 50 7 3.5 min 50 50 8 10.0 sec 100 100 6 9.0 min 100 100 7 47.0 sec 100 100 8 10.0 sec 200 200 6 2.0 min 200 200 7 9.0 sec 200 200 8 5.0 sec
    [0197] The time required for gel formation decreased with increasing pH and increasing tetra-amino PEG and tetra SE-PEG concentrations. [0197] EXAMPLE 7 (Culturing of Cells in Crosslinked Multi-amino PEG Matrix)
    [0198] Thirty (30) milligrams of tetra-amino PEG (10,000 MW, obtained from Shearwater Polymers, Huntsville, Ala.) was dissolved in 0.6 ml PBS, then sterile filtered. Thirty (30) milligrams of tetrafunctionally activated SE-PEG (“tetra SE- PEG”, 10,000 MW, also obtained from Shearwater Polymers) was dissolved in 0.6 ml of PBS, then sterile filtered. [0198]
    [0199] The solutions of tetra-amino PEG and tetra SE-PEG were mixed together with a pellet containing human skin fibroblast (“HSF” ) cells (CRL #1885, passage 4, obtained from American Tissue Type Culture Collection, Rockville, Md.). Two hundred fifty (250) microliters of the resulting cell-containing tetra-amino PEG / tetra SE-PEG (PEG-PEG) solution was dispensed into each of two wells on a 48-well culture plate and allowed to gel for approximately 5 minutes at room temperature. One (1) milliter of Dulbecco Modified Eagle's Media (supplemented with 10% fetal bovine serum, L-glutamine, penicillin-streptomycin, and non-essential amino acids) was added to each of the two wells. The concentration of cells was approximately 3×10[0199] 5 cells per milliliter of tetra- amino PEG / tetra SE-PEG solution, or 7.5×105 cells per well.
    [0200] To prepare a control, a pellet of HSF cells were suspended in 1.2 ml of complete media. Two hundred fifty (250) microliters of the control mixture was dispensed into each of three wells on the same 48-well culture plate as used above. Each well was estimated to contain approximately 7.5×10[0200] 5 cells. Each well was given fresh media every other day.
    [0201] Initially, the cell-containing tetra-amino PEG tetra SE-PEG gels were clear and the cells were found to be densely populated and spheroidal in morphology, indicating that there was little adhesion between the cells and the PEG/PEG gel (the cells would normally assume a flattened, spindle-shaped morphology when adhered to a substrate, such as to the treated plastic of the tissue culture plates). After three 3 days incubation at 37° C., the media in the wells containing the PEG/PEG gels was found to have lightened in color (Dulbecco Modified Eagle's Media is normally red in color), indicating a pH change in the media. This indicated that the cells were alive and feeding. At 7 days incubation at 37° C., the cells were still spheroidal in morphology (indicating lack of adhesion to the gel) and the media had lightened even further, indicating that the cells were still viable and continued to feed. [0201]
    [0202] On day 7, the contents of each well were placed in a 10% formalin solution for histological evaluation. According to histological evaluation, an estimated 75% of the cells in the wells containing the PEG/PEG gels appeared to be alive, but did not appear to be reproducing. [0202]
    [0203] The results of the experiment indicate that HSF cells are viable in the tetra- amino PEG/tetra SE-PEG crosslinked gels, but did not seem to adhere to the gel and did not appear to reproduce while entrapped within the gel matrix. As described above, adherence or non-adherence of cells to a substrate material can influence the cells' morphology. In certain types of cells, cellular morphology can, in turn, influence certain cellular functions. Therefore, non-adherence of the cells to the PEG - PEG gel matrix may be an advantage in the delivery of particular cell types whose function is influenced by cell morphology. For example, the ability of cartilage cells to produce extracellular matrix materials is influenced by cellular morphology: when the cells are in the flattened, spindle- shaped configuration, the cells are in reproductive mode; when the cells are in the spheroidal configuration, reproduction stops, and the cells begin to produce extracellular matrix components. [0203]
    [0204] Because the PEG - PEG gels are not readily degraded in vivo, the gels may be particularly useful in cell delivery applications where it is desirable that the cells remain entrapped within the matrix for extended periods-of time: [0204]
    权利要求:
    Claims (65)
    [1" id="US-20010003126-A1-CLM-00001] 1. A composition comprising a first synthetic polymer having nucleophilic groups, and a second synthetic polymer having electrophilic groups, wherein said nucleophilic groups and said electrophylic groups are capable of reacting to form covalent bonds between the first synthetic polymer and the second synthetic polymer which results in formation of a three-dimensional matrix.
    [2" id="US-20010003126-A1-CLM-00002] 2. The composition of
    claim 1 , wherein said first synthetic polymer has m nucleophilic groups, and said second synthetic polymer has n nucleophilic groups, wherein m and n are each greater than or equal to 2, and wherein m+n is greater than or equal to 5.
    [3" id="US-20010003126-A1-CLM-00003] 3. The composition of
    claim 2 , wherein m is greater than or equal to two, and n=2.
    [4" id="US-20010003126-A1-CLM-00004] 4. The composition of
    claim 2 wherein m=2, and n is greater than or equal to two.
    [5" id="US-20010003126-A1-CLM-00005] 5. The composition of
    claim 2 , wherein m and n are each greater than or equal to three.
    [6" id="US-20010003126-A1-CLM-00006] 6. The composition of
    claim 1 , wherein the first synthetic polymer is a synthetic polypeptide that contains two or more nucleophilic groups selected from a primary amino group and a thiol group.
    [7" id="US-20010003126-A1-CLM-00007] 7. The composition of
    claim 6 , wherein the first synthetic polymer is a synthetic polypeptide that contains two or more lysine residues.
    [8" id="US-20010003126-A1-CLM-00008] 8. The composition of
    claim 7 , wherein the synthetic polypeptide is a poly(lysine).
    [9" id="US-20010003126-A1-CLM-00009] 9. The composition of
    claim 6 , wherein the first synthetic polymer is a synthetic polypeptide that contains two or more cysteine residues.
    [10" id="US-20010003126-A1-CLM-00010] 10. The composition of
    claim 1 , wherein the first synthetic polymer is a polyethylene glycol that has been modified to contain two or more nucleophilic groups selected from a primary amino group and a thiol group.
    [11" id="US-20010003126-A1-CLM-00011] 11. The composition of
    claim 1 , wherein the second synthetic polymer is a synthetic hydrophilic polymer containing two or more electrophilic groups.
    [12" id="US-20010003126-A1-CLM-00012] 12. The composition of
    claim 10 , wherein the synthetic hydrophilic polymer contains two or more succinimidyl groups.
    [13" id="US-20010003126-A1-CLM-00013] 13. The composition of
    claim 10 , wherein the synthetic hydrophilic polymer is a polyethylene glycol derivative.
    [14" id="US-20010003126-A1-CLM-00014] 14. The composition of
    claim 1 , wherein the second synthetic polymer is a synthetic hydrophobic polymer containing two or more succinimidyl groups.
    [15" id="US-20010003126-A1-CLM-00015] 15. The composition of
    claim 11 , wherein the synthetic hydrophobic polymer is selected from the group consisting of: disuccinimidyl suberate, bis(sulfosuccinimidyl) suberate, dithiobis(succinimidylpropionate), bis(2- succinimidooxycarbonyloxy)ethyl sulfone, 3,3′-dithiobis (sulfosuccinimidylpropionate), and their analogs and derivatives.
    [16" id="US-20010003126-A1-CLM-00016] 16. The composition of
    claim 13 , wherein the synthetic hydrophobic polymer has been chemically derivatized to contain two or more succinimidyl groups.
    [17" id="US-20010003126-A1-CLM-00017] 17. The composition of
    claim 15 , wherein the hydrophobic polymer is a polyacid.
    [18" id="US-20010003126-A1-CLM-00018] 18. The composition of
    claim 16 , wherein the polyacid is selected from the group consisting of: trimethylolpropane-based tricarboxylic acid, di(trimethylol propane)-based tetracarboxylic acid, heptanedioic acid, octanedioic acid, and hexadecanedioic acid.
    [19" id="US-20010003126-A1-CLM-00019] 19. The composition of
    claim 1 further comprising a polysaccharide or a protein.
    [20" id="US-20010003126-A1-CLM-00020] 20. The composition of
    claim 18 , wherein the polysaccharide is a glycosaminoglycan.
    [21" id="US-20010003126-A1-CLM-00021] 21. The composition of
    claim 19 , wherein the glycosaminoglycan is selected from the group consisting of: hyaluronic acid, chitin, chondroitin sulfate A, chondroitin sulfate B, chondroitin sulfate C, keratin sulfate, keratosulfate, heparin, and derivatives thereof.
    [22" id="US-20010003126-A1-CLM-00022] 22. The composition of
    claim 18 , wherein the protein is collagen or a derivative thereof.
    [23" id="US-20010003126-A1-CLM-00023] 23. A composition comprising a first polyethylene glycol having primary amino groups, and a second polyethylene glycol having succinimidyl groups.
    [24" id="US-20010003126-A1-CLM-00024] 24. The composition of
    claim 23 , wherein said first polyethylene glycol has m primary amino groups, and said second polyethylene glycol has n succinimidyl groups, wherein m and n are each greater than or equal to 2, and wherein m+n is greater than or equal to 5.
    [25" id="US-20010003126-A1-CLM-00025] 25. The composition of
    claim 24 , wherein m is greater than 3, and n=2.
    [26" id="US-20010003126-A1-CLM-00026] 26. The composition of
    claim 24 , wherein m=2 and n is greater than or equal to 3.
    [27" id="US-20010003126-A1-CLM-00027] 27. The composition of
    claim 24 , wherein m and n are each greater than or equal to 3.
    [28" id="US-20010003126-A1-CLM-00028] 28. The composition of
    claim 23 further comprising a naturally occurring polysaccharide or a naturally occurring protein.
    [29" id="US-20010003126-A1-CLM-00029] 29. The composition of
    claim 28 , wherein the naturally occurring polysaccharide is a glycosaminoglycan.
    [30" id="US-20010003126-A1-CLM-00030] 30. The composition of
    claim 29 , wherein the glycosaminoglycan is selected from the following group: hyaluronic acid, chitin, chondroitin sulfate A, chondroitin sulfate B, chondroitin sulfate C, keratin sulfate, keratosulfate, heparin, and derivatives thereof.
    [31" id="US-20010003126-A1-CLM-00031] 31. The composition of
    claim 28 , wherein the naturally occurring protein is collagen or a derivative thereof.
    [32" id="US-20010003126-A1-CLM-00032] 32. A method for effecting the nonsurgical attachment of a first surface to a second surface, comprising the steps of:
    providing a first synthetic polymer containing nucleophilic groups and a second synthetic polymer containing electrophilic groups;
    mixing the first synthetic polymer and the second synthetic polymer to initiate crosslinking;
    applying the mixture to a first surface before substantial crosslinking has occurred; and
    contacting the first surface with a second surface to effect adhesion between the first surface and the second surface.
    [33" id="US-20010003126-A1-CLM-00033] 33. The method of
    claim 32 , wherein said first synthetic polymer has m nucleophilic groups and said second synthetic polymer has n electrophilic groups, wherein m and n are each greater than or equal to 2, and wherein m+n is greater than or equal to 5.
    [34" id="US-20010003126-A1-CLM-00034] 34. The method of
    claim 32 , wherein one of the first and second surfaces is a native tissue surface and the other of the first and second surfaces is selected from a non-native tissue surface and a surface of a synthetic implant.
    [35" id="US-20010003126-A1-CLM-00035] 35. The method of
    claim 32 , wherein both the first and second surfaces are native tissue surfaces.
    [36" id="US-20010003126-A1-CLM-00036] 36. A method for introducing a crosslinked synthetic polymer composition into a tissue within a body of a mammalian subject, comprising the steps of:
    providing a first synthetic polymer containing nucleophilic groups and a second synthetic polymer containing electrophilic groups;
    administering the first synthetic polymer and the second synthetic polymer simultaneously to the tissue; and
    allowing the first synthetic polymer and the second synthetic polymer to crosslink in situ.
    [37" id="US-20010003126-A1-CLM-00037] 37. The method of
    claim 36 , wherein said first synthetic polymer has m nucleophilic groups and said second synthetic polymer has n electrophilic groups, wherein m and n are each greater than or equal to 2, and wherein m+n is greater than or equal to 5.
    [38" id="US-20010003126-A1-CLM-00038] 38. The method of
    claim 36 , wherein the tissue is soft tissue.
    [39" id="US-20010003126-A1-CLM-00039] 39. The method of
    claim 36 , wherein the tissue is hard tissue.
    [40" id="US-20010003126-A1-CLM-00040] 40. The method of
    claim 36 , wherein the first synthetic polymer and the second synthetic polymer are contained within separate barrels of and administered from a dual-compartment syringe.
    [41" id="US-20010003126-A1-CLM-00041] 41. The method of
    claim 36 comprising the additional step of forming a mixture by mixing the first synthetic polymer and the second synthetic polymer before administration, wherein the mixture is administered within 60 seconds of mixing.
    [42" id="US-20010003126-A1-CLM-00042] 42. A method for preventing the adhesion of a first tissue and a second tissue, comprising the steps of:
    providing a first synthetic polymer containing nucleophilic groups and a second synthetic polymer containing electrophilic groups;
    forming a mixture by mixing the first synthetic polymer and the second synthetic polymer to initiate crosslinking;
    applying the mixture to the first tissue before substantial crosslinking has occurred; and
    allowing the first synthetic polymer and the second synthetic polymer to continue crosslinking in situ.
    [43" id="US-20010003126-A1-CLM-00043] 43. The method of
    claim 42 , wherein said first synthetic polymer has m nucleophilic groups and said second synthetic polymer has n electrophilic groups, wherein m and n are each greater than or equal to 2, and wherein m+n is greater than or equal to 5.
    [44" id="US-20010003126-A1-CLM-00044] 44. A method for coating a surface of a synthetic implant, comprising the steps of:
    providing a first synthetic polymer containing nucleophilic groups and a second synthetic polymer containing electrophilic groups;
    forming a mixture by mixing the first synthetic polymer and the second synthetic polymer to initiate crosslinking;
    applying the mixture to a surface of a synthetic implant; and
    allowing the first synthetic polymer and the second synthetic polymer to crosslink with each other on the surface of the synthetic implant.
    [45" id="US-20010003126-A1-CLM-00045] 45. The method of
    claim 44 , wherein said first synthetic polymer has m nucleophilic groups and said second synthetic polymer has n electrophilic groups, wherein m and n are each greater than or equal to 2, and wherein m+n is greater than or equal to 5.
    [46" id="US-20010003126-A1-CLM-00046] 46. The method of
    claim 44 , wherein the synthetic implant is selected from the group consisting of: artificial blood vessels, artificial heart valves, vascular grafts, vascular stents, vascular stent/graft combinations, surgical membranes, surgical meshes, and breast implants.
    [47" id="US-20010003126-A1-CLM-00047] 47. The method of
    claim 44 , wherein the mixture has a net neutral charge.
    [48" id="US-20010003126-A1-CLM-00048] 48. A method for preparing a negatively charged compound-containing matrix useful for delivery of a negatively charged compound to a mammalian subject, comprising the steps of:
    providing a first synthetic polymer containing nucleophilic groups and a second synthetic polymer containing electrophilic groups;
    forming a mixture by mixing the first synthetic polymer and the second synthetic polymer to initiate crosslinking, wherein the first synthetic polymer is present in the mixture in molar excess compared to the second synthetic polymer;
    allowing the first synthetic polymer and the second synthetic polymer to continue crosslinking to form a positively charged crosslinked synthetic polymer matrix; and
    reacting the matrix with the negatively charged compound.
    [49" id="US-20010003126-A1-CLM-00049] 49. The method of
    claim 48 , wherein said first synthetic polymer has m nucleophilic groups and said second synthetic polymer has n electrophilic groups, wherein m and n are each greater than or equal to 2, and wherein m+n is greater than or equal to 5.
    [50" id="US-20010003126-A1-CLM-00050] 50. The method of
    claim 48 , wherein the first synthetic polymer is a polyethylene glycol, and wherein the nucleophilic groups are selected from a primary amino group and a thiol group.
    [51" id="US-20010003126-A1-CLM-00051] 51. The method of
    claim 48 , wherein the second synthetic polymer is a polyethylene glycol derivative, and wherein the electrophilic groups are succinimidyl groups.
    [52" id="US-20010003126-A1-CLM-00052] 52. The method of
    claim 48 , wherein the negatively charged compound is succinylated collagen.
    [53" id="US-20010003126-A1-CLM-00053] 53. The method of
    claim 48 , wherein the negatively charged compound is a negatively charged glycosaminoglycan derivative selected from the group consisting of: sodium hyaluronate, keratan sulfate, keratosulfate, sodium chondroitin sulfate A, sodium dermatan sulfate B, sodium chondroitin sulfate C, heparin, esterified chondroitin sulfate C, esterified heparin, and combinations thereof.
    [54" id="US-20010003126-A1-CLM-00054] 54. A method for preparing a positively charged compound-containing matrix useful for delivery of a positively charged compound to a mammalian subject, comprising the steps of:
    providing a first synthetic polymer containing nucleophilic groups and a second synthetic polymer containing electrophilic groups;
    forming a mixture by mixing the first synthetic polymer and the second synthetic polymer to initiate crosslinking, wherein the second synthetic polymer is present in the mixture in molar excess compared to the second synthetic polymer;
    allowing the first synthetic polymer and the second synthetic polymer to continue crosslinking to form a negatively charged crosslinked synthetic polymer matrix; and
    reacting the matrix with the positively charged compound.
    [55" id="US-20010003126-A1-CLM-00055] 55. The method of
    claim 54 , wherein said first synthetic polymer has m nucleophilic groups and said second synthetic polymer has n electrophilic groups, wherein m and n are each greater than or equal to 2, and wherein m+n is greater than or equal to 5.
    [56" id="US-20010003126-A1-CLM-00056] 56. The method of
    claim 54 , wherein the first synthetic polymer is a polyethylene glycol, and wherein the nucleophilic groups are selected from a primary amino group and a thiol group.
    [57" id="US-20010003126-A1-CLM-00057] 57. The method of
    claim 54 , wherein the second synthetic polymer is a polyethylene glycol, and wherein the electrophilic groups are succinimidyl groups.
    [58" id="US-20010003126-A1-CLM-00058] 58. The method of
    claim 54 , wherein the positively charged compound is methylated collagen.
    [59" id="US-20010003126-A1-CLM-00059] 59. The method of
    claim 54 , wherein the positively charged compound is a glycosaminoglycan derivative selected from the group consisting of:
    esterified deacetylated hyaluronic acid, esterified deacetylated desulfated chondroitin sulfate A, esterified deacetylated desulfated chondroitin sulfate C, deacetylated desulfated keratan sulfate, deacetylated desulfated keratosulfate, esterified desulfated heparin, chitosan, and combinations thereof.
    [60" id="US-20010003126-A1-CLM-00060] 60. A method for making a synthetic lenticule, comprising the steps of:
    providing a first synthetic polymer containing nucleophilic groups and a second synthetic polymer containing electrophilic groups;
    forming a mixture by mixing the first synthetic polymer and the second synthetic polymer to initiate crosslinking;
    placing said mixture into a lenticular shaped mold or onto a surface of an eye; and
    allowing the first synthetic polymer and the second synthetic polymer to continue crosslinking to form a clear lenticule.
    [61" id="US-20010003126-A1-CLM-00061] 61. The method of
    claim 60 , wherein said first synthetic polymer has m nucleophilic groups and said second synthetic polymer has n electrophilic groups, wherein m and n are each greater than or equal to 2, and wherein m+n is greater than or equal to 5.
    [62" id="US-20010003126-A1-CLM-00062] 62. The method of
    claim 60 , wherein the first synthetic polymer is a polyethylene glycol, and wherein the nucleophilic groups are selected from a primary amino group and a thiol group.
    [63" id="US-20010003126-A1-CLM-00063] 63. The method of
    claim 60 , wherein the second synthetic polymer is a polyethylene glycol derivative, and wherein the electrophilic groups are succinimidyl groups.
    [64" id="US-20010003126-A1-CLM-00064] 64. The method of
    claim 60 further comprising a protein.
    [65" id="US-20010003126-A1-CLM-00065] 65. The method of
    claim 64 wherein said protein is collagen or a derivative thereof.
    类似技术:
    公开号 | 公开日 | 专利标题
    US8197802B2|2012-06-12|Method for treating or inhibiting the formation of adhesions following surgery or injury
    WO1997022371A9|1997-09-04|Crosslinked polymer compositions and methods for their use
    AU2002315188B2|2008-08-14|Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
    US6624245B2|2003-09-23|Rapid-gelling biocompatible polymer composition and associated methods of preparation and use
    同族专利:
    公开号 | 公开日
    DE69636289D1|2006-08-03|
    US20030149173A1|2003-08-07|
    AU1334497A|1997-07-14|
    US6166130A|2000-12-26|
    JP2004244639A|2004-09-02|
    US20110195040A1|2011-08-11|
    PT876165E|2006-10-31|
    US20050027069A1|2005-02-03|
    EP2111876A2|2009-10-28|
    US20050027070A1|2005-02-03|
    JP2007231249A|2007-09-13|
    AT330644T|2006-07-15|
    US6911496B2|2005-06-28|
    DK2111876T3|2011-12-12|
    US6534591B2|2003-03-18|
    DK0876165T3|2007-08-06|
    US20040186231A1|2004-09-23|
    PT2111876E|2011-12-23|
    US7176256B2|2007-02-13|
    US6323278B2|2001-11-27|
    US7883694B2|2011-02-08|
    EP0876165A1|1998-11-11|
    US6051648A|2000-04-18|
    DK1704878T3|2013-07-01|
    US20040185084A1|2004-09-23|
    EP2111876A3|2009-12-23|
    JP4193917B2|2008-12-10|
    ES2373200T3|2012-02-01|
    AT523211T|2011-09-15|
    US20020013408A1|2002-01-31|
    US6969400B2|2005-11-29|
    JP2000502380A|2000-02-29|
    EP1704878A3|2007-04-25|
    DE69636289T2|2007-05-10|
    WO1997022371A1|1997-06-26|
    EP1704878B1|2013-04-10|
    CA2239775C|2008-07-15|
    ES2268714T3|2007-03-16|
    US20040235708A1|2004-11-25|
    US8197802B2|2012-06-12|
    JP2009035744A|2009-02-19|
    ES2420106T3|2013-08-22|
    EP1704878A2|2006-09-27|
    EP0876165B1|2006-06-21|
    EP2111876B1|2011-09-07|
    PT1704878E|2013-07-17|
    US20040186230A1|2004-09-23|
    US7151135B2|2006-12-19|
    US5874500A|1999-02-23|
    US20050159544A1|2005-07-21|
    CA2239775A1|1997-06-26|
    AU717660B2|2000-03-30|
    JP4283719B2|2009-06-24|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US20030162841A1|1998-12-04|2003-08-28|Incept|Biocompatible crosslinked polymers|
    WO2003097759A1|2002-05-21|2003-11-27|Commonwealth Scientific And Industrial Research Organisation|Biomedical adhesive|
    WO2004014969A1|2002-08-09|2004-02-19|Ottawa Health Research Institute|Bio-synthetic matrix and uses thereof|
    WO2004060388A1|2002-11-08|2004-07-22|Eyegene Inc.|Composition for preventing the formation of new scar comprising bmp-7|
    US20050175665A1|2003-11-20|2005-08-11|Angiotech International Ag|Polymer compositions and methods for their use|
    US20050281883A1|2004-04-28|2005-12-22|Daniloff George Y|Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use|
    US20060094643A1|2002-07-03|2006-05-04|Yuri Svirkin|Compositions of hyaluronic acid and methods of use|
    US7273896B2|2003-04-10|2007-09-25|Angiotech Pharmaceuticals , Inc.|Compositions and methods of using a transient colorant|
    US20080260802A1|1996-09-23|2008-10-23|Sawhney Amarpreet S|Biocompatible hydrogels made with small molecule precursors|
    US20090005867A1|2007-06-26|2009-01-01|Olivier Lefranc|Mesh implant|
    US20090047349A1|2007-08-13|2009-02-19|Confluent Surgical, Inc.|Drug delivery device|
    US20110251699A1|2008-10-17|2011-10-13|Sofradim Production|Auto-sealant matrix for tissue repair|
    US20130004546A1|2010-01-20|2013-01-03|Biopharmex Holding Limited|Hydrogel of microspheres|
    WO2014153038A1|2013-03-14|2014-09-25|Medicus Biosciences Llc|Biocompatible hydrogel polymer matrix for delivery of cells|
    US9072809B2|2012-05-11|2015-07-07|Medical Biosciences Llc|Biocompatible hydrogel treatments for retinal detachment|
    US9353218B2|2004-09-17|2016-05-31|Angiotech Pharmaceuticals, Inc.|Kit for multifunctional compounds forming crosslinked biomaterials|
    US10111985B2|2011-08-10|2018-10-30|Medicus Biosciences, Llc|Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules|
    US10189773B2|2010-05-07|2019-01-29|Medicus Biosciences, Llc|In-vivo gelling pharmaceutical pre-formulation|
    US11083821B2|2011-08-10|2021-08-10|C.P. Medical Corporation|Biocompatible hydrogel polymer formulations for the controlled delivery of biomolecules|GB697334A|1950-04-29|1953-09-23|Wingfoot Corp|Preparation of polyesters, polyamides or polyesteramides of high molecular weight|
    BE506611A|1950-10-30||||
    NL126192C|1964-07-16||||
    US3619371A|1967-07-03|1971-11-09|Nat Res Dev|Production of a polymeric matrix having a biologically active substance bound thereto|
    SE343210B|1967-12-20|1972-03-06|Pharmacia Ab||
    US4008341A|1968-10-11|1977-02-15|W. R. Grace & Co.|Curable liquid polymer compositions|
    US3742955A|1970-09-29|1973-07-03|Fmc Corp|Fibrous collagen derived product having hemostatic and wound binding properties|
    US3810473A|1972-12-04|1974-05-14|Avicon Inc|Liquid-laid, non-woven, fibrous collagen derived surgical web having hemostatic and wound sealing properties|
    US3876501A|1973-05-17|1975-04-08|Baxter Laboratories Inc|Binding enzymes to activated water-soluble carbohydrates|
    GB1479268A|1973-07-05|1977-07-13|Beecham Group Ltd|Pharmaceutical compositions|
    US4179337A|1973-07-20|1979-12-18|Davis Frank F|Non-immunogenic polypeptides|
    DE2360794C2|1973-12-06|1984-12-06|Hoechst Ag, 6230 Frankfurt|Process for the production of peptides|
    US3949073A|1974-11-18|1976-04-06|The Board Of Trustees Of Leland Stanford Junior University|Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution|
    CH596313A5|1975-05-30|1978-03-15|Battelle Memorial Institute||
    US4237229A|1975-06-10|1980-12-02|W. R. Grace & Co.|Immobilization of biological material with polyurethane polymers|
    IL47468A|1975-06-12|1979-05-31|Rehovot Res Prod|Process for the cross-linking of proteins using water soluble cross-linking agents|
    US4488911A|1975-10-22|1984-12-18|Luck Edward E|Non-antigenic collagen and articles of manufacture|
    US4002531A|1976-01-22|1977-01-11|Pierce Chemical Company|Modifying enzymes with polyethylene glycol and product produced thereby|
    NL7704659A|1976-05-12|1977-11-15|Battelle Institut E V|BONE REPLACEMENT, BONE JOINT, OR PROSTHESIS ANCHORING MATERIAL.|
    GB1578348A|1976-08-17|1980-11-05|Pharmacia Ab|Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic|
    SE431758B|1977-03-04|1984-02-27|Pharmacia Fine Chemicals Ab|AS THE USE OF THE TIOLATION REAGENT OR BERRY MATRIX FOR ENZYMERS DERIVATIVE OF A SH GROUPING POLYMER|
    US4164559A|1977-09-21|1979-08-14|Cornell Research Foundation, Inc.|Collagen drug delivery device|
    US4238480A|1978-05-19|1980-12-09|Sawyer Philip Nicholas|Method for preparing an improved hemostatic agent and method of employing the same|
    US4390519A|1978-05-19|1983-06-28|Sawyer Philip Nicholas|Bandage with hemostatic agent and methods for preparing and employing the same|
    US4404970A|1978-05-19|1983-09-20|Sawyer Philip Nicholas|Hemostatic article and methods for preparing and employing the same|
    FR2449610B1|1979-01-02|1983-01-21|Remy Ets Pierre||
    JPS6023084B2|1979-07-11|1985-06-05|Ajinomoto Kk||
    US4412947A|1979-09-12|1983-11-01|Seton Company|Collagen sponge|
    US4279812A|1979-09-12|1981-07-21|Seton Company|Process for preparing macromolecular biologically active collagen|
    DE2943520C2|1979-10-27|1982-05-19|Fa. Carl Freudenberg, 6940 Weinheim|Process for the production of collagen sponge for medical or cosmetic purposes|
    CA1156529A|1980-06-12|1983-11-08|Avicon, Inc.|Fibrous collagenous hemostatic-adhesive webs|
    CS216992B1|1980-07-21|1982-12-31|Miroslav Stol|Composite polymere material for the biological and medicinal utilitation and method of preparation thereof|
    US4314380A|1980-09-26|1982-02-09|Koken Co., Ltd.|Artificial bone|
    US4415665A|1980-12-12|1983-11-15|Pharmacia Fine Chemicals Ab|Method of covalently binding biologically active organic substances to polymeric substances|
    US4414147A|1981-04-17|1983-11-08|Massachusetts Institute Of Technology|Methods of decreasing the hydrophobicity of fibroblast and other interferons|
    JPH026337B2|1981-06-10|1990-02-08|Ajinomoto Kk||
    GB2108517B|1981-06-12|1985-06-12|Nat Res Dev|Hydrogels|
    US4451568A|1981-07-13|1984-05-29|Battelle Memorial Institute|Composition for binding bioactive substances|
    US4357274A|1981-08-06|1982-11-02|Intermedicat Gmbh|Process for the manufacture of sclero protein transplants with increased biological stability|
    US4415628A|1981-10-26|1983-11-15|Seton Company|Moisture vapor permeable sheet materials|
    JPH0525470B2|1981-10-30|1993-04-13|Nippon Chemiphar Co||
    US4424208A|1982-01-11|1984-01-03|Collagen Corporation|Collagen implant material and method for augmenting soft tissue|
    US4582640A|1982-03-08|1986-04-15|Collagen Corporation|Injectable cross-linked collagen implant material|
    US4578067A|1982-04-12|1986-03-25|Alcon Inc.|Hemostatic-adhesive, collagen dressing for severed biological surfaces|
    JPS6320143B2|1982-04-19|1988-04-26|Koken Kk||
    US4563351A|1983-08-01|1986-01-07|Forsyth Dental Infirmary For Children|Self-gelling therapeutic compositions for topical application|
    US4461298A|1982-07-26|1984-07-24|Ethicon, Inc.|Composite sutures of silk and hydrophobic thermoplastic elastomers|
    US4544516A|1982-07-28|1985-10-01|Battelle Development Corporation|Collagen orientation|
    US4737544A|1982-08-12|1988-04-12|Biospecific Technologies, Inc.|Biospecific polymers|
    US4973493A|1982-09-29|1990-11-27|Bio-Metric Systems, Inc.|Method of improving the biocompatibility of solid surfaces|
    JPS6237020B2|1983-07-27|1987-08-10|Koken Kk||
    US4515637A|1983-11-16|1985-05-07|Seton Company|Collagen-thrombin compositions|
    US4496689A|1983-12-27|1985-01-29|Miles Laboratories, Inc.|Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer|
    US4745098A|1984-02-24|1988-05-17|The Regents Of The University Of California|Compositions and method for improving wound healing|
    CA1295796C|1984-03-27|1992-02-18|Conrad Whyne|Biodegradable matrix and methods for producing same|
    AU4041685A|1984-04-02|1985-10-10|National Jewish Hospital And Research Center|Collagen matrix|
    CA1259914A|1984-07-06|1989-09-26|Donald G. Wallace|Methods of bone repair using collagen|
    US4789663A|1984-07-06|1988-12-06|Collagen Corporation|Methods of bone repair using collagen|
    JPH0575429B2|1984-08-07|1993-10-20|Ube Industries||
    US4553974A|1984-08-14|1985-11-19|Mayo Foundation|Treatment of collagenous tissue with glutaraldehyde and aminodiphosphonate calcification inhibitor|
    US4687820A|1984-08-22|1987-08-18|Cuno Incorporated|Modified polypeptide supports|
    US4557764A|1984-09-05|1985-12-10|Collagen Corporation|Process for preparing malleable collagen and the product thereof|
    US4563350A|1984-10-24|1986-01-07|Collagen Corporation|Inductive collagen based bone repair preparations|
    GB8430252D0|1984-11-30|1985-01-09|Beecham Group Plc|Compounds|
    US4600533A|1984-12-24|1986-07-15|Collagen Corporation|Collagen membranes for medical use|
    US4732863A|1984-12-31|1988-03-22|University Of New Mexico|PEG-modified antibody with reduced affinity for cell surface Fc receptors|
    US4695602A|1985-02-28|1987-09-22|Lnp Corporation|Fiber reinforced thermoplastics containing silicone interpenetrating polymer networks|
    US4839345A|1985-03-09|1989-06-13|Nippon Oil And Fats Co., Ltd.|Hydrated adhesive gel and method for preparing the same|
    US4642117A|1985-03-22|1987-02-10|Collagen Corporation|Mechanically sheared collagen implant material and method|
    CA1260391A|1985-03-28|1989-09-26|Karl A. Piez|Xenogeneic collagen/mineral preparations in bonerepair|
    DE3521684C2|1985-06-18|1989-04-06|Dr. Mueller-Lierheim Kg, Biologische Laboratorien, 8033 Planegg, De||
    EP0206448B1|1985-06-19|1990-11-14|Ajinomoto Co., Inc.|Hemoglobin combined with a poly|
    US4766106A|1985-06-26|1988-08-23|Cetus Corporation|Solubilization of proteins for pharmaceutical compositions using polymer conjugation|
    US4851513A|1985-09-06|1989-07-25|Minnesota Mining And Manufacturing Company|Viscoelastic collagen solution for opthalmic use and method of preparation|
    EP0250571B1|1986-01-06|1991-05-22|The University Of Melbourne|Precipitation of collagen in tactoid form|
    US4774227A|1986-02-14|1988-09-27|Collagen Corporation|Collagen compositions for bone repair containing autogeneic marrow|
    US4983580A|1986-04-04|1991-01-08|Allergan, Inc.|Methods and materials for use in corneal wound healing|
    CA1294546C|1986-04-23|1992-01-21|John S. Sundsmo|Wound healing composition containing collagen|
    US4745180A|1986-06-27|1988-05-17|Cetus Corporation|Solubilization of proteins for pharmaceutical compositions using heparin fragments|
    US4979959A|1986-10-17|1990-12-25|Bio-Metric Systems, Inc.|Biocompatible coating for solid surfaces|
    US4829099A|1987-07-17|1989-05-09|Bioresearch, Inc.|Metabolically acceptable polyisocyanate adhesives|
    US6174999B1|1987-09-18|2001-01-16|Genzyme Corporation|Water insoluble derivatives of polyanionic polysaccharides|
    US6235726B1|1987-09-18|2001-05-22|Genzyme Corporation|Water insoluble derivatives of polyanionic polysaccharides|
    US4937270A|1987-09-18|1990-06-26|Genzyme Corporation|Water insoluble derivatives of hyaluronic acid|
    US6030958A|1987-09-18|2000-02-29|Genzyme Corporation|Water insoluble derivatives of hyaluronic acid|
    US5364622A|1987-12-04|1994-11-15|Dr. Karl Thomae Gmbh|Methods for preventing adhesions to organs and parts of organs by application of tissue plasminogen activator and hydroxyethylcellulose hydrogel|
    US4886866A|1987-12-21|1989-12-12|W. R. Grace & Co.-Conn.|Contact lenses based on biocompatible polyurethane and polyurea-urethane hydrated polymers|
    US4950699A|1988-01-11|1990-08-21|Genetic Laboratories, Inc.|Wound dressing incorporating collagen in adhesive layer|
    US4847325A|1988-01-20|1989-07-11|Cetus Corporation|Conjugation of polymer to colony stimulating factor-1|
    US5192316A|1988-02-16|1993-03-09|Allergan, Inc.|Ocular device|
    US4969912A|1988-02-18|1990-11-13|Kelman Charles D|Human collagen processing and autoimplant use|
    US5024742A|1988-02-24|1991-06-18|Cedars-Sinai Medical Center|Method of crosslinking amino acid containing polymers using photoactivatable chemical crosslinkers|
    FR2628634B1|1988-03-15|1990-07-13|Imedex|VISCERAL SURGERY PATCH|
    ES2064439T3|1988-05-02|1995-02-01|Project Hear|SURGICAL ADHESIVE MATERIAL.|
    US5290552A|1988-05-02|1994-03-01|Matrix Pharmaceutical, Inc./Project Hear|Surgical adhesive material|
    US4950483A|1988-06-30|1990-08-21|Collagen Corporation|Collagen wound healing matrices and process for their production|
    US5167960A|1988-08-03|1992-12-01|New England Deaconess Hospital Corporation|Hirudin-coated biocompatible substance|
    JPH0270749A|1988-09-07|1990-03-09|Nippon Shokubai Kagaku Kogyo Co Ltd|Curable composition|
    US5162430A|1988-11-21|1992-11-10|Collagen Corporation|Collagen-polymer conjugates|
    US5304595A|1988-11-21|1994-04-19|Collagen Corporation|Collagen-polymer conjugates|
    US5510418A|1988-11-21|1996-04-23|Collagen Corporation|Glycosaminoglycan-synthetic polymer conjugates|
    JPH08502082A|1992-07-02|1996-03-05|コラーゲンコーポレイション|Biocompatible polymer conjugate|
    US5936035A|1988-11-21|1999-08-10|Cohesion Technologies, Inc.|Biocompatible adhesive compositions|
    US5643464A|1988-11-21|1997-07-01|Collagen Corporation|Process for preparing a sterile, dry crosslinking agent|
    US5550187A|1988-11-21|1996-08-27|Collagen Corporation|Method of preparing crosslinked biomaterial compositions for use in tissue augmentation|
    US5527856A|1988-11-21|1996-06-18|Collagen Corporation|Method of preparing crosslinked biomaterial compositions for use in tissue augmentation|
    US5475052A|1988-11-21|1995-12-12|Collagen Corporation|Collagen-synthetic polymer matrices prepared using a multiple step reaction|
    US5306500A|1988-11-21|1994-04-26|Collagen Corporation|Method of augmenting tissue with collagen-polymer conjugates|
    US5565519A|1988-11-21|1996-10-15|Collagen Corporation|Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications|
    US5264214A|1988-11-21|1993-11-23|Collagen Corporation|Composition for bone repair|
    US5614587A|1988-11-21|1997-03-25|Collagen Corporation|Collagen-based bioadhesive compositions|
    DE3903672C1|1989-02-08|1990-02-01|Lohmann Gmbh & Co Kg||
    US5324844A|1989-04-19|1994-06-28|Enzon, Inc.|Active carbonates of polyalkylene oxides for modification of polypeptides|
    US5122614A|1989-04-19|1992-06-16|Enzon, Inc.|Active carbonates of polyalkylene oxides for modification of polypeptides|
    US5141747A|1989-05-23|1992-08-25|Minnesota Mining And Manufacturing Company|Denatured collagen membrane|
    AU630484B2|1989-08-11|1992-10-29|Isover Saint-Gobain|Glass fibres capable of decomposing in a physiological medium|
    JPH0790241B2|1989-09-01|1995-10-04|日本鋼管株式会社|Rolling method for bar steel|
    KR970005110B1|1989-10-18|1997-04-12|도오레 찌오코올 가부시기가이샤|Polysulfide polyether, method of producing the same, polymer composition and curable composition|
    JPH0568992B2|1989-12-05|1993-09-30|Hoechst Japan||
    US5201764A|1990-02-28|1993-04-13|Autogenesis Technologies, Inc.|Biologically compatible collagenous reaction product and articles useful as medical implants produced therefrom|
    US5104957A|1990-02-28|1992-04-14|Autogenesis Technologies, Inc.|Biologically compatible collagenous reaction product and articles useful as medical implants produced therefrom|
    US5275838A|1990-02-28|1994-01-04|Massachusetts Institute Of Technology|Immobilized polyethylene oxide star molecules for bioapplications|
    AU660924B2|1990-04-02|1995-07-13|Procter & Gamble Company, The|Particulate, absorbent, polymeric compositions containing interparticle crosslinked aggregates|
    JPH0832784B2|1990-04-25|1996-03-29|東レチオコール株式会社|Polysulfide polymer, method for producing the same, and curable composition thereof|
    US5204110A|1990-05-02|1993-04-20|Ndm Acquisition Corp.|High absorbency hydrogel wound dressing|
    US5017229A|1990-06-25|1991-05-21|Genzyme Corporation|Water insoluble derivatives of hyaluronic acid|
    US5219564A|1990-07-06|1993-06-15|Enzon, Inc.|Poly amino acid copolymers and drug carriers and charged copolymers based thereon|
    EP0466383A1|1990-07-09|1992-01-15|BAUSCH &amp; LOMB INCORPORATED|A collagen medical adhesive and its uses|
    US5209776A|1990-07-27|1993-05-11|The Trustees Of Columbia University In The City Of New York|Tissue bonding and sealing composition and method of using the same|
    SE466754B|1990-09-13|1992-03-30|Berol Nobel Ab|COVALENT BINDING POLYMERS TO HYDROPHILIC SURFACES|
    US5410016A|1990-10-15|1995-04-25|Board Of Regents, The University Of Texas System|Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers|
    US5626863A|1992-02-28|1997-05-06|Board Of Regents, The University Of Texas System|Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers|
    US5169754A|1990-10-31|1992-12-08|Coulter Corporation|Biodegradable particle coatings having a protein covalently immobilized by means of a crosslinking agent and processes for making same|
    US6559119B1|1990-11-27|2003-05-06|Loyola University Of Chicago|Method of preparing a tissue sealant-treated biomedical material|
    US5219895A|1991-01-29|1993-06-15|Autogenesis Technologies, Inc.|Collagen-based adhesives and sealants and methods of preparation and use thereof|
    US5156613A|1991-02-13|1992-10-20|Interface Biomedical Laboratories Corp.|Collagen welding rod material for use in tissue welding|
    EP0610441A4|1991-10-29|1996-01-10|Clover Cons Ltd|Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release.|
    JPH07501103A|1991-11-12|1995-02-02|||
    US5147374A|1991-12-05|1992-09-15|Alfredo Fernandez|Prosthetic mesh patch for hernia repair|
    US5176692A|1991-12-09|1993-01-05|Wilk Peter J|Method and surgical instrument for repairing hernia|
    FR2692582B1|1992-06-18|1998-09-18|Flamel Tech Sa|NEW CROSSLINKABLE DERIVATIVES OF COLLAGEN, THEIR PROCESS FOR OBTAINING IT AND THEIR APPLICATION TO THE PREPARATION OF BIOMATERIALS.|
    US5428022A|1992-07-29|1995-06-27|Collagen Corporation|Composition of low type III content human placental collagen|
    US5514379A|1992-08-07|1996-05-07|The General Hospital Corporation|Hydrogel compositions and methods of use|
    US5614549A|1992-08-21|1997-03-25|Enzon, Inc.|High molecular weight polymer-based prodrugs|
    AU675252B2|1992-12-18|1997-01-30|Tremco, Inc.|Fast-curing, high strength, two-part sealants using acetoacetate-amine cure chemistry|
    US5298643A|1992-12-22|1994-03-29|Enzon, Inc.|Aryl imidate activated polyalkylene oxides|
    US5349001A|1993-01-19|1994-09-20|Enzon, Inc.|Cyclic imide thione activated polyalkylene oxides|
    US5667839A|1993-01-28|1997-09-16|Collagen Corporation|Human recombinant collagen in the milk of transgenic animals|
    US5321095A|1993-02-02|1994-06-14|Enzon, Inc.|Azlactone activated polyalkylene oxides|
    WO1994025503A1|1993-04-27|1994-11-10|Cytotherapeutics, Inc.|Membrane formed by an acrylonitrile-based polymer|
    US5549904A|1993-06-03|1996-08-27|Orthogene, Inc.|Biological adhesive composition and method of promoting adhesion between tissue surfaces|
    FR2707992B1|1993-07-21|1995-10-13|Flamel Tech Sa|New organic products containing reactive thiol functions, one of their preparation processes and the biomaterials containing them.|
    FR2707878B1|1993-07-21|1997-02-14|||
    US5939385A|1993-08-13|1999-08-17|Zymogenetics, Inc.|Transglutaminase cross-linkable polypeptides and methods relating thereto|
    CA2130295A1|1993-08-26|1995-02-27|Richard A. Berg|Ionically crosslinked glycosaminoglycan gels for soft tissue augmentation and drug delivery|
    US5834007A|1993-09-16|1998-11-10|Ogita Biomaterial Laboratories Co. Ltd.|Wound-covering material and wound-covering composition|
    US5643575A|1993-10-27|1997-07-01|Enzon, Inc.|Non-antigenic branched polymer conjugates|
    WO1995015352A1|1993-12-01|1995-06-08|Universite Du Quebec A Montreal|Albumin based hydrogel|
    US5578661A|1994-03-31|1996-11-26|Nepera, Inc.|Gel forming system for use as wound dressings|
    US5505952A|1994-04-19|1996-04-09|United States Surgical Corporation|Modified synthetic cross-linked amino acid polymers and medical devices formed therefrom|
    US5583114A|1994-07-27|1996-12-10|Minnesota Mining And Manufacturing Company|Adhesive sealant composition|
    FR2726571B1|1994-11-03|1997-08-08|Izoret Georges|BIOLOGICAL GLUE, PREPARATION METHOD AND APPLICATION DEVICE FOR BIOLOGICAL GLUE, AND HARDENERS FOR BIOLOGICAL GLUE|
    US5932462A|1995-01-10|1999-08-03|Shearwater Polymers, Inc.|Multiarmed, monofunctional, polymer for coupling to molecules and surfaces|
    CA2167455A1|1995-01-19|1996-07-20|Kevin Cooper|Absorbable polyalkylene diglycolates|
    US5550172A|1995-02-07|1996-08-27|Ethicon, Inc.|Utilization of biocompatible adhesive/sealant materials for securing surgical devices|
    US5464929A|1995-03-06|1995-11-07|Ethicon, Inc.|Absorbable polyoxaesters|
    CA2165728A1|1995-03-14|1996-09-15|Woonza M. Rhee|Use of hydrophobic crosslinking agents to prepare crosslinked biomaterial compositions|
    US5580923A|1995-03-14|1996-12-03|Collagen Corporation|Anti-adhesion films and compositions for medical use|
    US5900245A|1996-03-22|1999-05-04|Focal, Inc.|Compliant tissue sealants|
    US5612052A|1995-04-13|1997-03-18|Poly-Med, Inc.|Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof|
    US5817303A|1995-05-05|1998-10-06|Protein Polymer Technologies, Inc.|Bonding together tissue with adhesive containing polyfunctional crosslinking agent and protein polymer|
    US5605976A|1995-05-15|1997-02-25|Enzon, Inc.|Method of preparing polyalkylene oxide carboxylic acids|
    US6833408B2|1995-12-18|2004-12-21|Cohesion Technologies, Inc.|Methods for tissue repair using adhesive materials|
    US6458889B1|1995-12-18|2002-10-01|Cohesion Technologies, Inc.|Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use|
    AU717660B2|1995-12-18|2000-03-30|Angiodevice International Gmbh|Crosslinked polymer compositions and methods for their use|
    US5752974A|1995-12-18|1998-05-19|Collagen Corporation|Injectable or implantable biomaterials for filling or blocking lumens and voids of the body|
    US5681904A|1996-04-01|1997-10-28|Minnesota Mining And Manufacturing Company|Azido polymers having improved burn rate|
    ZA987019B|1997-08-06|1999-06-04|Focal Inc|Hemostatic tissue sealants|
    US5854382A|1997-08-18|1998-12-29|Meadox Medicals, Inc.|Bioresorbable compositions for implantable prostheses|
    AU743819B2|1997-10-27|2002-02-07|California Institute Of Technology|Methods and pharmaceutical compositions for the closure of retinal breaks|
    US6566406B1|1998-12-04|2003-05-20|Incept, Llc|Biocompatible crosslinked polymers|
    CA2359318C|1999-02-01|2009-06-30|Donald Elbert|Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups|
    US6312725B1|1999-04-16|2001-11-06|Cohesion Technologies, Inc.|Rapid gelling biocompatible polymer composition|
    US6258124B1|1999-05-10|2001-07-10|C. R. Bard, Inc.|Prosthetic repair fabric|
    PT2093245E|1999-08-27|2012-05-29|Angiodevice Internat Gmbh|Biocompatible polymer device|
    JP4227265B2|1999-10-18|2009-02-18|キヤノン株式会社|Laser light quantity control device|
    US6296607B1|2000-10-20|2001-10-02|Praxis, Llc.|In situ bulking device|
    EP2628634B1|2010-12-24|2016-04-27|Honda Motor Co., Ltd.|Vehicle seat back structure|
    JP6070972B2|2013-03-15|2017-02-01|デーナ、オータモウティヴ、システィムズ、グループ、エルエルシー|Parking lock mechanism for transmission|KR100361933B1|1993-09-08|2003-02-14|라 졸라 파마슈티칼 컴파니|Chemically defined nonpolymeric bonds form the platform molecule and its conjugate|
    US7682647B2|1999-09-03|2010-03-23|Advanced Cardiovascular Systems, Inc.|Thermal treatment of a drug eluting implantable medical device|
    US20040176801A1|1997-03-12|2004-09-09|Neomend, Inc.|Pretreatment method for enhancing tissue adhesion|
    US6743248B2|1996-12-18|2004-06-01|Neomend, Inc.|Pretreatment method for enhancing tissue adhesion|
    US6551574B2|1995-06-07|2003-04-22|Rhomed Incorporated|Tuftsin metallopeptide analogs and uses thereof|
    US7883693B2|1995-12-18|2011-02-08|Angiodevice International Gmbh|Compositions and systems for forming crosslinked biomaterials and methods of preparation of use|
    US6458889B1|1995-12-18|2002-10-01|Cohesion Technologies, Inc.|Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use|
    US6833408B2|1995-12-18|2004-12-21|Cohesion Technologies, Inc.|Methods for tissue repair using adhesive materials|
    AU717660B2|1995-12-18|2000-03-30|Angiodevice International Gmbh|Crosslinked polymer compositions and methods for their use|
    US6126682A|1996-08-13|2000-10-03|Oratec Interventions, Inc.|Method for treating annular fissures in intervertebral discs|
    US7449019B2|1999-01-25|2008-11-11|Smith & Nephew, Inc.|Intervertebral decompression|
    US6066325A|1996-08-27|2000-05-23|Fusion Medical Technologies, Inc.|Fragmented polymeric compositions and methods for their use|
    US8603511B2|1996-08-27|2013-12-10|Baxter International, Inc.|Fragmented polymeric compositions and methods for their use|
    US8303981B2|1996-08-27|2012-11-06|Baxter International Inc.|Fragmented polymeric compositions and methods for their use|
    US6229009B1|1997-08-29|2001-05-08|Societe De Conseils De Recherches Et D'applications Scientifiques |Polycarboxylic based cross-linked copolymers|
    US20020064546A1|1996-09-13|2002-05-30|J. Milton Harris|Degradable poly hydrogels with controlled half-life and precursors therefor|
    US7347850B2|1998-08-14|2008-03-25|Incept Llc|Adhesion barriers applicable by minimally invasive surgery and methods of use thereof|
    AU4648697A|1996-09-23|1998-04-14|Chandrashekar Pathak|Methods and devices for preparing protein concentrates|
    US7009034B2|1996-09-23|2006-03-07|Incept, Llc|Biocompatible crosslinked polymers|
    US20090324721A1|1996-09-23|2009-12-31|Jack Kennedy|Hydrogels Suitable For Use In Polyp Removal|
    US20080114092A1|1998-12-04|2008-05-15|Incept Llc|Adhesion barriers applicable by minimally invasive surgery and methods of use thereof|
    US6258351B1|1996-11-06|2001-07-10|Shearwater Corporation|Delivery of poly-modified molecules from degradable hydrogels|
    JP2002505592A|1996-11-15|2002-02-19|アドバンストバイオサーフェイシズ，インコーポレイティド|Biomaterial systems used to repair tissue in situ|
    US6994686B2|1998-08-26|2006-02-07|Neomend, Inc.|Systems for applying cross-linked mechanical barriers|
    US20030191496A1|1997-03-12|2003-10-09|Neomend, Inc.|Vascular sealing device with microwave antenna|
    JP4860817B2|1998-08-26|2012-01-25|ネオメンド、インク．|Compositions, systems and methods for in situ creation of chemically cross-linked mechanical barriers or coating structures|
    US6240616B1|1997-04-15|2001-06-05|Advanced Cardiovascular Systems, Inc.|Method of manufacturing a medicated porous metal prosthesis|
    US10028851B2|1997-04-15|2018-07-24|Advanced Cardiovascular Systems, Inc.|Coatings for controlling erosion of a substrate of an implantable medical device|
    US8172897B2|1997-04-15|2012-05-08|Advanced Cardiovascular Systems, Inc.|Polymer and metal composite implantable medical devices|
    US7192984B2|1997-06-17|2007-03-20|Fziomed, Inc.|Compositions of polyacids and polyethers and methods for their use as dermal fillers|
    US6303585B1|1997-07-03|2001-10-16|Orquest, Inc.|Cross-linked polysaccharide drug carrier|
    GB2328443B|1997-08-21|2001-09-05|Reckitt & Colmann Prod Ltd|In situ formation of pharmaceutically acceptable polymeric material|
    US7662409B2|1998-09-25|2010-02-16|Gel-Del Technologies, Inc.|Protein matrix materials, devices and methods of making and using thereof|
    JP2002507437A|1998-02-27|2002-03-12|バイオエラスチックス・リサーチ・リミテッド|Injectable implant for tissue augmentation and recovery|
    US6992066B2|1998-10-16|2006-01-31|Zimmer Orthobiologics, Inc.|Povidone-containing carriers for polypeptide growth factors|
    US7087577B2|1998-10-16|2006-08-08|Zimmer Orthobiologies, Inc.|Method of promoting natural bypass|
    JP2002515418A|1998-05-20|2002-05-28|エクスプレッション・ジェネティックス・インコーポレーテッド|Polymer gene carrier for polyethylene glycol conjugated poly-L-lysine targeting hepatocytes|
    MXPA00000009A|1998-06-22|2005-09-08|Autologous Wound Therapy Inc|Enriched platelet wound healant.|
    US20020022588A1|1998-06-23|2002-02-21|James Wilkie|Methods and compositions for sealing tissue leaks|
    US6605294B2|1998-08-14|2003-08-12|Incept Llc|Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels|
    US6152943A|1998-08-14|2000-11-28|Incept Llc|Methods and apparatus for intraluminal deposition of hydrogels|
    US6818018B1|1998-08-14|2004-11-16|Incept Llc|In situ polymerizable hydrogels|
    US7790192B2|1998-08-14|2010-09-07|Accessclosure, Inc.|Apparatus and methods for sealing a vascular puncture|
    US6632457B1|1998-08-14|2003-10-14|Incept Llc|Composite hydrogel drug delivery systems|
    US6514534B1|1998-08-14|2003-02-04|Incept Llc|Methods for forming regional tissue adherent barriers and drug delivery systems|
    AU6151799A|1998-09-17|2000-04-03|Focal, Inc.|Self-cleaning fluid delivery device for medical applications|
    US6899889B1|1998-11-06|2005-05-31|Neomend, Inc.|Biocompatible material composition adaptable to diverse therapeutic indications|
    US7279001B2|1998-11-06|2007-10-09|Neomend, Inc.|Systems, methods, and compositions for achieving closure of vascular puncture sites|
    US6371975B2|1998-11-06|2002-04-16|Neomend, Inc.|Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers|
    US7351249B2|1998-11-06|2008-04-01|Neomend, Inc.|Systems, methods, and compositions for achieving closure of suture sites|
    US6830756B2|1998-11-06|2004-12-14|Neomend, Inc.|Systems, methods, and compositions for achieving closure of vascular puncture sites|
    US6458147B1|1998-11-06|2002-10-01|Neomend, Inc.|Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue|
    US6949114B2|1998-11-06|2005-09-27|Neomend, Inc.|Systems, methods, and compositions for achieving closure of vascular puncture sites|
    GB9824562D0|1998-11-09|1999-01-06|Cole Polytechnique Fudurale De|Materials and methods relating to surface functioning polymers for tissue engineering|
    US6458953B1|1998-12-09|2002-10-01|La Jolla Pharmaceutical Company|Valency platform molecules comprising carbamate linkages|
    US6958212B1|1999-02-01|2005-10-25|Eidgenossische Technische Hochschule Zurich|Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds|
    US7291673B2|2000-06-02|2007-11-06|Eidgenossiche Technische Hochschule Zurich|Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds|
    CA2359318C|1999-02-01|2009-06-30|Donald Elbert|Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups|
    US6416776B1|1999-02-18|2002-07-09|St. Francis Medical Technologies, Inc.|Biological disk replacement, bone morphogenic proteincarriers, and anti-adhesion materials|
    US6656496B1|1999-03-01|2003-12-02|The Uab Research Foundation|Porous tissue scaffolding materials and uses thereof|
    US6340465B1|1999-04-12|2002-01-22|Edwards Lifesciences Corp.|Lubricious coatings for medical devices|
    US6312725B1|1999-04-16|2001-11-06|Cohesion Technologies, Inc.|Rapid gelling biocompatible polymer composition|
    JP2002542339A|1999-04-16|2002-12-10|ダブリューエム・マーシュ・ライス・ユニバーシティー|Functionalized polyandcopolymers|
    US6884778B2|2000-04-14|2005-04-26|William Marsh Rice University|Biocompatible macromers|
    US8038708B2|2001-02-05|2011-10-18|Cook Medical Technologies Llc|Implantable device with remodelable material and covering material|
    EP1183230A1|1999-06-08|2002-03-06|La Jolla Pharmaceutical|Valency platform molecules comprising aminooxy groups|
    DE60031114T2|1999-06-11|2007-05-03|Cytyc Corp., Marlborough|LIQUID GEL FORMULATION FOR DETECTING MILK CHANNELS IN THE CHEST BEFORE SURGICAL ABLATION OF THE BREAST TISSUE|
    JP2003503367A|1999-06-11|2003-01-28|シアウォーター・コーポレイション|Hydrogels derived from chitosan and polyor related polymers|
    WO2000078285A1|1999-06-18|2000-12-28|University Of Medicine And Dentistry Of New Jersey|Controlled release of therapeutics by in-situ entrapment by matrix cross-linking|
    US6521431B1|1999-06-22|2003-02-18|Access Pharmaceuticals, Inc.|Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments|
    US6309660B1|1999-07-28|2001-10-30|Edwards Lifesciences Corp.|Universal biocompatible coating platform for medical devices|
    PT2093245E|1999-08-27|2012-05-29|Angiodevice Internat Gmbh|Biocompatible polymer device|
    US6790228B2|1999-12-23|2004-09-14|Advanced Cardiovascular Systems, Inc.|Coating for implantable devices and a method of forming the same|
    US6908624B2|1999-12-23|2005-06-21|Advanced Cardiovascular Systems, Inc.|Coating for implantable devices and a method of forming the same|
    US20050238686A1|1999-12-23|2005-10-27|Advanced Cardiovascular Systems, Inc.|Coating for implantable devices and a method of forming the same|
    US20040029952A1|1999-09-03|2004-02-12|Yung-Ming Chen|Ethylene vinyl alcohol composition and coating|
    US7807211B2|1999-09-03|2010-10-05|Advanced Cardiovascular Systems, Inc.|Thermal treatment of an implantable medical device|
    US6759054B2|1999-09-03|2004-07-06|Advanced Cardiovascular Systems, Inc.|Ethylene vinyl alcohol composition and coating|
    CN2389638Y|1999-09-07|2000-08-02|曹孟君|Polyacrylamide aquogel breast prosthesis|
    US7008635B1|1999-09-10|2006-03-07|Genzyme Corporation|Hydrogels for orthopedic repair|
    US6783546B2|1999-09-13|2004-08-31|Keraplast Technologies, Ltd.|Implantable prosthetic or tissue expanding device|
    US6371984B1|1999-09-13|2002-04-16|Keraplast Technologies, Ltd.|Implantable prosthetic or tissue expanding device|
    WO2002034304A1|2000-10-23|2002-05-02|Tissuemed Limited|Self-adhesive hydratable matrix for topical therapeutic use|
    US20080299213A2|1999-11-05|2008-12-04|Donald Kleinsek|Augmentation and repair of spincter defects with cells including adipocytic cells|
    US20090074729A2|1999-11-05|2009-03-19|Donald Kleinsek|Augmentation and repair of spincter defects with cells including fibroblasts|
    US20090130066A1|2000-11-06|2009-05-21|Gerigene Medical Corporation|Augmentation and repair of sphincter defects with cells including muscle cells|
    US20080286242A2|1999-11-05|2008-11-20|Donald Kleinsek|Augmentation and repair of spincter defects with cells including mesenchymal cells|
    WO2001036000A1|1999-11-15|2001-05-25|Bio Syntech Canada, Inc.|Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution|
    JP4672947B2|1999-12-06|2011-04-20|ウォーソー・オーソペディック・インコーポレーテッド|Intervertebral disc treatment apparatus and method|
    US8435550B2|2002-12-16|2013-05-07|Abbot Cardiovascular Systems Inc.|Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device|
    AU778318B2|2000-02-03|2004-11-25|Tissuemed Limited|Device for the closure of a surgical puncture|
    WO2001062299A2|2000-02-28|2001-08-30|Shearwater Corporation|Water-soluble polymer conjugates of artelinic acid|
    AU2001245660B2|2000-03-13|2006-06-15|Biocompatibles Uk Limited|Embolic compositions|
    WO2001068721A1|2000-03-13|2001-09-20|Biocure, Inc.|Tissue bulking and coating compositions|
    US6652883B2|2000-03-13|2003-11-25|Biocure, Inc.|Tissue bulking and coating compositions|
    US8460367B2|2000-03-15|2013-06-11|Orbusneich Medical, Inc.|Progenitor endothelial cell capturing with a drug eluting implantable medical device|
    US9522217B2|2000-03-15|2016-12-20|Orbusneich Medical, Inc.|Medical device with coating for capturing genetically-altered cells and methods for using same|
    US8088060B2|2000-03-15|2012-01-03|Orbusneich Medical, Inc.|Progenitor endothelial cell capturing with a drug eluting implantable medical device|
    AT362382T|2000-03-15|2007-06-15|Orbusneich Medical Inc|COATING THAT STIMULATES A PLUG OF ENDOTHELIAL CELLS|
    JP4505933B2|2000-03-29|2010-07-21|東亞合成株式会社|Composition|
    US7504125B1|2001-04-27|2009-03-17|Advanced Cardiovascular Systems, Inc.|System and method for coating implantable devices|
    US6723335B1|2000-04-07|2004-04-20|Jeffrey William Moehlenbruck|Methods and compositions for treating intervertebral disc degeneration|
    US8109994B2|2003-01-10|2012-02-07|Abbott Cardiovascular Systems, Inc.|Biodegradable drug delivery material for stent|
    US6527801B1|2000-04-13|2003-03-04|Advanced Cardiovascular Systems, Inc.|Biodegradable drug delivery material for stent|
    US7875283B2|2000-04-13|2011-01-25|Advanced Cardiovascular Systems, Inc.|Biodegradable polymers for use with implantable medical devices|
    PT1276486E|2000-04-25|2011-02-07|Osiris Therapeutics Inc|Joint repair using mesenchymal stem cells|
    US6800298B1|2000-05-11|2004-10-05|Clemson University|Biological lubricant composition and method of applying lubricant composition|
    US7682648B1|2000-05-31|2010-03-23|Advanced Cardiovascular Systems, Inc.|Methods for forming polymeric coatings on stents|
    AU6822801A|2000-06-08|2001-12-17|Jolla Pharma|Multivalent platform molecules comprising high molecular weight polyethylene oxide|
    US20020076443A1|2000-06-19|2002-06-20|Stanley Stein|Multiple phase cross-linked compositions and uses thereof|
    PT1295611E|2000-06-20|2010-09-14|Dainippon Sumitomo Pharma Co|Oligonucleotide-transferring preparations|
    AU6888201A|2000-06-29|2002-01-08|Biosyntech Canada Inc|Composition and method for the repair and regeneration of cartilage and other tissues|
    AU1876902A|2000-07-12|2002-01-21|Gryphon Sciences|Chemokine receptor modulators, production and use|
    US20040077835A1|2001-07-12|2004-04-22|Robin Offord|Chemokine receptor modulators, production and use|
    US6451373B1|2000-08-04|2002-09-17|Advanced Cardiovascular Systems, Inc.|Method of forming a therapeutic coating onto a surface of an implantable prosthesis|
    CA2412279A1|2000-09-08|2002-03-14|Gryphon Therapeutics, Inc.|"pseudo"-native chemical ligation|
    US7118737B2|2000-09-08|2006-10-10|Amylin Pharmaceuticals, Inc.|Polymer-modified synthetic proteins|
    CA2422065A1|2000-09-12|2002-04-11|Peter K. Law|Myogenic cell transfer catheter and method|
    US20050165428A1|2000-09-25|2005-07-28|Franco Kenneth L.|Absorable surgical structure|
    AU9310901A|2000-09-25|2002-04-02|Cohesion Tech Inc|Resorbable anastomosis stents and plugs and their use in patients|
    US6953560B1|2000-09-28|2005-10-11|Advanced Cardiovascular Systems, Inc.|Barriers for polymer-coated implantable medical devices and methods for making the same|
    EP1355965B1|2000-10-19|2012-09-19|Ecole Polytechnique Fédérale de Lausanne |Method of synthesizing block copolymers for multifunctional self-assembled systems|
    AU1538702A|2000-10-24|2002-05-06|Cryolife Inc|In situ bioprosthetic filler and methods, particularly for the in situ formationof vertebral disc bioprosthetics|
    US7807210B1|2000-10-31|2010-10-05|Advanced Cardiovascular Systems, Inc.|Hemocompatible polymers on hydrophobic porous polymers|
    US7226615B2|2000-11-07|2007-06-05|Cryolife, Inc.|Expandable foam-like biomaterials and methods|
    CA2429168C|2000-11-15|2010-06-08|Bio Syntech Canada Inc.|Method for restoring a damaged or degenerated intervertebral disc|
    US6824559B2|2000-12-22|2004-11-30|Advanced Cardiovascular Systems, Inc.|Ethylene-carboxyl copolymers as drug delivery matrices|
    US6663662B2|2000-12-28|2003-12-16|Advanced Cardiovascular Systems, Inc.|Diffusion barrier layer for implantable devices|
    TWI246524B|2001-01-19|2006-01-01|Shearwater Corp|Multi-arm block copolymers as drug delivery vehicles|
    US7265186B2|2001-01-19|2007-09-04|Nektar Therapeutics Al, Corporation|Multi-arm block copolymers as drug delivery vehicles|
    US6703047B2|2001-02-02|2004-03-09|Incept Llc|Dehydrated hydrogel precursor-based, tissue adherent compositions and methods of use|
    US20040131582A1|2002-02-26|2004-07-08|Grinstaff Mark W.|Novel dendritic polymers and their biomedical uses|
    JP2004523624A|2001-02-26|2004-08-05|デュークユニバーシティ|Novel dendritic polymer and its biomedical use|
    US20020177223A1|2001-03-12|2002-11-28|Ogle Mathew F.|Methods and compositions for crosslinking tissue|
    MXPA03008498A|2001-03-20|2005-06-30|Univ Zuerich|Two-phase processing of thermosensitive polymers for use as biomaterials.|
    US6780424B2|2001-03-30|2004-08-24|Charles David Claude|Controlled morphologies in polymer drug for release of drugs from polymer films|
    CA2444880C|2001-04-23|2009-11-24|Wisconsin Alumni Research Foundation|Bifunctional-modified hydrogels|
    US20050276858A1|2001-04-23|2005-12-15|Kao Weiyuan J|Bifunctional-modified hydrogels|
    US6712845B2|2001-04-24|2004-03-30|Advanced Cardiovascular Systems, Inc.|Coating for a stent and a method of forming the same|
    WO2002089679A1|2001-05-04|2002-11-14|Concentric Medical|Hydrogel vaso-occlusive device|
    WO2002089865A2|2001-05-04|2002-11-14|Concentric Medical|Coated combination vaso-occlusive device|
    EP1392175A2|2001-05-04|2004-03-03|Concentric Medical|Hydrogel filament vaso-occlusive device|
    US6656506B1|2001-05-09|2003-12-02|Advanced Cardiovascular Systems, Inc.|Microparticle coated medical device|
    US20030166197A1|2001-05-10|2003-09-04|Ecker Joseph R.|Ethylene insensitive plants|
    US6743462B1|2001-05-31|2004-06-01|Advanced Cardiovascular Systems, Inc.|Apparatus and method for coating implantable devices|
    US20070078435A1|2001-06-14|2007-04-05|Corbett Stone|Tissue augmentation methods using a medical injection apparatus|
    CN1313158C|2001-06-20|2007-05-02|大日本住友制药株式会社|Method of promoting nucleic acid transfer|
    US8608661B1|2001-11-30|2013-12-17|Advanced Cardiovascular Systems, Inc.|Method for intravascular delivery of a treatment agent beyond a blood vessel wall|
    US6702744B2|2001-06-20|2004-03-09|Advanced Cardiovascular Systems, Inc.|Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery|
    US20040115271A1|2002-06-21|2004-06-17|Alex Sacharoff|Hydration compositions for corneal pre-surgery treatment|
    US7175873B1|2001-06-27|2007-02-13|Advanced Cardiovascular Systems, Inc.|Rate limiting barriers for implantable devices and methods for fabrication thereof|
    US6695920B1|2001-06-27|2004-02-24|Advanced Cardiovascular Systems, Inc.|Mandrel for supporting a stent and a method of using the mandrel to coat a stent|
    US8741378B1|2001-06-27|2014-06-03|Advanced Cardiovascular Systems, Inc.|Methods of coating an implantable device|
    US7622146B2|2002-07-18|2009-11-24|Advanced Cardiovascular Systems, Inc.|Rate limiting barriers for implantable devices and methods for fabrication thereof|
    US7247313B2|2001-06-27|2007-07-24|Advanced Cardiovascular Systems, Inc.|Polyacrylates coatings for implantable medical devices|
    US7246321B2|2001-07-13|2007-07-17|Anoto Ab|Editing data|
    US7435425B2|2001-07-17|2008-10-14|Baxter International, Inc.|Dry hemostatic compositions and methods for their preparation|
    US7682669B1|2001-07-30|2010-03-23|Advanced Cardiovascular Systems, Inc.|Methods for covalently immobilizing anti-thrombogenic material into a coating on a medical device|
    US6663596B2|2001-08-13|2003-12-16|Scimed Life Systems, Inc.|Delivering material to a patient|
    US7022135B2|2001-08-17|2006-04-04|Medtronic, Inc.|Film with highly porous vascular graft prostheses|
    JP4230135B2|2001-08-21|2009-02-25|独立行政法人科学技術振興機構|Method for producing glycosaminoglycan-collagen complex cross-linked by multifunctional cross-linking agent|
    AU2002330798B2|2001-08-31|2007-06-21|Keratec Limited|The production of biopolymer film, fibre, foam and adhesive materials from soluble S-sulfonated keratin derivatives|
    US8303651B1|2001-09-07|2012-11-06|Advanced Cardiovascular Systems, Inc.|Polymeric coating for reducing the rate of release of a therapeutic substance from a stent|
    US7989018B2|2001-09-17|2011-08-02|Advanced Cardiovascular Systems, Inc.|Fluid treatment of a polymeric coating on an implantable medical device|
    US6863683B2|2001-09-19|2005-03-08|Abbott Laboratoris Vascular Entities Limited|Cold-molding process for loading a stent onto a stent delivery system|
    US7223282B1|2001-09-27|2007-05-29|Advanced Cardiovascular Systems, Inc.|Remote activation of an implantable device|
    US6753071B1|2001-09-27|2004-06-22|Advanced Cardiovascular Systems, Inc.|Rate-reducing membrane for release of an agent|
    EP1435877B1|2001-10-15|2009-04-15|Hemoteq AG|Coating of stents for preventing restenosis|
    CA2464287C|2001-10-23|2011-02-08|Tyco Healthcare Group Lp|Surgical fasteners|
    DE10152407A1|2001-10-24|2003-05-08|Aesculap Ag & Co Kg|Composition of at least two biocompatible chemically crosslinkable components|
    US20030093111A1|2001-10-26|2003-05-15|Concentric Medical|Device for vaso-occlusion and interventional therapy|
    EP1448089A4|2001-11-01|2008-06-04|Spine Wave Inc|Devices and methods for the restoration of a spinal disc|
    US7799833B2|2001-11-01|2010-09-21|Spine Wave, Inc.|System and method for the pretreatment of the endplates of an intervertebral disc|
    AU2002363343B2|2001-11-07|2008-07-24|Eidgenossische Technische Hochschule Zurich|Synthetic matrix for controlled cell ingrowth and tissue regeneration|
    JP4758608B2|2001-11-07|2011-08-31|ネクターセラピューティックス|Branched polymers and their conjugates|
    US20070264227A1|2001-11-07|2007-11-15|Eidgenossische Technische Hochschule Zurich|Synthetic Matrix for Controlled Cell Ingrowth and Tissue Regeneration|
    US7585516B2|2001-11-12|2009-09-08|Advanced Cardiovascular Systems, Inc.|Coatings for drug delivery devices|
    US7629388B2|2001-11-20|2009-12-08|William Marsh Rice University|Synthesis and characterization of biodegradable cationic poly copolymer hydrogels modified with agmatine for enhanced cell adhesion|
    CA2482309A1|2001-12-10|2003-06-19|Colbar Lifescience Ltd.|Methods, devices, and preparations for intervertebral disc treatment|
    US7232802B2|2001-12-21|2007-06-19|Zimmer Orthobiologics, Inc.|Compositions and methods for promoting myocardial and peripheral angiogenesis|
    US6709514B1|2001-12-28|2004-03-23|Advanced Cardiovascular Systems, Inc.|Rotary coating apparatus for coating implantable medical devices|
    US20030181371A1|2001-12-28|2003-09-25|Angiotech Pharmaceuticals, Inc.|Compositions and methods of using collajolie|
    WO2003063926A1|2002-02-01|2003-08-07|Sustech Gmbh & Co. Kg|Stellate prepolymers for the production of ultra-thin coatings that form hydrogels|
    US20030229333A1|2002-02-22|2003-12-11|Control Delivery Systems, Inc.|Methods for treating otic disorders|
    US7630403B2|2002-03-08|2009-12-08|Texas Instruments Incorporated|MAC aggregation frame with MSDU and fragment of MSDU|
    US20030179692A1|2002-03-19|2003-09-25|Yoshitaka Ohotomo|Storage medium|
    US6812211B2|2002-03-19|2004-11-02|Michael Andrew Slivka|Method for nonsurgical treatment of the intervertebral disc and kit therefor|
    US7919075B1|2002-03-20|2011-04-05|Advanced Cardiovascular Systems, Inc.|Coatings for implantable medical devices|
    US7022334B1|2002-03-20|2006-04-04|Advanced Cardiovascular Systems, Inc.|Therapeutic composition and a method of coating implantable medical devices|
    US8282912B2|2002-03-22|2012-10-09|Kuros Biosurgery, AG|Compositions for tissue augmentation|
    AU2003226688B2|2002-03-22|2009-08-13|Kuros Biosurgery Ag|Composition for hard tissue augmentation|
    US6953465B2|2002-03-25|2005-10-11|Concentric Medical, Inc.|Containers and methods for delivering vaso-occluding filaments and particles|
    US20070032853A1|2002-03-27|2007-02-08|Hossainy Syed F|40-O-ethyl-rapamycin coated stent|
    US7297342B2|2002-06-10|2007-11-20|Keratec Limited|Orthopaedic materials derived from keratin|
    US7037983B2|2002-06-14|2006-05-02|Kimberly-Clark Worldwide, Inc.|Methods of making functional biodegradable polymers|
    US20030232088A1|2002-06-14|2003-12-18|Kimberly-Clark Worldwide, Inc.|Materials with both bioadhesive and biodegradable components|
    US8506617B1|2002-06-21|2013-08-13|Advanced Cardiovascular Systems, Inc.|Micronized peptide coated stent|
    US7794743B2|2002-06-21|2010-09-14|Advanced Cardiovascular Systems, Inc.|Polycationic peptide coatings and methods of making the same|
    US7056523B1|2002-06-21|2006-06-06|Advanced Cardiovascular Systems, Inc.|Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine|
    US7396539B1|2002-06-21|2008-07-08|Advanced Cardiovascular Systems, Inc.|Stent coatings with engineered drug release rate|
    US7033602B1|2002-06-21|2006-04-25|Advanced Cardiovascular Systems, Inc.|Polycationic peptide coatings and methods of coating implantable medical devices|
    US7217426B1|2002-06-21|2007-05-15|Advanced Cardiovascular Systems, Inc.|Coatings containing polycationic peptides for cardiovascular therapy|
    ES2424348T3|2002-06-24|2013-10-01|Incept, Llc|Loads and methods to move tissues to improve radiological results|
    US7361368B2|2002-06-28|2008-04-22|Advanced Cardiovascular Systems, Inc.|Device and method for combining a treatment agent and a gel|
    MXPA04002145A|2002-06-29|2005-03-07|Aquanova Ger Solubilisate Tech|Isoflavone concentrate and method for production thereof.|
    US7294329B1|2002-07-18|2007-11-13|Advanced Cardiovascular Systems, Inc.|Poly coatings for implantable medical devices|
    US7598224B2|2002-08-20|2009-10-06|Biosurface Engineering Technologies, Inc.|Dual chain synthetic heparin-binding growth factor analogs|
    US7166574B2|2002-08-20|2007-01-23|Biosurface Engineering Technologies, Inc.|Synthetic heparin-binding growth factor analogs|
    CA2495818A1|2002-08-20|2004-03-04|John N. Semertzides|Compositions comprising epithelial cells for the treatment and prevention of tissue adhesions|
    US8227411B2|2002-08-20|2012-07-24|BioSurface Engineering Technologies, Incle|FGF growth factor analogs|
    US7363074B1|2002-08-20|2008-04-22|Advanced Cardiovascular Systems, Inc.|Coatings comprising self-assembled molecular structures and a method of delivering a drug using the same|
    US7846141B2|2002-09-03|2010-12-07|Bluesky Medical Group Incorporated|Reduced pressure treatment system|
    US7732535B2|2002-09-05|2010-06-08|Advanced Cardiovascular Systems, Inc.|Coating for controlled release of drugs from implantable medical devices|
    US20040054104A1|2002-09-05|2004-03-18|Pacetti Stephen D.|Coatings for drug delivery devices comprising modified poly|
    AR047712A1|2002-09-07|2006-02-15|Royal Veterinary College|TREATMENT METHOD OF A NATURAL SOFT SKELETTIC TISSUE INJURY MANAGING A COMPOSITION OF MESENQUIMATOSE MOTHER CELLS|
    JP5156890B2|2002-09-11|2013-03-06|独立行政法人物質・材料研究機構|Crosslinked polymer and method for producing the same|
    EP1549255A4|2002-09-13|2007-12-19|Coopervision Inc|Devices and methods for improving vision|
    US7201935B1|2002-09-17|2007-04-10|Advanced Cardiovascular Systems, Inc.|Plasma-generated coatings for medical devices and methods for fabricating thereof|
    US20040054414A1|2002-09-18|2004-03-18|Trieu Hai H.|Collagen-based materials and methods for augmenting intervertebral discs|
    US20040063805A1|2002-09-19|2004-04-01|Pacetti Stephen D.|Coatings for implantable medical devices and methods for fabrication thereof|
    US7438722B1|2002-09-20|2008-10-21|Advanced Cardiovascular Systems, Inc.|Method for treatment of restenosis|
    US7217254B2|2002-09-20|2007-05-15|Genzyme Corporation|Multi-pressure biocompatible agent delivery device and method|
    US7232573B1|2002-09-26|2007-06-19|Advanced Cardiovascular Systems, Inc.|Stent coatings containing self-assembled monolayers|
    US8202530B2|2002-09-27|2012-06-19|Advanced Cardiovascular Systems, Inc.|Biocompatible coatings for stents|
    US7404979B1|2002-09-30|2008-07-29|Advanced Cardiovascular Systems Inc.|Spin coating apparatus and a method for coating implantable devices|
    US8337937B2|2002-09-30|2012-12-25|Abbott Cardiovascular Systems Inc.|Stent spin coating method|
    US7087263B2|2002-10-09|2006-08-08|Advanced Cardiovascular Systems, Inc.|Rare limiting barriers for implantable medical devices|
    GB0224986D0|2002-10-28|2002-12-04|Smith & Nephew|Apparatus|
    US7497859B2|2002-10-29|2009-03-03|Kyphon Sarl|Tools for implanting an artificial vertebral disk|
    US6966929B2|2002-10-29|2005-11-22|St. Francis Medical Technologies, Inc.|Artificial vertebral disk replacement implant with a spacer|
    US7022372B1|2002-11-12|2006-04-04|Advanced Cardiovascular Systems, Inc.|Compositions for coating implantable medical devices|
    US8034361B2|2002-11-12|2011-10-11|Advanced Cardiovascular Systems, Inc.|Stent coatings incorporating nanoparticles|
    US6833467B2|2002-11-12|2004-12-21|Chung-Shan Institute Of Science & Technology|Method for preparing pentaerythritol phosphate alcohol by mechanochemical synthesis|
    US6896965B1|2002-11-12|2005-05-24|Advanced Cardiovascular Systems, Inc.|Rate limiting barriers for implantable devices|
    CN100394989C|2002-11-15|2008-06-18|华沙整形外科股份有限公司|Collagen-based materials and methods for augmenting intervertebral discs|
    US6761651B2|2002-11-22|2004-07-13|Chin-Dong Pai|Aluminum tennis racket|
    US6992543B2|2002-11-22|2006-01-31|Raytheon Company|Mems-tuned high power, high efficiency, wide bandwidth power amplifier|
    US6982004B1|2002-11-26|2006-01-03|Advanced Cardiovascular Systems, Inc.|Electrostatic loading of drugs on implantable medical devices|
    JP2004173941A|2002-11-27|2004-06-24|Olympus Corp|Calcium gradient material and its manufacturing method|
    CA2506847A1|2002-11-28|2004-06-10|Keratec Limited|Personal care formulations containing keratin|
    US7211150B1|2002-12-09|2007-05-01|Advanced Cardiovascular Systems, Inc.|Apparatus and method for coating and drying multiple stents|
    US7468210B1|2002-12-10|2008-12-23|Biosurface Engineering Technologies, Inc.|Cross-linked heparin coatings and methods|
    US7758880B2|2002-12-11|2010-07-20|Advanced Cardiovascular Systems, Inc.|Biocompatible polyacrylate compositions for medical applications|
    US7776926B1|2002-12-11|2010-08-17|Advanced Cardiovascular Systems, Inc.|Biocompatible coating for implantable medical devices|
    US7074276B1|2002-12-12|2006-07-11|Advanced Cardiovascular Systems, Inc.|Clamp mandrel fixture and a method of using the same to minimize coating defects|
    US20040115164A1|2002-12-17|2004-06-17|Pierce Ryan K.|Soft filament occlusive device delivery system|
    BR0317715A|2002-12-27|2005-11-22|Angiotech Int Ag|Compositions and processes of use of collajolie|
    CA2511521C|2002-12-30|2012-02-07|Angiotech International Ag|Drug delivery from rapid gelling polymer composition|
    AU2003303595A1|2002-12-30|2004-07-29|Gryphon Therapeutics, Inc.|Water-soluble thioester and selenoester compounds and methods for making and using the same|
    AU2003303513A1|2002-12-30|2004-07-29|Angiotech International Ag|Tissue reactive compounds and compositions and uses thereof|
    JP4585743B2|2003-02-13|2010-11-24|独立行政法人物質・材料研究機構|Biodegradable absorbable adhesive medical material|
    US7485719B2|2003-02-21|2009-02-03|Terumo Kabushiki Kaisha|Crosslinkable polysaccharide derivative, process for producing the same, crosslinkable polysaccharide composition, and medical treatment material|
    US7255891B1|2003-02-26|2007-08-14|Advanced Cardiovascular Systems, Inc.|Method for coating implantable medical devices|
    US6926919B1|2003-02-26|2005-08-09|Advanced Cardiovascular Systems, Inc.|Method for fabricating a coating for a medical device|
    US7563483B2|2003-02-26|2009-07-21|Advanced Cardiovascular Systems Inc.|Methods for fabricating a coating for implantable medical devices|
    US8715771B2|2003-02-26|2014-05-06|Abbott Cardiovascular Systems Inc.|Coated stent and method of making the same|
    US7288609B1|2003-03-04|2007-10-30|Advanced Cardiovascular Systems, Inc.|Coatings for drug delivery devices based on poly |
    BRPI0408853A|2003-04-04|2006-04-04|Tissuemed Ltd|fabric adhesion formulations|
    US8038991B1|2003-04-15|2011-10-18|Abbott Cardiovascular Systems Inc.|High-viscosity hyaluronic acid compositions to treat myocardial conditions|
    US7641643B2|2003-04-15|2010-01-05|Abbott Cardiovascular Systems Inc.|Methods and compositions to treat myocardial conditions|
    US8821473B2|2003-04-15|2014-09-02|Abbott Cardiovascular Systems Inc.|Methods and compositions to treat myocardial conditions|
    US7563454B1|2003-05-01|2009-07-21|Advanced Cardiovascular Systems, Inc.|Coatings for implantable medical devices|
    US8791171B2|2003-05-01|2014-07-29|Abbott Cardiovascular Systems Inc.|Biodegradable coatings for implantable medical devices|
    US7279174B2|2003-05-08|2007-10-09|Advanced Cardiovascular Systems, Inc.|Stent coatings comprising hydrophilic additives|
    CN101137388A|2003-05-15|2008-03-05|犹他卅大学研究基金会|Anti-adhesion composites and methods os use thereof|
    US7323209B1|2003-05-15|2008-01-29|Advanced Cardiovascular Systems, Inc.|Apparatus and method for coating stents|
    US7192450B2|2003-05-21|2007-03-20|Dexcom, Inc.|Porous membranes for use with implantable devices|
    US8834864B2|2003-06-05|2014-09-16|Baxter International Inc.|Methods for repairing and regenerating human dura mater|
    US7186789B2|2003-06-11|2007-03-06|Advanced Cardiovascular Systems, Inc.|Bioabsorbable, biobeneficial polyester polymers for use in drug eluting stent coatings|
    US8465537B2|2003-06-17|2013-06-18|Gel-Del Technologies, Inc.|Encapsulated or coated stent systems|
    US7285304B1|2003-06-25|2007-10-23|Advanced Cardiovascular Systems, Inc.|Fluid treatment of a polymeric coating on an implantable medical device|
    US7645504B1|2003-06-26|2010-01-12|Advanced Cardiovascular Systems, Inc.|Coatings for implantable medical devices comprising hydrophobic and hydrophilic polymers|
    US7875285B1|2003-07-15|2011-01-25|Advanced Cardiovascular Systems, Inc.|Medicated coatings for implantable medical devices having controlled rate of release|
    US20050021127A1|2003-07-21|2005-01-27|Kawula Paul John|Porous glass fused onto stent for drug retention|
    US7169404B2|2003-07-30|2007-01-30|Advanced Cardiovasular Systems, Inc.|Biologically absorbable coatings for implantable devices and methods for fabricating the same|
    US7056591B1|2003-07-30|2006-06-06|Advanced Cardiovascular Systems, Inc.|Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same|
    US7785512B1|2003-07-31|2010-08-31|Advanced Cardiovascular Systems, Inc.|Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices|
    US7431959B1|2003-07-31|2008-10-07|Advanced Cardiovascular Systems Inc.|Method and system for irradiation of a drug eluting implantable medical device|
    US7645474B1|2003-07-31|2010-01-12|Advanced Cardiovascular Systems, Inc.|Method and system of purifying polymers for use with implantable medical devices|
    US7927626B2|2003-08-07|2011-04-19|Ethicon, Inc.|Process of making flowable hemostatic compositions and devices containing such compositions|
    US7217294B2|2003-08-20|2007-05-15|Histogenics Corp.|Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and method for use thereof|
    CA2536104A1|2003-08-20|2005-03-03|Histogenics Corporation|Acellular matrix implanted into an articular cartilage or osteochondral lesion protected with a biodegradable polymer modified to have extended polymerization time and methods forpreparation and use thereof|
    JP4874795B2|2003-08-22|2012-02-15|ヴィスタサイエンティフィックエルエルシー|Carrier|
    US7767756B2|2003-09-19|2010-08-03|Keraplast Technologies, Ltd.|Composite materials containing keratin|
    US7441513B1|2003-09-26|2008-10-28|Advanced Cardiovascular Systems, Inc.|Plasma-generated coating apparatus for medical devices and a method of coating deposition|
    US7318932B2|2003-09-30|2008-01-15|Advanced Cardiovascular Systems, Inc.|Coatings for drug delivery devices comprising hydrolitically stable adducts of poly and methods for fabricating the same|
    US7198675B2|2003-09-30|2007-04-03|Advanced Cardiovascular Systems|Stent mandrel fixture and method for selectively coating surfaces of a stent|
    US7704544B2|2003-10-07|2010-04-27|Advanced Cardiovascular Systems, Inc.|System and method for coating a tubular implantable medical device|
    WO2005039641A2|2003-10-15|2005-05-06|The Regents Of The University Of California|Biomacromolecule polymer conjugates|
    US7320707B2|2003-11-05|2008-01-22|St. Francis Medical Technologies, Inc.|Method of laterally inserting an artificial vertebral disk replacement implant with crossbar spacer|
    US7329413B1|2003-11-06|2008-02-12|Advanced Cardiovascular Systems, Inc.|Coatings for drug delivery devices having gradient of hydration and methods for fabricating thereof|
    WO2005065079A2|2003-11-10|2005-07-21|Angiotech International Ag|Medical implants and fibrosis-inducing agents|
    US7261946B2|2003-11-14|2007-08-28|Advanced Cardiovascular Systems, Inc.|Block copolymers of acrylates and methacrylates with fluoroalkenes|
    US7943388B2|2003-11-14|2011-05-17|3M Innovative Properties Company|Acoustic sensors and methods|
    US9066912B2|2003-11-17|2015-06-30|Ethicon, Inc.|Drug-enhanced adhesion prevention|
    US9114198B2|2003-11-19|2015-08-25|Advanced Cardiovascular Systems, Inc.|Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same|
    US8192752B2|2003-11-21|2012-06-05|Advanced Cardiovascular Systems, Inc.|Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same|
    US7670377B2|2003-11-21|2010-03-02|Kyphon Sarl|Laterally insertable artifical vertebral disk replacement implant with curved spacer|
    US7560492B1|2003-11-25|2009-07-14|Advanced Cardiovascular Systems, Inc.|Polysulfone block copolymers as drug-eluting coating material|
    US7807722B2|2003-11-26|2010-10-05|Advanced Cardiovascular Systems, Inc.|Biobeneficial coating compositions and methods of making and using thereof|
    US20050118344A1|2003-12-01|2005-06-02|Pacetti Stephen D.|Temperature controlled crimping|
    US20050154462A1|2003-12-02|2005-07-14|St. Francis Medical Technologies, Inc.|Laterally insertable artificial vertebral disk replacement implant with translating pivot point|
    CA2549295C|2003-12-04|2016-05-03|University Of Utah Research Foundation|Modified macromolecules and methods of making and using thereof|
    US20080176205A1|2003-12-04|2008-07-24|University Of Utah Research Foundation|Process and Formulation to Improve Viability of Stored Cells and Tissue|
    US20100330143A1|2003-12-04|2010-12-30|University Of Utah Research Foundation|Modified macromolecules and methods of making and using thereof|
    EP1691746B1|2003-12-08|2015-05-27|Gel-Del Technologies, Inc.|Mucoadhesive drug delivery devices and methods of making and using thereof|
    EP2338441B1|2003-12-11|2013-01-23|Isto Technologies Inc.|Particulate cartilage system|
    JP4912565B2|2003-12-15|2012-04-11|独立行政法人物質・材料研究機構|Biodegradable absorbable adhesive medical material|
    US7220816B2|2003-12-16|2007-05-22|Advanced Cardiovascular Systems, Inc.|Biologically absorbable coatings for implantable devices based on poly and methods for fabricating the same|
    US7435788B2|2003-12-19|2008-10-14|Advanced Cardiovascular Systems, Inc.|Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents|
    AU2004298392A1|2003-12-19|2005-06-30|Keratec Limited|Wound care products containing keratin|
    WO2005061717A1|2003-12-19|2005-07-07|Dainippon Sumitomo Pharma Co., Ltd.|Novel method of nucleic acid transfer|
    US8309112B2|2003-12-24|2012-11-13|Advanced Cardiovascular Systems, Inc.|Coatings for implantable medical devices comprising hydrophilic substances and methods for fabricating the same|
    SE0303588D0|2003-12-30|2003-12-30|Bioactive Polymers Ab C O Lund|Surface protection of exposed biological tissues|
    CN1917896B|2003-12-30|2011-07-20|生物活性聚合体股份公司|Surface protection of exposed biological tissues|
    US20050142161A1|2003-12-30|2005-06-30|Freeman Lynetta J.|Collagen matrix for soft tissue augmentation|
    US7803178B2|2004-01-30|2010-09-28|Trivascular, Inc.|Inflatable porous implants and methods for drug delivery|
    US7414028B1|2004-02-04|2008-08-19|Biosurface Engineering Technologies, Inc.|Growth factor analogs|
    US7671012B2|2004-02-10|2010-03-02|Biosurface Engineering Technologies, Inc.|Formulations and methods for delivery of growth factor analogs|
    US7528105B1|2004-02-10|2009-05-05|Biosurface Engineering Technologies|Heterodimeric chain synthetic heparin-binding growth factor analogs|
    US20060024347A1|2004-02-10|2006-02-02|Biosurface Engineering Technologies, Inc.|Bioactive peptide coatings|
    US8277831B2|2004-02-17|2012-10-02|Advanced Technologies And Regenerative Medicine, Llc.|Drug-enhanced adhesion prevention|
    US7709439B2|2004-02-20|2010-05-04|Boston Scientific Scimed, Inc.|Biomaterials for enhanced healing|
    JP4895826B2|2004-02-20|2012-03-14|バイオサーフェスエンジニアリングテクノロジーズ，インク．|Bone morphogenetic protein-2 positive modulator|
    WO2005087289A1|2004-03-15|2005-09-22|Terumo Kabushiki Kaisha|Adhesion preventive material|
    US8685431B2|2004-03-16|2014-04-01|Advanced Cardiovascular Systems, Inc.|Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same|
    US20060135959A1|2004-03-22|2006-06-22|Disc Dynamics, Inc.|Nuclectomy method and apparatus|
    US8029511B2|2004-03-22|2011-10-04|Disc Dynamics, Inc.|Multi-stage biomaterial injection system for spinal implants|
    US20050208093A1|2004-03-22|2005-09-22|Thierry Glauser|Phosphoryl choline coating compositions|
    US8551512B2|2004-03-22|2013-10-08|Advanced Cardiovascular Systems, Inc.|Polyethylene glycol/poly copolymer coated devices including EVEROLIMUS|
    US20090264939A9|2004-12-16|2009-10-22|Martz Erik O|Instrument set and method for performing spinal nuclectomy|
    US20050214339A1|2004-03-29|2005-09-29|Yiwen Tang|Biologically degradable compositions for medical applications|
    US8778014B1|2004-03-31|2014-07-15|Advanced Cardiovascular Systems, Inc.|Coatings for preventing balloon damage to polymer coated stents|
    US7909805B2|2004-04-05|2011-03-22|Bluesky Medical Group Incorporated|Flexible reduced pressure treatment appliance|
    US10058642B2|2004-04-05|2018-08-28|Bluesky Medical Group Incorporated|Reduced pressure treatment system|
    US8337482B2|2004-04-19|2012-12-25|The Invention Science Fund I, Llc|System for perfusion management|
    US7998060B2|2004-04-19|2011-08-16|The Invention Science Fund I, Llc|Lumen-traveling delivery device|
    US7850676B2|2004-04-19|2010-12-14|The Invention Science Fund I, Llc|System with a reservoir for perfusion management|
    US8361013B2|2004-04-19|2013-01-29|The Invention Science Fund I, Llc|Telescoping perfusion management system|
    US8000784B2|2004-04-19|2011-08-16|The Invention Science Fund I, Llc|Lumen-traveling device|
    US20120035439A1|2006-04-12|2012-02-09|Bran Ferren|Map-based navigation of a body tube tree by a lumen traveling device|
    US8353896B2|2004-04-19|2013-01-15|The Invention Science Fund I, Llc|Controllable release nasal system|
    US8512219B2|2004-04-19|2013-08-20|The Invention Science Fund I, Llc|Bioelectromagnetic interface system|
    US8019413B2|2007-03-19|2011-09-13|The Invention Science Fund I, Llc|Lumen-traveling biological interface device and method of use|
    US9011329B2|2004-04-19|2015-04-21|Searete Llc|Lumenally-active device|
    GB0409446D0|2004-04-28|2004-06-02|Smith & Nephew|Apparatus|
    US8293890B2|2004-04-30|2012-10-23|Advanced Cardiovascular Systems, Inc.|Hyaluronic acid based copolymers|
    US7820732B2|2004-04-30|2010-10-26|Advanced Cardiovascular Systems, Inc.|Methods for modulating thermal and mechanical properties of coatings on implantable devices|
    CA2565818C|2004-05-07|2013-07-30|Seikagaku Corporation|Nucleus pulposus filler comprising crosslinked chondroitin sulfate|
    US20050255045A1|2004-05-13|2005-11-17|Woltering Eugene A|Surgical marking composition and method|
    US7758654B2|2004-05-20|2010-07-20|Kensey Nash Corporation|Anti-adhesion device|
    US8062272B2|2004-05-21|2011-11-22|Bluesky Medical Group Incorporated|Flexible reduced pressure treatment appliance|
    US20050281866A1|2004-05-24|2005-12-22|Genzyme Corporation|Adherent polymeric compositions|
    US9561309B2|2004-05-27|2017-02-07|Advanced Cardiovascular Systems, Inc.|Antifouling heparin coatings|
    US7282584B2|2004-06-16|2007-10-16|Straumann Holding Ag|Methylene blue|
    AT385423T|2004-06-16|2008-02-15|Straumann Holding Ag|covering membrane|
    US7563780B1|2004-06-18|2009-07-21|Advanced Cardiovascular Systems, Inc.|Heparin prodrugs and drug delivery stents formed therefrom|
    US20090117070A1|2004-06-23|2009-05-07|Angiotech Pharmaceuticals , Inc.|Methods and Crosslinked Polymer Compositions for Cartilage Repair|
    US8568469B1|2004-06-28|2013-10-29|Advanced Cardiovascular Systems, Inc.|Stent locking element and a method of securing a stent on a delivery system|
    DE102004031258A1|2004-06-29|2006-02-09|Jennissen, Herbert P., Prof. Dr.|Protein hybrids with polyhydroxyaromatic amino acid epitopes|
    US20050287184A1|2004-06-29|2005-12-29|Hossainy Syed F A|Drug-delivery stent formulations for restenosis and vulnerable plaque|
    US8337557B2|2004-06-29|2012-12-25|Spine Wave, Inc.|Apparatus and kit for injecting a curable biomaterial into an intervertebral space|
    CA2572603C|2004-06-29|2013-01-15|Biocure, Inc.|Spinal disc nucleus pulposus implant|
    US8241554B1|2004-06-29|2012-08-14|Advanced Cardiovascular Systems, Inc.|Method of forming a stent pattern on a tube|
    US20060002968A1|2004-06-30|2006-01-05|Gordon Stewart|Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders|
    JP2008505099A|2004-06-30|2008-02-21|タイコヘルスケアグループリミテッドパートナーシップ|Isocyanate-based compositions and uses thereof|
    US7758881B2|2004-06-30|2010-07-20|Advanced Cardiovascular Systems, Inc.|Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device|
    US10022078B2|2004-07-13|2018-07-17|Dexcom, Inc.|Analyte sensor|
    US9247900B2|2004-07-13|2016-02-02|Dexcom, Inc.|Analyte sensor|
    US8515516B2|2004-07-13|2013-08-20|Dexcom, Inc.|Transcutaneous analyte sensor|
    US7494665B1|2004-07-30|2009-02-24|Advanced Cardiovascular Systems, Inc.|Polymers containing siloxane monomers|
    US8357391B2|2004-07-30|2013-01-22|Advanced Cardiovascular Systems, Inc.|Coatings for implantable devices comprising polyand diacid linkages|
    BRPI0514106A|2004-08-03|2008-05-27|Tissuemed Ltd|fabric adhesive materials|
    WO2006020994A2|2004-08-13|2006-02-23|Angiotech International Ag|Compositions and methods using hyaluronic acid and hyluronidase inhibitors|
    US7442389B2|2004-08-20|2008-10-28|Artes Medical, Inc.|Methods of administering microparticles combined with autologous body components|
    US20060041102A1|2004-08-23|2006-02-23|Advanced Cardiovascular Systems, Inc.|Implantable devices comprising biologically absorbable polymers having constant rate of degradation and methods for fabricating the same|
    US9283099B2|2004-08-25|2016-03-15|Advanced Cardiovascular Systems, Inc.|Stent-catheter assembly with a releasable connection for stent retention|
    US7648727B2|2004-08-26|2010-01-19|Advanced Cardiovascular Systems, Inc.|Methods for manufacturing a coated stent-balloon assembly|
    US7244443B2|2004-08-31|2007-07-17|Advanced Cardiovascular Systems, Inc.|Polymers of fluorinated monomers and hydrophilic monomers|
    US20060045902A1|2004-09-01|2006-03-02|Serbousek Jon C|Polymeric wrap for in vivo delivery of osteoinductive formulations|
    JP2008512174A|2004-09-10|2008-04-24|スティッチングダッチポリマーインスティテュート|Radiopaque prosthetic disc nucleus|
    US7229471B2|2004-09-10|2007-06-12|Advanced Cardiovascular Systems, Inc.|Compositions containing fast-leaching plasticizers for improved performance of medical devices|
    US8110211B2|2004-09-22|2012-02-07|Advanced Cardiovascular Systems, Inc.|Medicated coatings for implantable medical devices including polyacrylates|
    US8092549B2|2004-09-24|2012-01-10|The Invention Science Fund I, Llc|Ciliated stent-like-system|
    US20060069438A1|2004-09-29|2006-03-30|Zucherman James F|Multi-piece artificial spinal disk replacement device with multi-segmented support plates|
    US7875233B2|2004-09-30|2011-01-25|Advanced Cardiovascular Systems, Inc.|Method of fabricating a biaxially oriented implantable medical device|
    US8043553B1|2004-09-30|2011-10-25|Advanced Cardiovascular Systems, Inc.|Controlled deformation of a polymer tube with a restraining surface in fabricating a medical article|
    US8173062B1|2004-09-30|2012-05-08|Advanced Cardiovascular Systems, Inc.|Controlled deformation of a polymer tube in fabricating a medical article|
    US8778256B1|2004-09-30|2014-07-15|Advanced Cardiovascular Systems, Inc.|Deformation of a polymer tube in the fabrication of a medical article|
    WO2006038866A1|2004-10-01|2006-04-13|Bio Polymer Products Of Sweden Ab|Improved coating comprising a bioadhesive polyphenolic protein derived from a byssus-forming mussel|
    US7166680B2|2004-10-06|2007-01-23|Advanced Cardiovascular Systems, Inc.|Blends of poly polymers|
    US8790632B2|2004-10-07|2014-07-29|Actamax Surgical Materials, Llc|Polymer-based tissue-adhesive form medical use|
    CN101035572B|2004-10-07|2010-12-08|纳幕尔杜邦公司|Polysaccharide-based polymer tissue adhesive for medical use|
    US7235592B2|2004-10-12|2007-06-26|Zimmer Gmbh|PVA hydrogel|
    US7845536B2|2004-10-18|2010-12-07|Tyco Healthcare Group Lp|Annular adhesive structure|
    US7938307B2|2004-10-18|2011-05-10|Tyco Healthcare Group Lp|Support structures and methods of using the same|
    US8603634B2|2004-10-27|2013-12-10|Abbott Cardiovascular Systems Inc.|End-capped poly copolymers|
    US20060089485A1|2004-10-27|2006-04-27|Desnoyer Jessica R|End-capped poly copolymers|
    US8535700B2|2004-10-28|2013-09-17|Surmodics, Inc.|Pro-fibrotic coatings|
    US8206448B2|2004-10-29|2012-06-26|Spinal Restoration, Inc.|Injection of fibrin sealant using reconstituted components in spinal applications|
    US20060095122A1|2004-10-29|2006-05-04|Advanced Cardiovascular Systems, Inc.|Implantable devices comprising biologically absorbable star polymers and methods for fabricating the same|
    US7390497B2|2004-10-29|2008-06-24|Advanced Cardiovascular Systems, Inc.|Poly filler blends for modulation of coating properties|
    US7597687B2|2004-10-29|2009-10-06|Spinal Restoration, Inc.|Injection of fibrin sealant including an anesthetic in spinal applications|
    US20110213464A1|2004-10-29|2011-09-01|Whitlock Steven I|Injection of fibrin sealant in the absence of corticosteroids in spinal applications|
    US8357147B2|2005-08-17|2013-01-22|Spinal Restoration, Inc.|Method for repairing intervertebral discs|
    US7201918B2|2004-11-16|2007-04-10|Microvention, Inc.|Compositions, systems and methods for treatment of defects in blood vessels|
    US7214759B2|2004-11-24|2007-05-08|Advanced Cardiovascular Systems, Inc.|Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same|
    US7588642B1|2004-11-29|2009-09-15|Advanced Cardiovascular Systems, Inc.|Abluminal stent coating apparatus and method using a brush assembly|
    US8609123B2|2004-11-29|2013-12-17|Advanced Cardiovascular Systems, Inc.|Derivatized poly as a biobeneficial coating|
    US7892592B1|2004-11-30|2011-02-22|Advanced Cardiovascular Systems, Inc.|Coating abluminal surfaces of stents and other implantable medical devices|
    US20060115449A1|2004-11-30|2006-06-01|Advanced Cardiovascular Systems, Inc.|Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings|
    EP1830863A2|2004-12-10|2007-09-12|Straumann Holding AG|Protein formulation|
    SE0403014D0|2004-12-10|2004-12-10|Straumann Holding Ag|New protein formulation|
    EP1862170B1|2004-12-10|2012-03-14|Straumann Holding AG|Enamel formulation with amelogenin|
    US7342082B2|2004-12-17|2008-03-11|3M Innovative Properties Company|Soluble polymers as amine capture agents and methods|
    US7402678B2|2004-12-17|2008-07-22|3M Innovative Properties Company|Multifunctional amine capture agents|
    US7854944B2|2004-12-17|2010-12-21|Advanced Cardiovascular Systems, Inc.|Tissue regeneration|
    US7604818B2|2004-12-22|2009-10-20|Advanced Cardiovascular Systems, Inc.|Polymers of fluorinated monomers and hydrocarbon monomers|
    US20090104254A1|2004-12-22|2009-04-23|Rutgers, The State University Of New Jersey|Controlled Release Hydrogels|
    JP2008529972A|2004-12-22|2008-08-07|クロス・バイオサージェリー・アクチェンゲゼルシャフト|Synthetic biomaterials incorporating bioactive factors through enzymatically degradable linkages|
    US7419504B2|2004-12-27|2008-09-02|Advanced Cardiovascular Systems, Inc.|Poly block copolymers|
    US8007775B2|2004-12-30|2011-08-30|Advanced Cardiovascular Systems, Inc.|Polymers containing poly and agents for use with medical articles and methods of fabricating the same|
    CA2592973A1|2005-01-06|2006-07-13|Kuros Biosurgery Ag|Supplemented matrices for the repair of bone fractures|
    US8575101B2|2005-01-06|2013-11-05|Kuros Biosurgery Ag|Supplemented matrices for the repair of bone fractures|
    WO2006073711A2|2005-01-06|2006-07-13|Kuros Biosurgery Ag|Use of a matrix comprising a contrast agent in soft tissues|
    US7202325B2|2005-01-14|2007-04-10|Advanced Cardiovascular Systems, Inc.|Poly and agents for use with medical articles|
    US7611494B2|2005-02-08|2009-11-03|Confluent Surgical, Inc.|Spray for fluent materials|
    CA2596506C|2005-02-09|2021-04-06|Avi Biopharma, Inc.|Antisense composition and method for treating muscle atrophy|
    AU2006213822B2|2005-02-09|2011-05-26|Covidien Lp|Synthetic sealants|
    US20080227696A1|2005-02-22|2008-09-18|Biosurface Engineering Technologies, Inc.|Single branch heparin-binding growth factor analogs|
    US20060264672A1|2005-02-23|2006-11-23|Andrews Mark A|Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers|
    EP1858984A1|2005-02-23|2007-11-28|Zimmer Technology, Inc.|Blend hydrogels and methods of making|
    US7920906B2|2005-03-10|2011-04-05|Dexcom, Inc.|System and methods for processing analyte sensor data for sensor calibration|
    US20090232784A1|2005-03-10|2009-09-17|Dale Feldman|Endothelial predecessor cell seeded wound healing scaffold|
    US7579317B2|2005-03-11|2009-08-25|Keratec, Ltd.|Nutraceutical composition comprising soluble keratin or derivative thereof|
    US9364229B2|2005-03-15|2016-06-14|Covidien Lp|Circular anastomosis structures|
    US20090062184A1|2005-03-24|2009-03-05|Dainippon Sumitomo Pharma Co., Ltd.|Fine particulate preparation comprising complex of nucleic acid molecule and collagen|
    US20060222596A1|2005-04-01|2006-10-05|Trivascular, Inc.|Non-degradable, low swelling, water soluble radiopaque hydrogel polymer|
    EP2279756A2|2005-04-05|2011-02-02|Instituto di Ricerche di Biologia Molecolare p Angeletti S.P.A.|Method for shielding functional sites or epitopes on proteins|
    US7381048B2|2005-04-12|2008-06-03|Advanced Cardiovascular Systems, Inc.|Stents with profiles for gripping a balloon catheter and molds for fabricating stents|
    US8187621B2|2005-04-19|2012-05-29|Advanced Cardiovascular Systems, Inc.|Methods and compositions for treating post-myocardial infarction damage|
    US8828433B2|2005-04-19|2014-09-09|Advanced Cardiovascular Systems, Inc.|Hydrogel bioscaffoldings and biomedical device coatings|
    US20080125745A1|2005-04-19|2008-05-29|Shubhayu Basu|Methods and compositions for treating post-cardial infarction damage|
    US9539410B2|2005-04-19|2017-01-10|Abbott Cardiovascular Systems Inc.|Methods and compositions for treating post-cardial infarction damage|
    US8303972B2|2005-04-19|2012-11-06|Advanced Cardiovascular Systems, Inc.|Hydrogel bioscaffoldings and biomedical device coatings|
    US7795467B1|2005-04-26|2010-09-14|Advanced Cardiovascular Systems, Inc.|Bioabsorbable, biobeneficial polyurethanes for use in medical devices|
    US9119901B2|2005-04-28|2015-09-01|Warsaw Orthopedic, Inc.|Surface treatments for promoting selective tissue attachment to medical impants|
    US8414907B2|2005-04-28|2013-04-09|Warsaw Orthopedic, Inc.|Coatings on medical implants to guide soft tissue healing|
    US8778375B2|2005-04-29|2014-07-15|Advanced Cardiovascular Systems, Inc.|Amorphous poly coating|
    US20060253199A1|2005-05-03|2006-11-09|Disc Dynamics, Inc.|Lordosis creating nucleus replacement method and apparatus|
    US20060253198A1|2005-05-03|2006-11-09|Disc Dynamics, Inc.|Multi-lumen mold for intervertebral prosthesis and method of using same|
    US7291166B2|2005-05-18|2007-11-06|Advanced Cardiovascular Systems, Inc.|Polymeric stent patterns|
    EP2298829B1|2005-05-31|2017-09-20|École Polytechnique Fédérale de Lausanne |Triblock copolymers for cytoplasmic delivery of gene-based drugs|
    US7823533B2|2005-06-30|2010-11-02|Advanced Cardiovascular Systems, Inc.|Stent fixture and method for reducing coating defects|
    US8021676B2|2005-07-08|2011-09-20|Advanced Cardiovascular Systems, Inc.|Functionalized chemically inert polymers for coatings|
    AT524509T|2005-07-18|2011-09-15|Nektar Therapeutics|BRANCHED FUNCTIONALIZED POLYMERS USING BRANCHED POLYOLS AS NUCLEARS|
    US7785647B2|2005-07-25|2010-08-31|Advanced Cardiovascular Systems, Inc.|Methods of providing antioxidants to a drug containing product|
    US7735449B1|2005-07-28|2010-06-15|Advanced Cardiovascular Systems, Inc.|Stent fixture having rounded support structures and method for use thereof|
    US7658880B2|2005-07-29|2010-02-09|Advanced Cardiovascular Systems, Inc.|Polymeric stent polishing method and apparatus|
    US7297758B2|2005-08-02|2007-11-20|Advanced Cardiovascular Systems, Inc.|Method for extending shelf-life of constructs of semi-crystallizable polymers|
    US20070031498A1|2005-08-02|2007-02-08|Wright Medical Technology, Inc.|Gel composition for cellular adhesion inhibition|
    US20070031468A1|2005-08-04|2007-02-08|Endomedix, Inc.|Modified chitosan for vascular embolization|
    US20070031467A1|2005-08-04|2007-02-08|Abrahams John M|Composition and method for vascular embolization|
    DK2046407T3|2006-08-02|2015-05-26|Khorionyx|Implantable preparation that can be used especially for tissue supplementation and wound healing|
    US20070038290A1|2005-08-15|2007-02-15|Bin Huang|Fiber reinforced composite stents|
    US7476245B2|2005-08-16|2009-01-13|Advanced Cardiovascular Systems, Inc.|Polymeric stent patterns|
    US9248034B2|2005-08-23|2016-02-02|Advanced Cardiovascular Systems, Inc.|Controlled disintegrating implantable medical devices|
    US8679536B2|2005-08-24|2014-03-25|Actamax Surgical Materials, Llc|Aldol-crosslinked polymeric hydrogel adhesives|
    US8679537B2|2005-08-24|2014-03-25|Actamaz Surgical Materials, LLC|Methods for sealing an orifice in tissue using an aldol-crosslinked polymeric hydrogel adhesive|
    AU2006282754A1|2005-08-26|2007-03-01|Zimmer, Inc.|Implants and methods for repair, replacement and treatment of joint disease|
    BRPI0615065A2|2005-09-02|2011-05-03|Colbar Lifescience Ltd|processes for preparing cross-linked polysaccharides, said polysaccharides, process for preparing a composite cross-linked matrix, and said matrix|
    CA2518298A1|2005-09-06|2007-03-06|Chaimed Technologies Inc.|Biodegradable polymers, their preparation and their use for the manufacture of bandages|
    KR101382083B1|2005-09-09|2014-04-10|오타와 하스피털 리서치 인스티튜트|Interpenetrating Networks, and Related Methods and Compositions|
    EP1764117A1|2005-09-20|2007-03-21|Zimmer GmbH|Implant for the repair of a cartilage defect and method for manufacturing the implant|
    WO2007038625A2|2005-09-28|2007-04-05|Northwestern University|Biodegradable nanocomposites with enhanced mechanical properties for soft tissue engineering.|
    US7544755B2|2005-09-30|2009-06-09|3M Innovative Properties Company|Crosslinked polymers with amine binding groups|
    US7544756B2|2005-09-30|2009-06-09|3M Innovative Properties Company|Crosslinked polymers with amine binding groups|
    US7544754B2|2005-09-30|2009-06-09|3M Innovative Properties Company|Crosslinked polymers with amine binding groups|
    US8083726B1|2005-09-30|2011-12-27|Advanced Cardiovascular Systems, Inc.|Encapsulating cells and lumen|
    WO2007067624A2|2005-12-06|2007-06-14|Tyco Healthcare Group Lp|Bioabsorbable compounds and compositions containing them|
    US8262730B2|2005-12-07|2012-09-11|Zimmer, Inc.|Methods of bonding or modifying hydrogels using irradiation|
    JP2009518522A|2005-12-08|2009-05-07|タイコヘルスケアグループリミテッドパートナーシップ|Sprayable composition with reduced viscosity|
    US20070135909A1|2005-12-08|2007-06-14|Desnoyer Jessica R|Adhesion polymers to improve stent retention|
    JP2009518142A|2005-12-08|2009-05-07|タイコヘルスケアグループリミテッドパートナーシップ|Biocompatible surgical composition|
    US7976891B1|2005-12-16|2011-07-12|Advanced Cardiovascular Systems, Inc.|Abluminal stent coating apparatus and method of using focused acoustic energy|
    US7867547B2|2005-12-19|2011-01-11|Advanced Cardiovascular Systems, Inc.|Selectively coating luminal surfaces of stents|
    CN1985778B|2005-12-20|2010-10-13|广东冠昊生物科技股份有限公司|Artificial biological cornea|
    US20070142287A1|2005-12-20|2007-06-21|Biomed Solutions, Llc|Compositions And Methods For Treatment Of Cancer|
    US8017107B2|2005-12-22|2011-09-13|Zimmer, Inc.|Perfluorocyclobutane crosslinked hydrogels|
    US8801790B2|2005-12-27|2014-08-12|Warsaw Orthopedic, Inc.|Intervertebral disc augmentation and rehydration with superabsorbent polymers|
    US20070149641A1|2005-12-28|2007-06-28|Goupil Dennis W|Injectable bone cement|
    US20070156230A1|2006-01-04|2007-07-05|Dugan Stephen R|Stents with radiopaque markers|
    US7951185B1|2006-01-06|2011-05-31|Advanced Cardiovascular Systems, Inc.|Delivery of a stent at an elevated temperature|
    EP1996243B1|2006-01-11|2014-04-23|HyperBranch Medical Technology, Inc.|Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices|
    US20070179219A1|2006-01-31|2007-08-02|Bin Huang|Method of fabricating an implantable medical device using gel extrusion and charge induced orientation|
    EP1979018B1|2006-02-03|2013-08-07|Tissuemed Limited|Tissue-adhesive materials|
    WO2007092583A2|2006-02-08|2007-08-16|Northwestern University|Functionalizing implantable devices with a polypolymer|
    US20070191931A1|2006-02-16|2007-08-16|Jan Weber|Bioerodible endoprostheses and methods of making the same|
    US20070196428A1|2006-02-17|2007-08-23|Thierry Glauser|Nitric oxide generating medical devices|
    US20090018575A1|2006-03-01|2009-01-15|Tissuemed Limited|Tissue-adhesive formulations|
    US7713637B2|2006-03-03|2010-05-11|Advanced Cardiovascular Systems, Inc.|Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer|
    US8110242B2|2006-03-24|2012-02-07|Zimmer, Inc.|Methods of preparing hydrogel coatings|
    US8795709B2|2006-03-29|2014-08-05|Incept Llc|Superabsorbent, freeze dried hydrogels for medical applications|
    US7964210B2|2006-03-31|2011-06-21|Abbott Cardiovascular Systems Inc.|Degradable polymeric implantable medical devices with a continuous phase and discrete phase|
    US7883520B2|2006-04-10|2011-02-08|Forsight Labs, Llc|Corneal epithelial pocket formation systems, components and methods|
    US7854923B2|2006-04-18|2010-12-21|Endomedix, Inc.|Biopolymer system for tissue sealing|
    US20070243130A1|2006-04-18|2007-10-18|Weiliam Chen|Biopolymer system for tissue sealing|
    US20080075657A1|2006-04-18|2008-03-27|Abrahams John M|Biopolymer system for tissue sealing|
    US8747870B2|2006-04-20|2014-06-10|University Of Utah Research Foundation|Polymeric compositions and methods of making and using thereof|
    AU2007240613B2|2006-04-20|2013-11-28|University Of Utah Research Foundation|Polymeric compositions and methods of making and using thereof|
    CA2650473C|2006-04-24|2013-06-18|Incept, Llc|Protein crosslinkers, crosslinking methods and applications thereof|
    US8747879B2|2006-04-28|2014-06-10|Advanced Cardiovascular Systems, Inc.|Method of fabricating an implantable medical device to reduce chance of late inflammatory response|
    US8747878B2|2006-04-28|2014-06-10|Advanced Cardiovascular Systems, Inc.|Method of fabricating an implantable medical device by controlling crystalline structure|
    US8003156B2|2006-05-04|2011-08-23|Advanced Cardiovascular Systems, Inc.|Rotatable support elements for stents|
    US8304012B2|2006-05-04|2012-11-06|Advanced Cardiovascular Systems, Inc.|Method for drying a stent|
    US7985441B1|2006-05-04|2011-07-26|Yiwen Tang|Purification of polymers for coating applications|
    US7761968B2|2006-05-25|2010-07-27|Advanced Cardiovascular Systems, Inc.|Method of crimping a polymeric stent|
    US7775178B2|2006-05-26|2010-08-17|Advanced Cardiovascular Systems, Inc.|Stent coating apparatus and method|
    US7951194B2|2006-05-26|2011-05-31|Abbott Cardiovascular Sysetms Inc.|Bioabsorbable stent with radiopaque coating|
    US8752268B2|2006-05-26|2014-06-17|Abbott Cardiovascular Systems Inc.|Method of making stents with radiopaque markers|
    US7971333B2|2006-05-30|2011-07-05|Advanced Cardiovascular Systems, Inc.|Manufacturing process for polymetric stents|
    US7959940B2|2006-05-30|2011-06-14|Advanced Cardiovascular Systems, Inc.|Polymer-bioceramic composite implantable medical devices|
    US7872068B2|2006-05-30|2011-01-18|Incept Llc|Materials formable in situ within a medical device|
    US8343530B2|2006-05-30|2013-01-01|Abbott Cardiovascular Systems Inc.|Polymer-and polymer blend-bioceramic composite implantable medical devices|
    US20070282434A1|2006-05-30|2007-12-06|Yunbing Wang|Copolymer-bioceramic composite implantable medical devices|
    US20080058916A1|2006-05-31|2008-03-06|Bin Huang|Method of fabricating polymeric self-expandable stent|
    US8568764B2|2006-05-31|2013-10-29|Advanced Cardiovascular Systems, Inc.|Methods of forming coating layers for medical devices utilizing flash vaporization|
    US9561351B2|2006-05-31|2017-02-07|Advanced Cardiovascular Systems, Inc.|Drug delivery spiral coil construct|
    JP5231401B2|2006-05-31|2013-07-10|バクスター・インターナショナル・インコーポレイテッド|Method of guided cell ingrowth and controlled tissue regeneration in spinal surgery|
    US8034287B2|2006-06-01|2011-10-11|Abbott Cardiovascular Systems Inc.|Radiation sterilization of medical devices|
    US7820172B1|2006-06-01|2010-10-26|Biosurface Engineering Technologies, Inc.|Laminin-derived multi-domain peptides|
    US8486135B2|2006-06-01|2013-07-16|Abbott Cardiovascular Systems Inc.|Implantable medical devices fabricated from branched polymers|
    US20070281073A1|2006-06-01|2007-12-06|Gale David C|Enhanced adhesion of drug delivery coatings on stents|
    US8703167B2|2006-06-05|2014-04-22|Advanced Cardiovascular Systems, Inc.|Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug|
    US8778376B2|2006-06-09|2014-07-15|Advanced Cardiovascular Systems, Inc.|Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating|
    US8603530B2|2006-06-14|2013-12-10|Abbott Cardiovascular Systems Inc.|Nanoshell therapy|
    US8114150B2|2006-06-14|2012-02-14|Advanced Cardiovascular Systems, Inc.|RGD peptide attached to bioabsorbable stents|
    US7731890B2|2006-06-15|2010-06-08|Advanced Cardiovascular Systems, Inc.|Methods of fabricating stents with enhanced fracture toughness|
    US8048448B2|2006-06-15|2011-11-01|Abbott Cardiovascular Systems Inc.|Nanoshells for drug delivery|
    US8535372B1|2006-06-16|2013-09-17|Abbott Cardiovascular Systems Inc.|Bioabsorbable stent with prohealing layer|
    US8333000B2|2006-06-19|2012-12-18|Advanced Cardiovascular Systems, Inc.|Methods for improving stent retention on a balloon catheter|
    EP2046350A4|2006-06-22|2011-09-14|Biosurface Eng Tech Inc|Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis|
    US8017237B2|2006-06-23|2011-09-13|Abbott Cardiovascular Systems, Inc.|Nanoshells on polymers|
    US9072820B2|2006-06-26|2015-07-07|Advanced Cardiovascular Systems, Inc.|Polymer composite stent with polymer particles|
    US8128688B2|2006-06-27|2012-03-06|Abbott Cardiovascular Systems Inc.|Carbon coating on an implantable device|
    US7794776B1|2006-06-29|2010-09-14|Abbott Cardiovascular Systems Inc.|Modification of polymer stents with radiation|
    US8399619B2|2006-06-30|2013-03-19|Warsaw Orthopedic, Inc.|Injectable collagen material|
    US8118779B2|2006-06-30|2012-02-21|Warsaw Orthopedic, Inc.|Collagen delivery device|
    US7740791B2|2006-06-30|2010-06-22|Advanced Cardiovascular Systems, Inc.|Method of fabricating a stent with features by blow molding|
    US7960498B2|2006-06-30|2011-06-14|Actamax Surgical Materials, Llc|Tissue adhesives with modified elasticity|
    US20080009938A1|2006-07-07|2008-01-10|Bin Huang|Stent with a radiopaque marker and method for making the same|
    US9028859B2|2006-07-07|2015-05-12|Advanced Cardiovascular Systems, Inc.|Phase-separated block copolymer coatings for implantable medical devices|
    US7823263B2|2006-07-11|2010-11-02|Abbott Cardiovascular Systems Inc.|Method of removing stent islands from a stent|
    EP2038309A2|2006-07-11|2009-03-25|University of Utah Research Foundation|Macromolecules modified with electrophilic groups and methods of making and using thereof|
    US20080014244A1|2006-07-13|2008-01-17|Gale David C|Implantable medical devices and coatings therefor comprising physically crosslinked block copolymers|
    US7757543B2|2006-07-13|2010-07-20|Advanced Cardiovascular Systems, Inc.|Radio frequency identification monitoring of stents|
    US7998404B2|2006-07-13|2011-08-16|Advanced Cardiovascular Systems, Inc.|Reduced temperature sterilization of stents|
    US8685430B1|2006-07-14|2014-04-01|Abbott Cardiovascular Systems Inc.|Tailored aliphatic polyesters for stent coatings|
    US7794495B2|2006-07-17|2010-09-14|Advanced Cardiovascular Systems, Inc.|Controlled degradation of stents|
    US7886419B2|2006-07-18|2011-02-15|Advanced Cardiovascular Systems, Inc.|Stent crimping apparatus and method|
    US7732190B2|2006-07-31|2010-06-08|Advanced Cardiovascular Systems, Inc.|Modified two-component gelation systems, methods of use and methods of manufacture|
    US8016879B2|2006-08-01|2011-09-13|Abbott Cardiovascular Systems Inc.|Drug delivery after biodegradation of the stent scaffolding|
    TWI436793B|2006-08-02|2014-05-11|Baxter Int|Rapidly acting dry sealant and methods for use and manufacture|
    US8129445B2|2006-08-09|2012-03-06|Ethicon, Inc.|Moisture activated latent curing adhesive or sealant|
    US7947758B2|2006-08-09|2011-05-24|Ethicon, Inc.|Moisture activated latent curing adhesive or sealant|
    US8703169B1|2006-08-15|2014-04-22|Abbott Cardiovascular Systems Inc.|Implantable device having a coating comprising carrageenan and a biostable polymer|
    US9173733B1|2006-08-21|2015-11-03|Abbott Cardiovascular Systems Inc.|Tracheobronchial implantable medical device and methods of use|
    US9242005B1|2006-08-21|2016-01-26|Abbott Cardiovascular Systems Inc.|Pro-healing agent formulation compositions, methods and treatments|
    US7923022B2|2006-09-13|2011-04-12|Advanced Cardiovascular Systems, Inc.|Degradable polymeric implantable medical devices with continuous phase and discrete phase|
    US7985783B2|2006-09-21|2011-07-26|The Regents Of The University Of California|Aldehyde tags, uses thereof in site-specific protein modification|
    DE602007010708D1|2006-09-29|2011-01-05|Nof Corp|Process for the preparation of biodegradable polyoxyalkylene|
    US7842737B2|2006-09-29|2010-11-30|Abbott Cardiovascular Systems Inc.|Polymer blend-bioceramic composite implantable medical devices|
    US7592009B2|2006-10-10|2009-09-22|Ecole Polytechnique Federale De Lausanne |Polypeptide ligands for targeting cartilage and methods of use thereof|
    JP2008093230A|2006-10-13|2008-04-24|Kanagawa Acad Of Sci & Technol|Gel forming composition|
    US8007992B2|2006-10-27|2011-08-30|Edwards Lifesciences Corporation|Method of treating glutaraldehyde-fixed pericardial tissue with a non-aqueous mixture of glycerol and a C1-C3 alcohol|
    US8580192B2|2006-10-31|2013-11-12|Ethicon, Inc.|Sterilization of polymeric materials|
    US8741326B2|2006-11-17|2014-06-03|Abbott Cardiovascular Systems Inc.|Modified two-component gelation systems, methods of use and methods of manufacture|
    US9005672B2|2006-11-17|2015-04-14|Abbott Cardiovascular Systems Inc.|Methods of modifying myocardial infarction expansion|
    EP2099845B1|2006-11-27|2020-12-23|Actamax Surgical Materials LLC|Multi-functional polyalkylene oxides, hydrogels andtissue adhesives|
    US8080593B2|2006-11-29|2011-12-20|University Of Southern California|Reversible thermoresponsive adhesives for implants|
    US8192760B2|2006-12-04|2012-06-05|Abbott Cardiovascular Systems Inc.|Methods and compositions for treating tissue using silk proteins|
    ES2515118T3|2006-12-06|2014-10-29|Keratec Limited|Fillers for bone gaps and their manufacturing procedures|
    CA2672529A1|2006-12-11|2008-06-19|Keratec, Ltd.|Porous keratin construct and method of making the same|
    US8099849B2|2006-12-13|2012-01-24|Abbott Cardiovascular Systems Inc.|Optimizing fracture toughness of polymeric stent|
    US8597673B2|2006-12-13|2013-12-03|Advanced Cardiovascular Systems, Inc.|Coating of fast absorption or dissolution|
    US7720533B2|2006-12-20|2010-05-18|Zimmer Orthobiologicals, Inc.|Apparatus and method for delivering a biocompatible material to a surgical site|
    US20080159975A1|2006-12-20|2008-07-03|Sunbio, Inc.|Hair treatment composition, hair treatment agent and method for treating hair by using the same|
    US20080154233A1|2006-12-20|2008-06-26|Zimmer Orthobiologics, Inc.|Apparatus for delivering a biocompatible material to a surgical site and method of using same|
    US8163549B2|2006-12-20|2012-04-24|Zimmer Orthobiologics, Inc.|Method of obtaining viable small tissue particles and use for tissue repair|
    WO2008089365A2|2007-01-19|2008-07-24|The Cleveland Clinic Foundation|Method for implanting a cardiovascular valve|
    EP2120555A1|2007-01-31|2009-11-25|Adam Heller|Methods and compositions for the treatment of pain|
    JP2010517638A|2007-02-02|2010-05-27|トアニエ，インコーポレイテッド|Systems and methods for repairing tendons and ligaments|
    CA2677532A1|2007-02-06|2008-08-14|Incept, Llc|Polymerization with precipitation of proteins for elution in physiological solution|
    US20090227981A1|2007-03-05|2009-09-10|Bennett Steven L|Low-Swelling Biocompatible Hydrogels|
    US20090227689A1|2007-03-05|2009-09-10|Bennett Steven L|Low-Swelling Biocompatible Hydrogels|
    US20080220047A1|2007-03-05|2008-09-11|Sawhney Amarpreet S|Low-swelling biocompatible hydrogels|
    US20080243228A1|2007-03-28|2008-10-02|Yunbing Wang|Implantable medical devices fabricated from block copolymers|
    EP2129339B1|2007-03-29|2015-03-04|Tyrx, Inc.|Biodegradable, polymer coverings for breast implants|
    US9693841B2|2007-04-02|2017-07-04|Ension, Inc.|Surface treated staples, sutures and dental floss and methods of manufacturing the same|
    US8262723B2|2007-04-09|2012-09-11|Abbott Cardiovascular Systems Inc.|Implantable medical devices fabricated from polymer blends with star-block copolymers|
    US8093039B2|2007-04-10|2012-01-10|The Trustees Of The Stevens Institute Of Technology|Surfaces differentially adhesive to eukaryotic cells and non-eukaryotic cells|
    EP2134297B1|2007-04-12|2017-03-08|Zimmer, Inc.|Apparatus for tissue repair|
    EP2136850B1|2007-04-13|2012-02-01|Kuros Biosurgery AG|Polymeric tissue sealant|
    EP2285312A4|2008-05-01|2014-03-12|Columna Pty Ltd|Systems methods and apparatuses for formation and insertion of tissue prostheses|
    US8147769B1|2007-05-16|2012-04-03|Abbott Cardiovascular Systems Inc.|Stent and delivery system with reduced chemical degradation|
    US20080287986A1|2007-05-18|2008-11-20|Possis Medical, Inc.|Closure device|
    US20080287633A1|2007-05-18|2008-11-20|Drumheller Paul D|Hydrogel Materials|
    BRPI0811784A2|2007-05-23|2011-05-10|Allergan Inc|cross-linked collagen and use thereof|
    EP2150612A4|2007-05-24|2010-06-09|Univ Columbia|Hybrid soft tissue implants from progenitor cells and biomaterials|
    US20080317826A1|2007-05-24|2008-12-25|Robert James Kelly|Porous keratin constructs, wound healing assemblies and methods using the same|
    US9056155B1|2007-05-29|2015-06-16|Abbott Cardiovascular Systems Inc.|Coatings having an elastic primer layer|
    US7829008B2|2007-05-30|2010-11-09|Abbott Cardiovascular Systems Inc.|Fabricating a stent from a blow molded tube|
    US7959857B2|2007-06-01|2011-06-14|Abbott Cardiovascular Systems Inc.|Radiation sterilization of medical devices|
    US8293260B2|2007-06-05|2012-10-23|Abbott Cardiovascular Systems Inc.|Elastomeric copolymer coatings containing polyfor implantable medical devices|
    US20080306582A1|2007-06-05|2008-12-11|Yunbing Wang|Implantable medical devices with elastomeric copolymer coatings|
    US8202528B2|2007-06-05|2012-06-19|Abbott Cardiovascular Systems Inc.|Implantable medical devices with elastomeric block copolymer coatings|
    US8425591B1|2007-06-11|2013-04-23|Abbott Cardiovascular Systems Inc.|Methods of forming polymer-bioceramic composite medical devices with bioceramic particles|
    US7665646B2|2007-06-18|2010-02-23|Tyco Healthcare Group Lp|Interlocking buttress material retention system|
    US8133553B2|2007-06-18|2012-03-13|Zimmer, Inc.|Process for forming a ceramic layer|
    US8309521B2|2007-06-19|2012-11-13|Zimmer, Inc.|Spacer with a coating thereon for use with an implant device|
    US7845533B2|2007-06-22|2010-12-07|Tyco Healthcare Group Lp|Detachable buttress material retention systems for use with a surgical stapling device|
    US8048441B2|2007-06-25|2011-11-01|Abbott Cardiovascular Systems, Inc.|Nanobead releasing medical devices|
    US8109904B1|2007-06-25|2012-02-07|Abbott Cardiovascular Systems Inc.|Drug delivery medical devices|
    US7901452B2|2007-06-27|2011-03-08|Abbott Cardiovascular Systems Inc.|Method to fabricate a stent having selected morphology to reduce restenosis|
    US7955381B1|2007-06-29|2011-06-07|Advanced Cardiovascular Systems, Inc.|Polymer-bioceramic composite implantable medical device with different types of bioceramic particles|
    US9125807B2|2007-07-09|2015-09-08|Incept Llc|Adhesive hydrogels for ophthalmic drug delivery|
    EP2182798B1|2007-07-16|2020-11-18|Allvivo Vascular, Inc.|Antimicrobial constructs|
    JP2010534515A|2007-07-23|2010-11-11|ハイパーブランチメディカルテクノロジー，インコーポレイテッド|Polymerization masking material for covering wound sites and methods of use thereof|
    EP2225325B1|2007-07-25|2011-06-01|Alcon, Inc.|High refractive index ophthalmic device materials|
    US20090035249A1|2007-08-02|2009-02-05|Bhatia Sujata K|Method of inhibiting proliferation of Escherichia coli|
    US7731988B2|2007-08-03|2010-06-08|Zimmer, Inc.|Multi-polymer hydrogels|
    GB0715514D0|2007-08-10|2007-09-19|Tissuemed Ltd|Coated medical devices|
    US8062739B2|2007-08-31|2011-11-22|Zimmer, Inc.|Hydrogels with gradient|
    US8608049B2|2007-10-10|2013-12-17|Zimmer, Inc.|Method for bonding a tantalum structure to a cobalt-alloy substrate|
    CA2703103C|2007-10-30|2017-05-09|Baxter Healthcare S.A.|Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects|
    US20090123519A1|2007-11-12|2009-05-14|Surmodics, Inc.|Swellable hydrogel matrix and methods|
    EP2214731B1|2007-11-14|2014-05-14|Actamax Surgical Materials LLC|Oxidized cationic polysaccharide-based polymer tissue adhesive for medical use|
    US7947784B2|2007-11-16|2011-05-24|Zimmer, Inc.|Reactive compounding of hydrogels|
    GB0722820D0|2007-11-21|2008-01-02|Smith & Nephew|Vacuum assisted wound dressing|
    US8808259B2|2007-11-21|2014-08-19|T.J. Smith & Nephew Limited|Suction device and dressing|
    WO2009066106A1|2007-11-21|2009-05-28|Smith & Nephew Plc|Wound dressing|
    GB0723875D0|2007-12-06|2008-01-16|Smith & Nephew|Wound management|
    US8629314B2|2007-12-18|2014-01-14|Ethicon, Inc.|Surgical barriers having adhesion inhibiting properties|
    US8299316B2|2007-12-18|2012-10-30|Ethicon, Inc.|Hemostatic device|
    US8211489B2|2007-12-19|2012-07-03|Abbott Cardiovascular Systems, Inc.|Methods for applying an application material to an implantable device|
    US8361538B2|2007-12-19|2013-01-29|Abbott Laboratories|Methods for applying an application material to an implantable device|
    WO2009083544A2|2007-12-28|2009-07-09|Kuros Biosurgery Ag|Pdgf fusion proteins incorporated into fibrin foams|
    US8034362B2|2008-01-04|2011-10-11|Zimmer, Inc.|Chemical composition of hydrogels for use as articulating surfaces|
    US7862538B2|2008-02-04|2011-01-04|Incept Llc|Surgical delivery system for medical sealant|
    US9044235B2|2008-02-18|2015-06-02|Covidien Lp|Magnetic clip for implant deployment device|
    US9034002B2|2008-02-18|2015-05-19|Covidien Lp|Lock bar spring and clip for implant deployment device|
    US8758373B2|2008-02-18|2014-06-24|Covidien Lp|Means and method for reversibly connecting a patch to a patch deployment device|
    US9393002B2|2008-02-18|2016-07-19|Covidien Lp|Clip for implant deployment device|
    US9301826B2|2008-02-18|2016-04-05|Covidien Lp|Lock bar spring and clip for implant deployment device|
    US8317808B2|2008-02-18|2012-11-27|Covidien Lp|Device and method for rolling and inserting a prosthetic patch into a body cavity|
    US9398944B2|2008-02-18|2016-07-26|Covidien Lp|Lock bar spring and clip for implant deployment device|
    US9833240B2|2008-02-18|2017-12-05|Covidien Lp|Lock bar spring and clip for implant deployment device|
    US9393093B2|2008-02-18|2016-07-19|Covidien Lp|Clip for implant deployment device|
    US8808314B2|2008-02-18|2014-08-19|Covidien Lp|Device and method for deploying and attaching an implant to a biological tissue|
    CA2715740C|2008-02-18|2014-05-27|Polytouch Medical Ltd.|A device and method for deploying and attaching a patch to a biological tissue|
    GB0803564D0|2008-02-27|2008-04-02|Smith & Nephew|Fluid collection|
    WO2009109194A2|2008-02-29|2009-09-11|Ferrosan A/S|Device for promotion of hemostasis and/or wound healing|
    US8293813B2|2008-03-05|2012-10-23|Biomet Manufacturing Corporation|Cohesive and compression resistant demineralized bone carrier matrix|
    DK2280720T3|2008-03-27|2019-06-11|Purdue Research Foundation|COLLAGEN BINDING SYNTHETIC PEPTIDOGLYCANES, MANUFACTURING AND PROCEDURE FOR USE|
    DE202008005131U1|2008-04-14|2008-08-28|Eidgenössische Technische Hochschule Zürich|Synthetic matrix for the controlled ingrowth of cells and tissue regeneration|
    WO2009132153A2|2008-04-22|2009-10-29|Angiotech Pharmaceuticals, Inc.|Biocompatible crosslinked hydrogels, drug-loaded hydrogels and methods of using the same|
    CA2721937C|2008-04-24|2016-07-12|Medtronic, Inc.|Protective gel based on chitosan and oxidized polysaccharide|
    JP5711113B2|2008-04-24|2015-04-30|メドトロニック，インコーポレイテッド|Thiolated chitosan gel|
    AU2009240509B2|2008-04-24|2014-08-21|Medtronic, Inc.|Rehydratable thiolated polysaccharide particles and sponge|
    ES2619515T3|2008-04-24|2017-06-26|Medtronic, Inc|Rehydratable and sponge polysaccharide particles|
    TW201000155A|2008-05-06|2010-01-01|Alcon Inc|High refractive index ophthalmic device materials|
    US8207264B2|2008-07-11|2012-06-26|Tyco Healthcare Group Lp|Functionalized inclusion complexes as crosslinkers|
    US20100015231A1|2008-07-17|2010-01-21|E.I. Du Pont De Nemours And Company|Low swell, long-lived hydrogel sealant|
    US8551136B2|2008-07-17|2013-10-08|Actamax Surgical Materials, Llc|High swell, long-lived hydrogel sealant|
    US9943302B2|2008-08-12|2018-04-17|Covidien Lp|Medical device for wound closure and method of use|
    US9271706B2|2008-08-12|2016-03-01|Covidien Lp|Medical device for wound closure and method of use|
    US20100100123A1|2008-10-17|2010-04-22|Confluent Surgical, Inc.|Hemostatic implant|
    US9889230B2|2008-10-17|2018-02-13|Covidien Lp|Hemostatic implant|
    EP2792307B1|2008-10-20|2017-10-04|Covidien LP|A device for attaching a patch to a biological tissue|
    WO2010059279A2|2008-11-19|2010-05-27|E. I. Du Pont De Nemours And Company|Hydrogel tissue adhesive formed from aminated polysaccharide and aldehyde-functionalized multi-arm polyether|
    US8466327B2|2008-11-19|2013-06-18|Actamax Surgical Materials, Llc|Aldehyde-functionalized polyethers and method of making same|
    US9271929B2|2008-11-25|2016-03-01|École Polytechnique Fédérale De Lausanne |Block copolymers and uses thereof|
    US20100147921A1|2008-12-16|2010-06-17|Lee Olson|Surgical Apparatus Including Surgical Buttress|
    US20100160960A1|2008-12-19|2010-06-24|E. I. Du Pont De Nemours And Company|Hydrogel tissue adhesive having increased degradation time|
    US20120122949A1|2008-12-19|2012-05-17|The University Of Tokyo|Ultra-high strength injectable hydrogel and process for producing the same|
    AU2010213612B2|2009-02-12|2015-04-30|Incept, Llc|Drug delivery through hydrogel plugs|
    JP4601725B2|2009-02-18|2010-12-22|オリンパスメディカルシステムズ株式会社|Endoscope insertion device|
    US9486215B2|2009-03-31|2016-11-08|Covidien Lp|Surgical stapling apparatus|
    US20100261652A1|2009-04-08|2010-10-14|California Institute Of Technology|Tissue Adhesive Using Engineered Proteins|
    WO2010118284A1|2009-04-09|2010-10-14|E. I. Du Pont De Nemours And Company|Hydrogel tissue adhesive having reduced degradation time|
    US9579103B2|2009-05-01|2017-02-28|Endologix, Inc.|Percutaneous method and device to treat dissections|
    US10772717B2|2009-05-01|2020-09-15|Endologix, Inc.|Percutaneous method and device to treat dissections|
    CA2977830C|2009-05-04|2019-09-17|Incept, Llc|Biomaterials for track and puncture closure|
    US9039783B2|2009-05-18|2015-05-26|Baxter International, Inc.|Method for the improvement of mesh implant biocompatibility|
    JP5719355B2|2009-06-16|2015-05-20|バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ|Hemostatic sponge|
    WO2011002888A2|2009-07-02|2011-01-06|E. I. Du Pont De Nemours And Company|Hydrogel tissue adhesive for medical use|
    US8796242B2|2009-07-02|2014-08-05|Actamax Surgical Materials, Llc|Hydrogel tissue adhesive for medical use|
    US8580951B2|2009-07-02|2013-11-12|Actamax Surgical Materials, Llc|Aldehyde-functionalized polysaccharides|
    US8580950B2|2009-07-02|2013-11-12|Actamax Surgical Materials, Llc|Aldehyde-functionalized polysaccharides|
    US8118856B2|2009-07-27|2012-02-21|Endologix, Inc.|Stent graft|
    KR101551681B1|2009-07-30|2015-09-09|카르빌란 테라퓨틱스, 인코포레이티드|Modified hyaluronic acid polymer compositions and related methods|
    US20110033515A1|2009-08-04|2011-02-10|Rst Implanted Cell Technology|Tissue contacting material|
    CA2769666C|2009-08-17|2018-02-13|Arie Levy|Means and method for reversibly connecting an implant to a deployment device|
    AU2010286117B9|2009-08-17|2014-07-10|Covidien Lp|Articulating patch deployment device and method of use|
    US10058837B2|2009-08-28|2018-08-28|The Trustees Of Columbia University In The City Of New York|Systems, methods, and devices for production of gas-filled microbubbles|
    JP2011052051A|2009-08-31|2011-03-17|Jsr Corp|Adhesive composition, method for processing or moving substrate using the same, and semiconductor element|
    US8470355B2|2009-10-01|2013-06-25|Covidien Lp|Mesh implant|
    US20110081398A1|2009-10-01|2011-04-07|Tyco Healthcare Group Lp|Multi-mechanism surgical compositions|
    WO2011041478A1|2009-10-02|2011-04-07|Baxter International Inc.|Hematopoietic stem cells for use in the treatment of a kidney injury|
    US20110081701A1|2009-10-02|2011-04-07|Timothy Sargeant|Surgical compositions|
    US8968785B2|2009-10-02|2015-03-03|Covidien Lp|Surgical compositions|
    US20110087273A1|2009-10-08|2011-04-14|Tyco Healthcare Group Lp|Wound Closure Device|
    US8617206B2|2009-10-08|2013-12-31|Covidien Lp|Wound closure device|
    US9833225B2|2009-10-08|2017-12-05|Covidien Lp|Wound closure device|
    US20110087274A1|2009-10-08|2011-04-14|Tyco Healtcare Group LP, New Haven, Ct|Wound Closure Device|
    US20150231409A1|2009-10-15|2015-08-20|Covidien Lp|Buttress brachytherapy and integrated staple line markers for margin identification|
    US10293553B2|2009-10-15|2019-05-21|Covidien Lp|Buttress brachytherapy and integrated staple line markers for margin identification|
    US9445795B2|2009-10-16|2016-09-20|Confluent Surgical, Inc.|Prevention of premature gelling of delivery devices for pH dependent forming materials|
    CA2730598C|2010-03-16|2018-03-13|Confluent Surgical, Inc.|Modulating drug release rate by controlling the kinetics of the ph transition in hydrogels|
    US20110091549A1|2009-10-16|2011-04-21|Confluent Surgical, Inc.|Modulating Drug Release Rate By Controlling The Kinetics Of The pH Transition In Hydrogels|
    US9132207B2|2009-10-27|2015-09-15|Spine Wave, Inc.|Radiopaque injectable nucleus hydrogel compositions|
    US8138236B2|2009-10-29|2012-03-20|Ethicon, Inc.|Solvent-free moisture activated latent curing surgical adhesive or sealant|
    EP2498763A4|2009-11-09|2015-10-07|Spotlight Technology Partners Llc|Polysaccharide based hydrogels|
    JP2013509963A|2009-11-09|2013-03-21|スポットライトテクノロジーパートナーズエルエルシー|Fragmented hydrogel|
    US8858592B2|2009-11-24|2014-10-14|Covidien Lp|Wound plugs|
    AU2010340067B2|2009-12-15|2015-03-19|Incept, Llc|Implants and biodegradable fiducial markers|
    EP2512588A4|2009-12-16|2014-06-04|Univ Columbia|Methods, devices, and systems for on-demand ultrasound-triggered drug delivery|
    CA2784432C|2009-12-16|2019-01-15|Baxter Healthcare S.A.|Hemostatic sponge|
    US9925140B2|2009-12-22|2018-03-27|National Cheng Kung University|Cell tissue gel containing collagen and hyaluronan|
    US8994666B2|2009-12-23|2015-03-31|Colin J. Karpfinger|Tactile touch-sensing interface system|
    US8568471B2|2010-01-30|2013-10-29|Abbott Cardiovascular Systems Inc.|Crush recoverable polymer scaffolds|
    US8808353B2|2010-01-30|2014-08-19|Abbott Cardiovascular Systems Inc.|Crush recoverable polymer scaffolds having a low crossing profile|
    EP2547328B1|2010-02-11|2017-06-07|Ecole Polytechnique Federale de Lausanne |Ccr7 ligand delivery and co-delivery in immunotherapy|
    US10065030B2|2010-02-23|2018-09-04|Viaderm Llc|Vacuum assisted percutaneous appliance|
    US8679404B2|2010-03-05|2014-03-25|Edwards Lifesciences Corporation|Dry prosthetic heart valve packaging system|
    JP5839814B2|2010-03-17|2016-01-06|グンゼ株式会社|DANCE protein-containing sustained release substrate and method for producing the sustained release substrate|
    US8685433B2|2010-03-31|2014-04-01|Abbott Cardiovascular Systems Inc.|Absorbable coating for implantable device|
    ES2546667T3|2010-04-07|2015-09-25|Baxter International Inc.|Hemostatic sponge|
    US9061095B2|2010-04-27|2015-06-23|Smith & Nephew Plc|Wound dressing and method of use|
    US8362177B1|2010-05-05|2013-01-29|Novartis Ag|High refractive index ophthalmic device materials with reduced tack|
    US8697111B2|2010-05-12|2014-04-15|Covidien Lp|Osteochondral implant comprising osseous phase and chondral phase|
    US8945156B2|2010-05-19|2015-02-03|University Of Utah Research Foundation|Tissue fixation|
    US8858577B2|2010-05-19|2014-10-14|University Of Utah Research Foundation|Tissue stabilization system|
    US8734824B2|2010-05-27|2014-05-27|Covidien LLP|Hydrogel implants with varying degrees of crosslinking|
    US8968783B2|2010-05-27|2015-03-03|Covidien Lp|Hydrogel implants with varying degrees of crosslinking|
    US8754564B2|2010-05-27|2014-06-17|Covidien Lp|Hydrogel implants with varying degrees of crosslinking|
    US8883185B2|2010-05-27|2014-11-11|Covidien Lp|Hydrogel implants with varying degrees of crosslinking|
    US8734930B2|2010-05-27|2014-05-27|Covidien Lp|Hydrogel implants with varying degrees of crosslinking|
    US8591929B2|2010-05-27|2013-11-26|Covidien Lp|Hydrogel implants with varying degrees of crosslinking|
    US8591950B2|2010-05-27|2013-11-26|Covidien Lp|Hydrogel implants with varying degrees of crosslinking|
    WO2011151386A1|2010-06-01|2011-12-08|Baxter International Inc.|Process for making dry and stable hemostatic compositions|
    CA2801120C|2010-06-01|2019-08-20|Baxter International Inc.|Process for making dry and stable hemostatic compositions|
    ES2676208T3|2010-06-01|2018-07-17|Baxter International Inc.|Process for the production of dry and stable hemostatic compositions|
    US8672237B2|2010-06-25|2014-03-18|Baxter International Inc.|Device for mixing and dispensing of two-component reactive surgical sealant|
    US9125633B2|2010-06-25|2015-09-08|Baxter International Inc.|Device for mixing and dispensing of two-component reactive surgical sealant|
    US9232805B2|2010-06-29|2016-01-12|Biocure, Inc.|In-situ forming hydrogel wound dressings containing antimicrobial agents|
    GB201011173D0|2010-07-02|2010-08-18|Smith & Nephew|Provision of wound filler|
    US8716204B2|2010-07-27|2014-05-06|Zimmer, Inc.|Synthetic synovial fluid compositions and methods for making the same|
    TWI669554B|2010-07-30|2019-08-21|瑞士商諾華公司|Readily-usable silicone hydrogel contact lenses|
    US8961501B2|2010-09-17|2015-02-24|Incept, Llc|Method for applying flowable hydrogels to a cornea|
    JP5846404B2|2010-10-14|2016-01-20|国立研究開発法人産業技術総合研究所|Photodegradable gel, cell culture instrument, cell arrangement / sorting device, cell arranging method and cell sorting method|
    US20140086975A1|2010-10-15|2014-03-27|Rutgers, The State University Of New Jersey|Hydrogel formulation for dermal and ocular delivery|
    WO2012068298A1|2010-11-17|2012-05-24|Endologix, Inc.|Devices and methods to treat vascular dissections|
    RU2597393C2|2010-11-25|2016-09-10|СМИТ ЭНД НЕФЬЮ ПиЭлСи|Composition i-ii, article containing same and use thereof|
    US9498317B2|2010-12-16|2016-11-22|Edwards Lifesciences Corporation|Prosthetic heart valve delivery systems and packaging|
    US8518440B2|2010-12-21|2013-08-27|Confluent Surgical, Inc.|Biodegradable osmotic pump implant for drug delivery|
    US8551525B2|2010-12-23|2013-10-08|Biostructures, Llc|Bone graft materialsand methods|
    CN103429268B|2011-01-04|2015-11-25|本德尔分析控股有限公司|The polymer through being cross-linked derived from parent's electricity activation Ju oxazoline and implant|
    US8360765B2|2011-01-07|2013-01-29|Covidien Lp|Systems and method for forming a coaxial implant|
    US8608775B2|2011-01-24|2013-12-17|Covidien Lp|Two part tape adhesive for wound closure|
    US9084602B2|2011-01-26|2015-07-21|Covidien Lp|Buttress film with hemostatic action for surgical stapling apparatus|
    US8852214B2|2011-02-04|2014-10-07|University Of Utah Research Foundation|System for tissue fixation to bone|
    US8479968B2|2011-03-10|2013-07-09|Covidien Lp|Surgical instrument buttress attachment|
    ES2882852T3|2011-03-16|2021-12-02|Kuros Biosurgery Ag|Pharmaceutical formulation for use in spinal fusion|
    DE102011007528A1|2011-04-15|2012-10-18|Aesculap Aktiengesellschaft|Thixotropic composition, in particular for post-surgical adhesion prophylaxis|
    LT2714718T|2011-05-24|2017-04-10|Symic Ip, Llc|Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use|
    US20120328557A1|2011-06-23|2012-12-27|Excel Med, Llc|Adhesive cell tissue gels|
    US9522963B2|2011-06-29|2016-12-20|Covidien Lp|Dissolution of oxidized cellulose|
    CA2840221A1|2011-07-05|2013-01-10|Bioasis Technologies Inc.|P97-antibody conjugates and methods of use|
    WO2013010045A1|2011-07-12|2013-01-17|Biotime Inc.|Novel methods and formulations for orthopedic cell therapy|
    US20130023736A1|2011-07-21|2013-01-24|Stanley Dale Harpstead|Systems for drug delivery and monitoring|
    US8726483B2|2011-07-29|2014-05-20|Abbott Cardiovascular Systems Inc.|Methods for uniform crimping and deployment of a polymer scaffold|
    US10226417B2|2011-09-16|2019-03-12|Peter Jarrett|Drug delivery systems and applications|
    US10849931B2|2011-09-30|2020-12-01|Depuy Synthes Products, Inc|Compositions and methods for platelet enriched fibrin constructs|
    EP2760431A1|2011-09-30|2014-08-06|Sofradim Production|Multilayer implants for delivery of therapeutic agents|
    US20130085139A1|2011-10-04|2013-04-04|Royal Holloway And Bedford New College|Oligomers|
    EP2766058A2|2011-10-11|2014-08-20|Baxter International Inc|Hemostatic compositions|
    WO2013053759A2|2011-10-11|2013-04-18|Baxter International Inc.|Hemostatic compositions|
    JP6017572B2|2011-10-12|2016-11-02|ノバルティス アーゲー|Method for producing UV-absorbing ophthalmic lens by coating|
    AR088531A1|2011-10-27|2014-06-18|Baxter Int|HEMOSTATIC COMPOSITIONS|
    US8584920B2|2011-11-04|2013-11-19|Covidien Lp|Surgical stapling apparatus including releasable buttress|
    RU2521194C2|2011-11-16|2014-06-27|Общество с ограниченной ответственностью предприятие "Репер"|Matrix for cell transplantology|
    EP3858847A1|2011-11-30|2021-08-04|Sarepta Therapeutics, Inc.|Oligonucleotides for treating expanded repeat diseases|
    EP2785840B8|2011-11-30|2019-05-22|Sarepta Therapeutics, Inc.|Induced exon inclusion in spinal muscle atrophy|
    US9205150B2|2011-12-05|2015-12-08|Incept, Llc|Medical organogel processes and compositions|
    US9113885B2|2011-12-14|2015-08-25|Covidien Lp|Buttress assembly for use with surgical stapling device|
    US9237892B2|2011-12-14|2016-01-19|Covidien Lp|Buttress attachment to the cartridge surface|
    US8967448B2|2011-12-14|2015-03-03|Covidien Lp|Surgical stapling apparatus including buttress attachment via tabs|
    US9351731B2|2011-12-14|2016-05-31|Covidien Lp|Surgical stapling apparatus including releasable surgical buttress|
    KR101444877B1|2011-12-30|2014-10-01|주식회사 삼양바이오팜|In situ crosslinking hydrogel comprising γ-polyglutamic acid and method for producing the same|
    ES2812281T3|2012-01-13|2021-03-16|Lifecell Corp|Methods for manufacturing breast prostheses|
    WO2013112381A2|2012-01-24|2013-08-01|Bvw Holding Ag|New class of anti-adhesion hydrogels with healing aspects|
    US9010612B2|2012-01-26|2015-04-21|Covidien Lp|Buttress support design for EEA anvil|
    US9010609B2|2012-01-26|2015-04-21|Covidien Lp|Circular stapler including buttress|
    US9326773B2|2012-01-26|2016-05-03|Covidien Lp|Surgical device including buttress material|
    CN104220098B|2012-02-14|2018-04-10|加利福尼亚大学董事会|Systemic delivery and modulated expression for angiocardiopathy and the paracrine gene of other patient's condition|
    JP2015508101A|2012-02-21|2015-03-16|バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ|Pharmaceutical composition comprising CD34 + cells|
    US8820606B2|2012-02-24|2014-09-02|Covidien Lp|Buttress retention system for linear endostaplers|
    JP6241624B2|2012-03-06|2017-12-06|フェロサン メディカル デバイシーズ エイ／エス|Pressurized container containing hemostatic paste|
    JP6153292B2|2012-05-09|2017-06-28|学校法人 関西大学|Compound-linked glycoprotein|
    US9168227B2|2012-05-31|2015-10-27|Covidien Lp|Multi-encapsulated microspheres made with oxidized cellulose for in-situ reactions|
    CA2826786A1|2012-09-17|2014-03-17|Confluent Surgical, Inc.|Multi-encapsulated formulations made with oxidized cellulose|
    US9271937B2|2012-05-31|2016-03-01|Covidien Lp|Oxidized cellulose microspheres|
    EP2977066A3|2012-06-12|2016-07-27|Ferrosan Medical Devices A/S|Dry haemostatic composition|
    US8864892B2|2012-06-21|2014-10-21|Empire Technology Development Llc|Tailorable lignosulfonate carbonate adhesives|
    ES2729152T3|2012-06-21|2019-10-30|Lifecell Corp|Implantable prosthesis that has acellular tissue junctions|
    US9499636B2|2012-06-28|2016-11-22|Covidien Lp|Dissolution of oxidized cellulose and particle preparation by cross-linking with multivalent cations|
    US10219804B2|2012-07-30|2019-03-05|Conextions, Inc.|Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone|
    US10835241B2|2012-07-30|2020-11-17|Conextions, Inc.|Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone|
    US9427309B2|2012-07-30|2016-08-30|Conextions, Inc.|Soft tissue repair devices, systems, and methods|
    US10390935B2|2012-07-30|2019-08-27|Conextions, Inc.|Soft tissue to bone repair devices, systems, and methods|
    AU2013296557B2|2012-07-31|2019-04-18|Bioasis Technologies Inc.|Dephosphorylated lysosomal storage disease proteins and methods of use thereof|
    US20140048580A1|2012-08-20|2014-02-20|Covidien Lp|Buttress attachment features for surgical stapling apparatus|
    US9395468B2|2012-08-27|2016-07-19|Ocular Dynamics, Llc|Contact lens with a hydrophilic layer|
    US20140067082A1|2012-09-06|2014-03-06|Xinyin Liu|Bioresorbable ceramic composition for forming a three dimensional scaffold|
    US9161753B2|2012-10-10|2015-10-20|Covidien Lp|Buttress fixation for a circular stapler|
    US20140131418A1|2012-11-09|2014-05-15|Covidien Lp|Surgical Stapling Apparatus Including Buttress Attachment|
    JP2016500058A|2012-11-12|2016-01-07|レッドウッド バイオサイエンス， インコーポレイテッド|Methods for producing compounds and conjugates|
    CA2890906A1|2012-11-16|2014-05-22|The Regents Of The University Of California|Pictet-spengler ligation for protein chemical modification|
    US9310374B2|2012-11-16|2016-04-12|Redwood Bioscience, Inc.|Hydrazinyl-indole compounds and methods for producing a conjugate|
    US8859705B2|2012-11-19|2014-10-14|Actamax Surgical Materials Llc|Hydrogel tissue adhesive having decreased gelation time and decreased degradation time|
    DE102012222365A1|2012-12-05|2014-06-05|Aesculap Ag|Composition for use in the prophylaxis of post-surgical adhesions|
    WO2014095690A1|2012-12-17|2014-06-26|Novartis Ag|Method for making improved uv-absorbing ophthalmic lenses|
    US20140178343A1|2012-12-21|2014-06-26|Jian Q. Yao|Supports and methods for promoting integration of cartilage tissue explants|
    US9792935B2|2012-12-21|2017-10-17|Seagate Technology Llc|Magnetic devices with variable overcoats|
    WO2014113540A1|2013-01-16|2014-07-24|Iowa State University Research Foundation, Inc.|A deep intronic target for splicing correction on spinal muscular atrophy gene|
    US9597426B2|2013-01-25|2017-03-21|Covidien Lp|Hydrogel filled barbed suture|
    US20140212355A1|2013-01-28|2014-07-31|Abbott Cardiovascular Systems Inc.|Trans-arterial drug delivery|
    US20140239047A1|2013-02-28|2014-08-28|Covidien Lp|Adherence concepts for non-woven absorbable felt buttresses|
    WO2014138021A1|2013-03-04|2014-09-12|DERMELLE, LLC d/b/a ETERNOGEN, LLC|Injectable in situ polymerizable collagen composition|
    US9782173B2|2013-03-07|2017-10-10|Covidien Lp|Circular stapling device including buttress release mechanism|
    EP2970433B1|2013-03-13|2019-09-18|Bioasis Technologies Inc.|Fragments of p97 and uses thereof|
    US9364199B2|2013-03-14|2016-06-14|Covidien Lp|Medical devices|
    US10624865B2|2013-03-14|2020-04-21|Pathak Holdings Llc|Methods, compositions, and devices for drug/live cell microarrays|
    US10328095B2|2013-03-15|2019-06-25|Covidien Lp|Resorbable oxidized cellulose embolization microspheres|
    CA2925606A1|2015-04-23|2016-10-23|Covidien Lp|Resorbable oxidized cellulose embolization solution|
    AU2017204280A1|2016-08-12|2018-03-01|Covidien Lp|Thixotropic oxidized cellulose solutions and medical applications thereof|
    KR20150130419A|2013-03-15|2015-11-23|시믹 바이오메디칼, 인크.|Extracellular matrix-binding synthetic peptidoglycans|
    US9782430B2|2013-03-15|2017-10-10|Covidien Lp|Resorbable oxidized cellulose embolization solution|
    US10413566B2|2013-03-15|2019-09-17|Covidien Lp|Thixotropic oxidized cellulose solutions and medical applications thereof|
    US9775928B2|2013-06-18|2017-10-03|Covidien Lp|Adhesive barbed filament|
    JP6390873B2|2013-06-21|2018-09-19|フェッローサン メディカル ディバイス エー／エス|Dry composition expanded under reduced pressure and syringe for holding the same|
    US9371423B2|2013-07-09|2016-06-21|General Electric Company|Methods and apparatus for crosslinking a silicon carbide fiber precursor polymer|
    WO2015013510A1|2013-07-25|2015-01-29|Ecole Polytechnique Federale De Lausanne Epfl|High aspect ratio nanofibril materials|
    EP3027659B1|2013-07-29|2020-12-09|Actamax Surgical Materials LLC|Low swell tissue adhesive and sealant formulations|
    US20150093399A1|2013-08-28|2015-04-02|Bioasis Technologies, Inc.|Cns-targeted conjugates having modified fc regions and methods of use thereof|
    MX2016002934A|2013-09-05|2016-12-20|Sarepta Therapeutics Inc|Antisense-induced exon2 inclusion in acid alpha-glucosidase.|
    EP3069195B8|2013-11-15|2019-07-10|Tangible Science, LLC|Contact lens with a hydrophilic layer|
    WO2015081282A1|2013-11-27|2015-06-04|Redwood Bioscience, Inc.|Hydrazinyl-pyrrolo compounds and methods for producing a conjugate|
    AU2014361291B2|2013-12-11|2017-11-30|Ferrosan Medical Devices A/S|Dry composition comprising an extrusion enhancer|
    CN105829081B|2013-12-17|2017-12-19|诺华股份有限公司|The silicone hydrogel lenses of hydrophilic coating with crosslinking|
    RU2699811C1|2014-03-07|2019-09-11|Айконлаб Инк.|Multipurpose implant with specified surface structure for soft tissue reconstruction|
    US10588732B2|2014-03-07|2020-03-17|IconLab USA, Inc.|Multipurpose implant with modeled surface structure for soft tissue reconstruction|
    WO2015138760A1|2014-03-12|2015-09-17|Conextions, Inc.|Soft tissue repair devices, systems, and methods|
    KR20160137908A|2014-04-03|2016-12-01|더 리젠츠 오브 더 유니버시티 오브 캘리포니아|Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunction and congestive heart failure|
    WO2015164822A1|2014-04-25|2015-10-29|Purdue Research Foundation|Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction|
    US9844378B2|2014-04-29|2017-12-19|Covidien Lp|Surgical stapling apparatus and methods of adhering a surgical buttress thereto|
    CA2948373A1|2014-05-16|2015-11-19|Oregon State University|Antisense antibacterial compounds and methods|
    US10391098B2|2014-05-19|2019-08-27|Board Of Regents, The University Of Texas System|Antisense antibacterial compounds and methods|
    WO2015179862A1|2014-05-23|2015-11-26|Viaderm, Llc|Vacuum assisted percutaneous appliance|
    WO2015181395A1|2014-05-30|2015-12-03|Sofradim Production|Method for preparing neutralized matrix of non-antigenic collagenous material|
    KR20170046691A|2014-08-26|2017-05-02|노파르티스 아게|Method for applying stable coating on silicone hydrogel contact lenses|
    CN105412975B|2014-09-18|2019-05-31|苏州安德佳生物科技有限公司|A kind of biocompatible hemostatic product and preparation method thereof|
    EP3000489B1|2014-09-24|2017-04-05|Sofradim Production|Method for preparing an anti-adhesion barrier film|
    US10449152B2|2014-09-26|2019-10-22|Covidien Lp|Drug loaded microspheres for post-operative chronic pain|
    AU2015333206B2|2014-10-13|2019-07-11|Ferrosan Medical Devices A/S.|Dry composition for use in haemostasis and wound healing|
    CN107206119B|2014-12-09|2021-01-29|实体科学公司|Medical device coating with biocompatible layer|
    US10835216B2|2014-12-24|2020-11-17|Covidien Lp|Spinneret for manufacture of melt blown nonwoven fabric|
    WO2016102446A1|2014-12-24|2016-06-30|Ferrosan Medical Devices A/S|Syringe for retaining and mixing first and second substances|
    CN105561405B|2015-01-07|2019-07-26|北京赛奇科科技有限公司|A kind of medical material and preparation method thereof for Embolism for fallopian tube|
    CN105561404B|2015-01-07|2019-07-26|北京赛奇科科技有限公司|A kind of medical material and preparation method thereof to prevent adhesion for gynemetrics|
    US10470767B2|2015-02-10|2019-11-12|Covidien Lp|Surgical stapling instrument having ultrasonic energy delivery|
    US9999527B2|2015-02-11|2018-06-19|Abbott Cardiovascular Systems Inc.|Scaffolds having radiopaque markers|
    MA41795A|2015-03-18|2018-01-23|Sarepta Therapeutics Inc|EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN|
    CA2981826A1|2015-04-10|2016-10-13|Covidien Lp|Surgical stapler with integrated bladder|
    EP3294889B1|2015-05-11|2021-01-06|Murdoch University|Multiple sclerosis treatment|
    US10010502B2|2015-05-19|2018-07-03|Amorphex Therapeutics Llc|Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation|
    EP3851531A1|2015-06-01|2021-07-21|Sarepta Therapeutics, Inc.|Antisense-induced exon exclusion in type vii collagen|
    US9700443B2|2015-06-12|2017-07-11|Abbott Cardiovascular Systems Inc.|Methods for attaching a radiopaque marker to a scaffold|
    CA2986981A1|2015-07-03|2017-01-12|Ferrosan Medical Devices A/S|Syringe for mixing two components and for retaining a vacuum in a storage condition|
    CN106337037A|2015-07-08|2017-01-18|中国科学院上海生命科学研究院|Medicinal composition for inducing direct conversion of fibroblasts into nerve cells, and use of medicinal composition|
    AU2016297642A1|2015-07-22|2018-02-15|Incept, Llc|Coated punctal plug|
    JP2018530560A|2015-10-09|2018-10-18|サレプタ セラピューティクス， インコーポレイテッド|Compositions and methods for the treatment of Duchenne muscular dystrophy and related disorders|
    SG11201803726VA|2015-12-15|2018-06-28|Novartis Ag|Method for applying stable coating on silicone hydrogel contact lenses|
    EP3394261A4|2015-12-23|2019-11-27|Oregon State University|Antisense antibacterial compounds and methods|
    CA3009342A1|2015-12-23|2017-06-29|Board Of Regents, The University Of Texas System|Antisense antibacterial compounds and methods|
    EA201892366A1|2016-04-18|2019-03-29|Сарепта Терапьютикс, Инк.|ANTISMINAL OLIGOMERS AND METHODS OF THEIR APPLICATION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH THE GENE OF THE ACID ALPHA-GLUCOSIDASE|
    US10668190B2|2016-05-03|2020-06-02|Bvw Holding Ag|Multiphase gel|
    US10959731B2|2016-06-14|2021-03-30|Covidien Lp|Buttress attachment for surgical stapling instrument|
    US11098203B2|2016-08-31|2021-08-24|Commonwealth Scientific And Industrial Research Organisation|Polymer coatings|
    GB2567122B|2016-09-21|2021-10-27|Law Peter|Autonomously controllable pull wire injection catheter, robotic system comprising said catheter and method for operating the same|
    EP3755236A4|2018-02-20|2021-11-17|Conextions, Inc.|Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone|
    US11026686B2|2016-11-08|2021-06-08|Covidien Lp|Structure for attaching buttress to anvil and/or cartridge of surgical stapling instrument|
    US10874768B2|2017-01-20|2020-12-29|Covidien Lp|Drug eluting medical device|
    US10925607B2|2017-02-28|2021-02-23|Covidien Lp|Surgical stapling apparatus with staple sheath|
    CN108498879B|2017-02-28|2021-12-28|苏州安德佳生物科技有限公司|Composition and reagent combination for submucosal injection and application thereof|
    US11202848B2|2017-03-08|2021-12-21|Baxter International Inc.|Surgical adhesive able to glue in wet conditions|
    US10912859B2|2017-03-08|2021-02-09|Baxter International Inc.|Additive able to provide underwater adhesion|
    US10368868B2|2017-03-09|2019-08-06|Covidien Lp|Structure for attaching buttress material to anvil and cartridge of surgical stapling instrument|
    US11096610B2|2017-03-28|2021-08-24|Covidien Lp|Surgical implants including sensing fibers|
    US10849625B2|2017-08-07|2020-12-01|Covidien Lp|Surgical buttress retention systems for surgical stapling apparatus|
    US10945733B2|2017-08-23|2021-03-16|Covidien Lp|Surgical buttress reload and tip attachment assemblies for surgical stapling apparatus|
    US11141151B2|2017-12-08|2021-10-12|Covidien Lp|Surgical buttress for circular stapling|
    US11029446B2|2017-12-13|2021-06-08|Alcon Inc.|Method for producing MPS-compatible water gradient contact lenses|
    US11065000B2|2018-02-22|2021-07-20|Covidien Lp|Surgical buttresses for surgical stapling apparatus|
    US10980913B2|2018-03-05|2021-04-20|Ethicon Llc|Sealant foam compositions for lung applications|
    US10758237B2|2018-04-30|2020-09-01|Covidien Lp|Circular stapling apparatus with pinned buttress|
    US11219460B2|2018-07-02|2022-01-11|Covidien Lp|Surgical stapling apparatus with anvil buttress|
    WO2020023300A1|2018-07-22|2020-01-30|Bioasis Technologies, Inc.|Treatment of lymmphatic metastases|
    CN112807480A|2018-08-20|2021-05-18|稳得希林生物科技有限公司|Polysaccharide-based tissue adhesive medical adhesive and application thereof|
    US10806459B2|2018-09-14|2020-10-20|Covidien Lp|Drug patterned reinforcement material for circular anastomosis|
    US10952729B2|2018-10-03|2021-03-23|Covidien Lp|Universal linear buttress retention/release assemblies and methods|
    US10517988B1|2018-11-19|2019-12-31|Endomedix, Inc.|Methods and compositions for achieving hemostasis and stable blood clot formation|
    US20210355468A1|2020-05-18|2021-11-18|Bioasis Technologies, Inc.|Compositions and methods for treating lewy body dementia|
    US20210393245A1|2020-06-10|2021-12-23|Ethicon, Inc.|Two component sealing systems including synthetic matrices and biosynthetic adhesives for sealing resected surfaces of organs to control bleeding, fluid leaks and air leaks|
    US20210393787A1|2020-06-17|2021-12-23|Bioasis Technologies, Inc.|Compositions and methods for treating frontotemporal dementia|
    CN111840631A|2020-07-23|2020-10-30|青岛大学附属医院|Injectable antibacterial hemostatic hydrogel adhesive and preparation method and application thereof|
    法律状态:
    2001-11-09| STCF| Information on status: patent grant|Free format text: PATENTED CASE |
    2005-05-27| FPAY| Fee payment|Year of fee payment: 4 |
    2005-06-21| AS| Assignment|Owner name: ANGIOTECH BIOMATERIALS CORP., WASHINGTON Free format text: CHANGE OF NAME;ASSIGNOR:COHESION TECHNOLOGIES, INC.;REEL/FRAME:016369/0932 Effective date: 20041221 |
    2006-03-13| AS| Assignment|Owner name: ANGIODEVICE INTERNATIONAL GMBH, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ANGIOTECH BIOMATERIALS CORPORATION;REEL/FRAME:017299/0949 Effective date: 20051102 |
    2009-05-27| FPAY| Fee payment|Year of fee payment: 8 |
    2013-03-14| FPAY| Fee payment|Year of fee payment: 12 |
    优先权:
    申请号 | 申请日 | 专利标题
    US53979995A| true| 1995-10-05|1995-10-05||
    US57379995A| true| 1995-12-18|1995-12-18||
    US08/769,806|US5874500A|1995-12-18|1996-12-18|Crosslinked polymer compositions and methods for their use|
    US09/229,851|US6051648A|1995-12-18|1999-01-13|Crosslinked polymer compositions and methods for their use|
    US09/302,852|US6166130A|1995-12-18|1999-04-30|Method of using crosslinked polymer compositions in tissue treatment applications|
    US09/733,739|US6323278B2|1995-10-05|2000-12-08|Method of making crosslinked polymer matrices in tissue treatment applications|US09/733,739| US6323278B2|1995-10-05|2000-12-08|Method of making crosslinked polymer matrices in tissue treatment applications|
    US09/883,138| US6458889B1|1995-12-18|2001-06-15|Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use|
    US09/932,536| US6534591B2|1995-12-18|2001-08-17|Cross-linked polymer compositions and methods for their use|
    AU2002315188A| AU2002315188B2|1995-12-18|2002-06-14|Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use|
    US10/262,640| US6833408B2|1995-12-18|2002-09-30|Methods for tissue repair using adhesive materials|
    US10/364,762| US20030149173A1|1995-12-18|2003-02-10|Crosslinked polymer compositions and methods for their use|
    US10/766,095| US20040186231A1|1995-12-18|2004-01-27|Dehydrated, shaped matrix and use thereof in the treatment of vascular malformation|
    US10/766,726| US6911496B2|1995-12-18|2004-01-27|Composition for administration of a biologically active compound|
    US10/766,146| US6969400B2|1995-12-18|2004-01-27|Synthetic implant with nonimmunogenicity coating|
    US10/766,104| US7883694B2|1995-12-18|2004-01-27|Method for preventing the formation of adhesions following surgery or injury|
    US10/873,833| US7176256B2|1995-12-18|2004-06-21|Biocompatible crosslinked composition|
    US10/918,502| US20050027070A1|1995-12-18|2004-08-13|Method for preparing a biocompatible crosslinked matrix and matrix provided thereby|
    US10/971,684| US8377466B2|1995-12-18|2004-10-22|Adhesive tissue repair patch|
    US11/078,254| US7151135B2|1995-12-18|2005-03-10|Crosslinked polymer compositions|
    US11/344,752| US7883693B2|1995-12-18|2006-01-31|Compositions and systems for forming crosslinked biomaterials and methods of preparation of use|
    US12/787,304| US8617584B2|1995-12-18|2010-05-25|Adhesive tissue repair patch and collagen sheets|
    US12/979,215| US20110159075A1|1995-12-18|2010-12-27|Compositions and systems for forming crosslinked biomaterials and methods of preparation and use|
    US12/979,883| US8197802B2|1995-12-18|2010-12-28|Method for treating or inhibiting the formation of adhesions following surgery or injury|
    [返回顶部]